{"id":"elexacaftor","rwe":[{"pmid":"41892019","year":"2026","title":"Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes.","finding":"","journal":"International journal of neonatal screening","studyType":"Clinical Study"},{"pmid":"41881763","year":"2026","title":"Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis.","finding":"","journal":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","studyType":"Clinical Study"},{"pmid":"41871565","year":"2026","title":"Response to modulator therapy in a cystic fibrosis patient with a single identified CFTR variant not eligible for modulator treatment.","finding":"","journal":"The Turkish journal of pediatrics","studyType":"Clinical Study"},{"pmid":"41869727","year":"2026","title":"Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.","finding":"","journal":"JCI insight","studyType":"Clinical Study"},{"pmid":"41865142","year":"2026","title":"Recalibration: Exploring the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Self-Concept for Adults with Cystic Fibrosis.","finding":"","journal":"The patient","studyType":"Clinical Study"}],"_fda":{"id":"d16848f4-2958-44c0-b688-8a9b25d9032f","set_id":"f354423a-85c2-41c3-a9db-0f3aee135d8d","openfda":{"rxcui":["1243046","1606868","2174388","2257011","2257012","2257013","2557214","2557215","2557216","2635013","2635020","2635021","2635022","2635024","2635025","2635026"],"spl_id":["d16848f4-2958-44c0-b688-8a9b25d9032f"],"brand_name":["Trikafta"],"spl_set_id":["f354423a-85c2-41c3-a9db-0f3aee135d8d"],"package_ndc":["51167-331-01","51167-431-14","51167-531-07","51167-106-02","51167-206-14","51167-306-07","51167-445-01","51167-545-07","51167-645-07","51167-446-01","51167-746-07","51167-846-07"],"product_ndc":["51167-106","51167-331","51167-445","51167-446"],"generic_name":["ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Vertex Pharmaceuticals Incorporated"],"application_number":["NDA212273","NDA217660"],"is_original_packager":[true]},"version":"22","pregnancy":["8.1 Pregnancy Risk Summary There are limited and incomplete human data from clinical trials on the use of TRIKAFTA or its individual components, elexacaftor, tezacaftor and ivacaftor, in pregnant women to inform a drug-associated risk. Although there are no animal reproduction studies with the concomitant administration of elexacaftor, tezacaftor and ivacaftor, separate reproductive and developmental studies were conducted with each active component of TRIKAFTA in pregnant rats and rabbits. In animal embryo fetal development (EFD) studies oral administration of elexacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 2 times the exposure at the maximum recommended human dose (MRHD) in rats and 4 times the MRHD in rabbits [based on summed AUCs of elexacaftor and its metabolite (for rat) and AUC of elexacaftor (for rabbit)]. Oral administration of tezacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 3 times the exposure at the MRHD in rats and 0.2 times the MRHD in rabbits (based on summed AUCs of tezacaftor and M1-TEZ). Oral administration of ivacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 5 and 14 times the exposure at the MRHD, respectively [based on summed AUCs of ivacaftor and its metabolites (for rat) and AUC of ivacaftor (for rabbit)]. No adverse developmental effects were observed after oral administration of elexacaftor, tezacaftor or ivacaftor to pregnant rats from the period of organogenesis through lactation at doses that produced maternal exposures approximately 1 time, approximately 1 time and 3 times the exposures at the MRHD, respectively [based on summed AUCs of parent and metabolite(s)] (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Elexacaftor In an EFD study, pregnant rats were administered oral doses of elexacaftor at 15, 25, and 40 mg/kg/day during the period of organogenesis from gestation Days 6-17. Elexacaftor did not cause adverse developmental outcomes at exposures up to 9 times the MRHD (based on summed AUCs for elexacaftor and its metabolite at maternal doses up to 40 mg/kg/day). Lower mean fetal body weights were observed at doses ≥25 mg/kg/day that produced maternal exposures ≥4 times the MRHD. Maternal toxicity was observed at 40 mg/kg/day (9 times the MRHD). In an EFD study, pregnant rabbits were administered oral doses of elexacaftor at 50, 100, or 125 mg/kg/day during the period of organogenesis from gestation Days 7-20. Elexacaftor was not teratogenic at exposures up to 4 times the MRHD (based on AUC of elexacaftor at maternal doses up to 125 mg/kg/day). Maternal toxicity was observed at 125 mg/kg/day (4 times the MRHD). In a pre- and postnatal development (PPND), pregnant rats were administered elexacaftor at oral doses of 5, 7.5, and 10 mg/kg/day from gestation Day 6 through lactation Day 18. Elexacaftor did not cause adverse developmental outcomes in pups at maternal doses up to 10 mg/kg/day (approximately 1 time the MRHD based on summed AUCs of elexacaftor and its metabolite). Placental transfer of elexacaftor was observed in pregnant rats. Tezacaftor In an EFD study, pregnant rats were administered tezacaftor at oral doses of 25, 50, or 100 mg/kg/day during the period of organogenesis from gestation Days 6-17. Tezacaftor did not cause adverse developmental effects at exposures up to 3 times the MRHD (based on summed AUCs of tezacaftor and M1-TEZ). Maternal toxicity in rats was observed at greater than or equal to 50 mg/kg/day (approximately greater than or equal to 1 time the MRHD). In an EFD study, pregnant rabbits were administered tezacaftor at oral doses of 10, 25, or 50 mg/kg/day during the period of organogenesis from gestation Days 7-20. Tezacaftor did not affect fetal developmental outcomes at exposures up to 0.2 times the MRHD (based on summed AUCs of tezacaftor and M1-TEZ). Lower fetal body weights were observed in rabbits at a maternally toxic dose that produced exposures approximately 1 time the MRHD (based on summed AUCs of tezacaftor and M1-TEZ at a maternal dose of 50 mg/kg/day). In a PPND study, pregnant rats were administered tezacaftor at oral doses of 25, 50, or 100 mg/kg/day from gestation Day 6 through lactation Day 18. Tezacaftor had no adverse developmental effects on pups at an exposure of approximately 1 time the MRHD (based on summed AUCs for tezacaftor and M1-TEZ at a maternal dose of 25 mg/kg/day). Decreased fetal body weights and early developmental delays in pinna detachment, eye opening, and righting reflex occurred at a maternally toxic dose (based on maternal weight loss) that produced exposures approximately 2 times the exposure at the MRHD (based on summed AUCs for tezacaftor and M1-TEZ). Placental transfer of tezacaftor was observed in pregnant rats. Ivacaftor In an EFD study, pregnant rats were administered ivacaftor at oral doses of 50, 100, or 200 mg/kg/day during the period of organogenesis from gestation Days 7-17. Ivacaftor did not affect fetal survival at exposures up to 5 times the MRHD (based on summed AUCs of ivacaftor and its metabolites at maternal oral doses up to 200 mg/kg/day). Maternal toxicity was observed at 100 and 200 mg/kg/day (3 and 5 times the exposure at the MRHD) and was associated with a decrease in fetal body weights at a maternal dose of 200 mg/kg/day (5 times the MRHD). In an EFD study, pregnant rabbits were administered ivacaftor at oral doses of 25, 50, or 100 mg/kg/day during the period of organogenesis from gestation Days 7-19. Ivacaftor did not affect fetal development or survival at exposures up to 14 times the MRHD (on an ivacaftor AUC basis at maternal oral doses up to 100 mg/kg/day). Maternal toxicity (i.e., death, decreased food consumption, decreased mean body weight and body weight gain, decreased clinical condition, abortions) was observed at doses greater than or equal to 50 mg/kg/day (approximately 5 times the MRHD). In a PPND study, pregnant rats were administered ivacaftor at oral doses of 50, 100, or 200 mg/kg/day from gestation Day 7 through lactation Day 20. Ivacaftor had no effects on delivery or growth and development of offspring at exposures up to 3 times the MRHD (based on summed AUCs for ivacaftor and its metabolites at maternal oral doses up to 100 mg/kg/day). Decreased fetal body weights were observed at a maternally toxic dose that produced exposures 5 times the MRHD (based on summed AUCs of ivacaftor and its metabolites). Placental transfer of ivacaftor was observed in pregnant rats and rabbits."],"overdosage":["10 OVERDOSAGE Treatment of overdosage consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient."],"description":["11 DESCRIPTION TRIKAFTA is a co-package of elexacaftor, tezacaftor and ivacaftor fixed-dose combination tablets or granules and ivacaftor tablets or granules. Both tablets and granules are for oral administration. The elexacaftor, tezacaftor and ivacaftor fixed-dose combination tablets are available as: orange, oblong-shaped, film-coated tablet containing 100 mg of elexacaftor, 50 mg of tezacaftor, 75 mg of ivacaftor, or light orange, oblong-shaped, film-coated tablet containing 50 mg of elexacaftor, 25 mg of tezacaftor, 37.5 mg of ivacaftor. The fixed-dose combination tablet contains the following inactive ingredients: croscarmellose sodium, hypromellose, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, talc, and titanium dioxide. The ivacaftor tablet is available as a light blue, oblong-shaped, film-coated tablet containing 150 mg or 75 mg of ivacaftor and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac. The elexacaftor, tezacaftor and ivacaftor fixed-dose combination oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in unit-dose packets. Each unit-dose packet contains 100 mg of elexacaftor, 50 mg of tezacaftor, 75 mg of ivacaftor or 80 mg of elexacaftor, 40 mg of tezacaftor, 60 mg of ivacaftor and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. The ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in unit-dose packets. Each unit-dose packet contains 75 mg or 59.5 mg of ivacaftor and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. The active ingredients of TRIKAFTA are described below. Elexacaftor Elexacaftor is a white solid that is practically insoluble in water (<1 mg/mL). Its chemical name is N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide. Its molecular formula is C 26 H 34 N 7 O 4 SF 3 and its molecular weight is 597.66. Elexacaftor has the following structural formula: Chemical Structure Tezacaftor Tezacaftor is a white to off-white solid that is practically insoluble in water (<5 microgram/mL). Its chemical name is 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide. Its molecular formula is C 26 H 27 N 2 F 3 O 6 and its molecular weight is 520.50. Tezacaftor has the following structural formula: Chemical Structure Ivacaftor Ivacaftor is a white to off-white crystalline solid that is practically insoluble in water (<0.05 microgram/mL). Pharmacologically it is a CFTR potentiator. Its chemical name is N -(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. Its molecular formula is C 24 H 28 N 2 O 3 and its molecular weight is 392.49. Ivacaftor has the following structural formula: Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING TRIKAFTA tablets are co-packaged blister pack sealed into a printed wallet, containing elexacaftor, tezacaftor and ivacaftor fixed-dose combination tablets and ivacaftor tablets. Four such wallets are placed in a printed outer carton. TRIKAFTA tablets are supplied as follows: Table 14: TRIKAFTA Tablets and Package Configuration Strengths Tablet Description Package Configuration NDC Elexacaftor 50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg tablets light orange, oblong-shaped, debossed with \"T50\" on one side and plain on the other 84-count carton containing 4 wallets, each wallet containing 14 tablets of elexacaftor, tezacaftor and ivacaftor, and 7 tablets of ivacaftor NDC 51167-106-02 Ivacaftor 75 mg light blue, film-coated, oblong-shaped, printed with the characters \"V 75\" in black ink on one side and plain on the other Elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg orange, oblong-shaped, debossed with \"T100\" on one side and plain on the other 84-count carton containing 4 wallets, each wallet containing 14 tablets of elexacaftor, tezacaftor and ivacaftor, and 7 tablets of ivacaftor NDC 51167-331-01 Ivacaftor 150 mg light blue, film-coated, oblong-shaped, printed with the characters \"V 150\" in black ink on one side and plain on the other TRIKAFTA oral granules are supplied in morning and evening unit-dose packets. The morning dose packets contain a fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor oral granules. The evening dose packets contain ivacaftor oral granules. The packets are placed into a printed wallet. Four such wallets are placed in a printed outer carton. TRIKAFTA granules are supplied as follows: Table 15: TRIKAFTA Oral Granules and Package Configuration Strengths Granule Description Package Configuration NDC Elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and blue unit-dose packets 56-count carton containing 4 wallets, each wallet containing 7 white and blue packets of elexacaftor, tezacaftor and ivacaftor, and 7 white and green packets of ivacaftor NDC 51167-445-01 Ivacaftor 59.5 mg white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and green unit-dose packets Elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and orange unit-dose packets 56-count carton containing 4 wallets, each wallet containing 7 white and orange packets of elexacaftor, tezacaftor and ivacaftor, and 7 white and pink packets of ivacaftor NDC 51167-446-01 Ivacaftor 75 mg white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and pink unit-dose packets Store at 20 ºC – 25 ºC (68 ºF – 77 ºF); excursions permitted to 15 ºC – 30 ºC (59 ºF – 86 ºF) [see USP Controlled Room Temperature]."],"spl_medguide":["This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 03/2026 MEDICATION GUIDE TRIKAFTA ® (tri-KAF-tuh) (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use (elexacaftor, tezacaftor, and ivacaftor oral granules; ivacaftor oral granules), co-packaged What is the most important information I should know about TRIKAFTA? TRIKAFTA can cause serious liver damage and liver failure. Liver failure leading to transplantation and death have been seen in some people with or without a history of liver problems taking TRIKAFTA. Your healthcare provider will do blood tests to check your liver: before you start TRIKAFTA then every month during your first 6 months of taking TRIKAFTA then every 3 months during the next 12 months of taking TRIKAFTA then at least every year while you are taking TRIKAFTA Your healthcare provider may do blood tests to check the liver more often if you have had high liver enzymes in your blood in the past or are experiencing signs or symptoms of liver injury. Stop taking TRIKAFTA and call your healthcare provider right away if you have any of the following symptoms of liver problems: pain, swelling, or discomfort in the upper right stomach (abdominal) area yellowing of your skin or the white part of your eyes mental changes nausea or vomiting dark, amber-colored urine loss of appetite have fluid in your stomach area (ascites) What is TRIKAFTA? TRIKAFTA is a prescription medicine for people aged 2 years and older who have a diagnosis of cystic fibrosis (CF) and who have at least one genetic change (variant) in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive to TRIKAFTA or results in the production of protein. Talk to your healthcare provider to learn if you have an indicated CF gene variant. It is not known if TRIKAFTA is safe and effective in children under 2 years of age. What should I tell my healthcare provider before taking TRIKAFTA? Before taking TRIKAFTA, tell your healthcare provider about all of your medical conditions, including if you: have or have had liver problems. are allergic to TRIKAFTA or any ingredients in TRIKAFTA. See the end of this Medication Guide for a complete list of ingredients in TRIKAFTA. have kidney problems. have or have had mental health problems. are pregnant or plan to become pregnant. It is not known if TRIKAFTA will harm your unborn baby. You and your healthcare provider should decide if you will take TRIKAFTA while you are pregnant. are breastfeeding or planning to breastfeed. It is not known if TRIKAFTA passes into your breast milk. You and your healthcare provider should decide if you will take TRIKAFTA while you are breastfeeding. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRIKAFTA may affect the way other medicines work and other medicines may affect how TRIKAFTA works. The dose of TRIKAFTA may need to be adjusted when taken with certain medicines. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Especially tell your healthcare provider if you take: antibiotics such as rifampin (RIFAMATE, RIFATER) or rifabutin (MYCOBUTIN). seizure medicines such as phenobarbital, carbamazepine (TEGRETOL, CARBATROL, EQUETRO), or phenytoin (DILANTIN, PHENYTEK). St. John's wort antifungal medicines including ketoconazole, itraconazole (such as SPORANOX), posaconazole (such as NOXAFIL), voriconazole (such as VFEND), or fluconazole (such as DIFLUCAN). antibiotics including telithromycin, clarithromycin (such as BIAXIN), or erythromycin (such as ERY-TAB). Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take TRIKAFTA? Take TRIKAFTA exactly as your healthcare provider tells you to take it. Take TRIKAFTA by mouth only. TRIKAFTA consists of 2 different doses (a morning dose and an evening dose taken about 12 hours apart). Each dose has different ingredients. Always take TRIKAFTA oral granules or tablets with food that contains fat . Examples of fat-containing foods include butter, oil, eggs, peanut butter, nuts, meat, and whole-milk dairy products such as whole milk, cheese, and yogurt. TRIKAFTA oral granules (age 2 to less than 6 years weighing less than 31 pounds (14 kg)): The white and blue packets each contain the medicines elexacaftor, tezacaftor, and ivacaftor. Take one morning dose packet in the morning. The white and green color packets each contain the medicine ivacaftor. Take one evening dose packet in the evening. TRIKAFTA oral granules (age 2 to less than 6 years weighing 31 pounds (14 kg) or more): The white and orange packets each contain the medicines elexacaftor, tezacaftor, and ivacaftor. Take one morning dose packet in the morning. The white and pink color packets each contain the medicine ivacaftor. Take one evening dose packet in the evening. To prepare TRIKAFTA oral granules: Hold the packet with the cut line on top. Shake the packet gently to settle the TRIKAFTA oral granules. Tear or cut the packet open along the cut line. Carefully pour all the TRIKAFTA oral granules in the packet into 1 teaspoon (5 mL) of soft food or liquid in a small container (like an empty bowl). Look inside the sachet to make sure there are no granules left inside. The food or liquid should be at or below room temperature. Some examples of soft foods or liquids include pureed fruits or vegetables, yogurt, applesauce, water, milk, or juice. Mix the TRIKAFTA granules with food or liquid. After mixing, give TRIKAFTA within 1 hour. Make sure all the medicine is taken. TRIKAFTA tablets (age 6 to less than 12 years weighing less than 66 pounds (30 kg)): The light orange tablet is marked with 'T50' and each tablet contains the medicines elexacaftor, tezacaftor and ivacaftor. Take 2 light orange tablets in the morning. The light blue tablet is marked with 'V 75' and contains the medicine ivacaftor. Take 1 light blue tablet in the evening. TRIKAFTA tablets (age 6 to less than 12 years weighing 66 pounds (30 kg) or more, and age 12 years and older): The orange tablet is marked with 'T100' and each tablet contains the medicines elexacaftor, tezacaftor and ivacaftor. Take 2 orange tablets in the morning. The light blue tablet is marked with 'V 150' and contains the medicine ivacaftor. Take 1 light blue tablet in the evening. Take TRIKAFTA tablets whole. If you miss a dose of TRIKAFTA and: it is 6 hours or less from the time you usually take the morning dose or the evening dose, take the missed dose with food that contains fat as soon as you can. Then take your next dose at your usual time. it is more than 6 hours from the time you usually take the morning dose, take the missed dose with food that contains fat as soon as you can. Do not take the evening dose . it is more than 6 hours from the time you usually take the evening dose, do not take the missed dose . Take your next morning dose at the usual time with food that contains fat. Do not take more than your usual dose of TRIKAFTA to make up for a missed dose. Do not take the morning and evening doses at the same time. If you have liver problems, your healthcare provider may tell you to take TRIKAFTA differently. If you are not sure about your dosing, call your healthcare provider. What should I avoid while taking TRIKAFTA? Avoid food or drink that contains grapefruit while you are taking TRIKAFTA. What are the possible or reasonably likely side effects of TRIKAFTA? TRIKAFTA can cause serious side effects, including: See \" What is the most important information I should know about TRIKAFTA? \" Serious Allergic Reactions can happen to people who are treated with TRIKAFTA. Call your healthcare provider or go to the emergency room right away if you have any symptoms of an allergic reaction. Symptoms of an allergic reaction may include: rash or hives tightness of the chest or throat or difficulty breathing swelling of the face, lips and/or tongue, difficulty swallowing light-headedness or dizziness Increased pressure around the brain (intracranial hypertension) has happened in people treated with TRIKAFTA. If you experience an unusual headache, blurred vision, double vision, or vision loss, call your healthcare provider right away. Serious mental health problems such as anxiety, depression, suicidal thoughts and behaviors, and trouble sleeping have happened in people treated with TRIKAFTA or medicines containing the same or similar ingredients as TRIKAFTA. If you experience new or worsening mental health problems, call your healthcare provider right away. Abnormality of the eye lens (cataract) has happened in some children and adolescents treated with TRIKAFTA. If you are a child or adolescent, your healthcare provider should perform eye examinations before and during treatment with TRIKAFTA to look for cataracts. The most common side effects of TRIKAFTA include: headache upper respiratory tract infection (common cold) including stuffy and runny nose stomach (abdominal) pain diarrhea rash increase in liver enzymes increase in a certain blood enzyme called creatine phosphokinase flu (influenza) inflamed sinuses increase in blood bilirubin constipation Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TRIKAFTA. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TRIKAFTA? Store TRIKAFTA at room temperature between 68ºF to 77ºF (20ºC to 25ºC). Keep TRIKAFTA and all medicines out of the reach of children. General information about the safe and effective use of TRIKAFTA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRIKAFTA for a condition for which it was not prescribed. Do not give TRIKAFTA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TRIKAFTA that is written for health professionals. What are the ingredients in TRIKAFTA? Elexacaftor/tezacaftor/ivacaftor tablets: Active ingredients: elexacaftor, tezacaftor and ivacaftor. Inactive ingredients: croscarmellose sodium, hypromellose, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The tablet film coat contains hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, talc, and titanium dioxide. Ivacaftor tablets: Active ingredients: ivacaftor. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium oxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac. Elexacaftor/tezacaftor/ivacaftor oral granules: Active ingredients: elexacaftor, tezacaftor, and ivacaftor. Inactive ingredients : colloidal silicon dioxide, croscarmellose sodium, hypromellose, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. Ivacaftor oral granules: Active ingredients : ivacaftor. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. Manufactured for: Vertex Pharmaceuticals Incorporated; 50 Northern Avenue, Boston, MA 02210 TRIKAFTA, VERTEX and associated logos are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. ©2026 Vertex Pharmaceuticals Incorporated For more information, go to www.trikafta.com or call 1-877-752-5933."],"boxed_warning":["WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ]. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA . Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating TRIKAFTA. Assess liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Use in Specific Populations (8.7) ] . Interrupt TRIKAFTA for significant elevations in liver function tests or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve, resume treatment only if the benefit is expected to outweigh the risk. Closer monitoring is advised after resuming TRIKAFTA [see Warnings and Precautions (5.1) ] . TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). If used, use with caution at a reduced dosage and monitor patients closely [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , Adverse Reactions (6) , Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE See full prescribing information for complete boxed warning. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Liver failure leading to transplantation and death has been reported. ( 5.1 , 6 ) Assess liver function tests (ALT, AST, alkaline phosphatase, bilirubin) in all patients prior to initiating TRIKAFTA. ( 2.1 , 5.1 ) Monitor liver function tests (ALT, AST, alkaline phosphatase, bilirubin) every month for the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually. ( 2.1 , 5.1 ) Interrupt TRIKAFTA for significant elevations in liver function tests or signs or symptoms of liver injury. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. ( 5.1 ) Resume TRIKAFTA if abnormalities resolve and only if the benefit is expected to outweigh the risk. ( 5.1 ) TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.3 , 5.1 , 8.7 , 12.3 )"],"geriatric_use":["8.5 Geriatric Use Clinical studies of TRIKAFTA did not include any patients aged 65 years and older."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of TRIKAFTA for the treatment of CF have been established in pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Use of TRIKAFTA for this indication for pediatric patients 12 years of age and older was supported by evidence from two adequate and well-controlled studies (Trials 1 and 2) in CF patients aged 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14) ]. Use of TRIKAFTA for this indication in pediatric patients 2 to less than 12 years of age is based on the following: Trial 1, 56 pediatric patients aged 12 to less than 18 years who had an F508del variant on one allele and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor [see Adverse Reactions (6) and Clinical Studies (14) ] . Trial 2, 16 pediatric patients aged 12 to less than 18 years who were homozygous for the F508del variant [see Adverse Reactions (6) and Clinical Studies (14) ] . Trial 3, 66 pediatric patients aged 6 to less than 12 years who were homozygous for the F508del variant or heterozygous for the F508del variant with a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor [see Adverse Reactions (6) and Clinical Pharmacology (12.3) ] . Trial 4, 75 pediatric patients aged 2 to less than 6 years who had at least one F508del variant or a variant known to be responsive to TRIKAFTA [see Adverse Reactions (6) and Clinical Pharmacology (12.3) ]. Trial 5, 64 pediatric patients aged 6 years to less than 18 years who had at least one qualifying non- F508del TRIKAFTA-responsive variant and did not have an exclusionary variant [see Adverse Reactions (6) and Clinical Studies (14.2) ]. The effectiveness of TRIKAFTA in patients aged 2 to less than 12 years was extrapolated from patients aged 12 years and older with support from population pharmacokinetic analyses showing elexacaftor, tezacaftor, and ivacaftor exposure levels in patients aged 2 to less than 12 years within the range of exposures observed in patients aged 12 years and older [see Clinical Pharmacology (12.3) ] . Safety of TRIKAFTA in patients aged 6 to less than 12 years was derived from a 24-week, open-label, clinical trial in 66 patients aged 6 to less than 12 years (mean age at baseline 9.3 years) administered either a total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening (for patients weighing less than 30 kg) or a total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150 mg in the evening (for patients weighing 30 kg or more) (Trial 3). Safety of TRIKAFTA in patients aged 2 to less than 6 years was derived from a 24-week, open-label, clinical trial in 75 patients aged 2 to less than 6 years (mean age at baseline 4.1 years) administered either a total dose of elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg in the morning and ivacaftor 59.5 mg in the evening (for patients weighing 10 kg to less than 14 kg) or a total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening (for patients weighing 14 kg or more) (Trial 4). The safety profile of patients in these trials was similar to that observed in Trial 1 [see Adverse Reactions (6) ]. The safety and effectiveness of TRIKAFTA in patients with CF younger than 2 years of age have not been established. Juvenile Animal Toxicity Data Findings of cataracts were observed in juvenile rats dosed from postnatal Day 7 through 35 with ivacaftor dose levels of 10 mg/kg/day and higher (0.21 times the MRHD based on systemic exposure of ivacaftor and its metabolites). This finding has not been observed in older animals [see Warnings and Precautions (5.7) ] . Studies were conducted with tezacaftor in juvenile rats starting at postnatal day (PND) 21 and ranging up to PNDs 35 to 49. Findings of convulsions and death were observed in juvenile rats that received a tezacaftor dose level of 100 mg/kg/day (approximately equivalent to 1.9 times the MRHD based on summed AUCs of tezacaftor and its metabolite, M1-TEZ). A no-effect dose level was identified at 30 mg/kg/day (approximately equivalent to 0.8 times the MRHD based on summed AUCs of tezacaftor and its metabolite, M1-TEZ). Findings were dose related and generally more severe when dosing with tezacaftor was initiated earlier in the postnatal period (PND 7, which would be approximately equivalent to a human neonate). Tezacaftor and its metabolite, M1-TEZ, are substrates for P-glycoprotein. Lower brain levels of P-glycoprotein activity in younger rats resulted in higher brain levels of tezacaftor and M1-TEZ. These findings are not relevant for the indicated pediatric population, 2 years of age and older, for whom levels of P-glycoprotein activity are equivalent to levels observed in adults."],"effective_time":"20260323","clinical_studies":["14 CLINICAL STUDIES 14.1 Clinical Studies in Patients with Cystic Fibrosis with at Least One F508del Variant The efficacy of TRIKAFTA in patients aged 12 years and older with cystic fibrosis (CF) with at least one F508del variant was evaluated in two randomized, double-blind, controlled trials (Trials 1 and 2). Trial 1 (NCT03525444) was a 24-week, randomized, double-blind, placebo-controlled study in patients who had an F508del variant on one allele and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor. An interim analysis was planned when at least 140 patients completed Week 4 and at least 100 patients completed Week 12. Trial 2 (NCT03525548) was a 4-week, randomized, double-blind, active-controlled study in patients who are homozygous for the F508del variant. Patients received tezacaftor 100 mg qd/ivacaftor 150 mg q12h during a 4-week, open-label run-in period and were then randomized and dosed to receive TRIKAFTA or tezacaftor 100 mg qd/ivacaftor 150 mg q12h during a 4-week, double-blind treatment period. Patients in Trials 1 and 2 had a confirmed diagnosis of CF and at least one F508del variant. Patients discontinued any previous CFTR modulator therapies, but continued on their other standard-of-care CF therapies (e.g., bronchodilators, inhaled antibiotics, dornase alfa and hypertonic saline). Patients had a ppFEV 1 at screening between 40-90%. Patients with a history of colonization with organisms associated with a more rapid decline in pulmonary status, including but not limited to Burkholderia cenocepacia , Burkholderia dolosa , or Mycobacterium abscessus , or who had an abnormal liver function test at screening (ALT, AST, ALP, or GGT ≥3 × ULN, or total bilirubin ≥2 × ULN), were excluded from the trials. Patients in Trials 1 and 2 were eligible to roll over into an open-label extension study. Trial 1 Trial 1 evaluated 403 patients (200 TRIKAFTA, 203 placebo) with CF aged 12 years and older (mean age 26.2 years). The mean ppFEV 1 at baseline was 61.4% (range: 32.3%, 97.1%). The primary endpoint assessed at the time of interim analysis was mean absolute change in ppFEV 1 from baseline at Week 4. The final analysis tested all key secondary endpoints in the 403 patients who completed the 24-week study participation, including absolute change in ppFEV 1 from baseline through Week 24; absolute change in sweat chloride from baseline at Week 4 and through Week 24; number of pulmonary exacerbations through Week 24; absolute change in BMI from baseline at Week 24, and absolute change in CFQ-R respiratory domain score (a measure of respiratory symptoms relevant to patients with CF, such as cough, sputum production and difficulty breathing) from baseline at Week 4 and through Week 24. Of the 403 patients included in the interim analysis, the treatment difference between TRIKAFTA and placebo for the mean absolute change from baseline in ppFEV 1 at Week 4 was 13.8 percentage points (95% CI: 12.1, 15.4; P <0.0001). The treatment difference between TRIKAFTA and placebo for mean absolute change in ppFEV 1 from baseline through Week 24 was 14.3 percentage points (95% CI: 12.7, 15.8; P <0.0001). Mean improvement in ppFEV 1 was observed at the first assessment on Day 15 and sustained through the 24-week treatment period (see Figure 1 ). Improvements in ppFEV 1 were observed regardless of age, baseline ppFEV 1 , sex and geographic region. See Table 11 for a summary of primary and key secondary outcomes in Trial 1. Table 11: Primary and Key Secondary Efficacy Analyses (Trial 1) Analysis Statistic Treatment Difference Treatment difference provided as the outcome measure for changes in ppFEV 1 , sweat chloride, CFQ-R and BMI; Rate ratio provided as the outcome measure for the number of pulmonary exacerbations. for TRIKAFTA (N=200) vs Placebo (N=203) ppFEV 1 : percent predicted Forced Expiratory Volume in 1 second; CI: Confidence Interval; CFQ-R: Cystic Fibrosis Questionnaire-Revised; BMI: Body Mass Index. Primary (Interim Full Analysis Set) Primary endpoint was based on interim analysis in 403 patients. Absolute change in ppFEV 1 from baseline at Week 4 (percentage points) Treatment difference (95% CI) P value 13.8 (12.1, 15.4) P <0.0001 Key Secondary (Full Analysis Set) Key secondary endpoints were tested at the final analysis in 403 patients. Absolute change in ppFEV 1 from baseline through Week 24 (percentage points) Treatment difference (95% CI) P value 14.3 (12.7, 15.8) P <0.0001 Number of pulmonary exacerbations from baseline through Week 24 A pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sino-pulmonary signs/symptoms. Number of pulmonary exacerbation events (event rate per year calculated based on 48 weeks per year) in the TRIKAFTA group were 41 (0.37) and 113 (0.98) in the placebo group. Rate ratio (95% CI) P value 0.37 (0.25, 0.55) P <0.0001 Absolute change in sweat chloride from baseline through Week 24 (mmol/L) Treatment difference (95% CI) P value -41.8 (-44.4, -39.3) P <0.0001 Absolute change in CFQ-R respiratory domain score from baseline through Week 24 (points) Treatment difference (95% CI) P value 20.2 (17.5, 23.0) P <0.0001 Absolute change in BMI from baseline at Week 24 (kg/m 2 ) Treatment difference (95% CI) P value 1.04 (0.85, 1.23) P <0.0001 Absolute change in sweat chloride from baseline at Week 4 (mmol/L) Treatment difference (95% CI) P value -41.2 (-44.0, -38.5) P <0.0001 Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points) Treatment difference (95% CI) P value 20.1 (16.9, 23.2) P <0.0001 Figure 1: Absolute Change from Baseline in Percent Predicted FEV 1 at Each Visit in Trial 1 Figure 1 Trial 2 Trial 2 evaluated 107 patients with CF aged 12 years and older (mean age 28.4 years). The mean ppFEV 1 at baseline, following the 4-week, open-label run-in period with tezacaftor/ivacaftor was 60.9% (range: 35.0%, 89.0%). The primary endpoint was mean absolute change in ppFEV 1 from baseline at Week 4 of the double-blind treatment period. The key secondary efficacy endpoints were absolute change in sweat chloride and CFQ-R respiratory domain score from baseline at Week 4. Treatment with TRIKAFTA compared to tezacaftor/ivacaftor resulted in a statistically significant improvement in ppFEV 1 of 10.0 percentage points (95% CI: 7.4, 12.6; P <0.0001). Mean improvement in ppFEV 1 was observed at the first assessment on Day 15. Improvements in ppFEV 1 were observed regardless of age, sex, baseline ppFEV 1 and geographic region. See Table 12 for a summary of primary and key secondary outcomes. Table 12: Primary and Key Secondary Efficacy Analyses, Full Analysis Set (Trial 2) Analysis Baseline for primary and key secondary endpoints is defined as the end of the 4-week tezacaftor/ivacaftor run-in period. Statistic Treatment Difference for TRIKAFTA (N=55) vs Tezacaftor/Ivacaftor Regimen of tezacaftor 100 mg qd/ivacaftor 150 mg q12h. (N=52) ppFEV 1 : percent predicted Forced Expiratory Volume in 1 second; CI: Confidence Interval; CFQ-R: Cystic Fibrosis Questionnaire-Revised. Primary Absolute change in ppFEV 1 from baseline at Week 4 (percentage points) Treatment difference (95% CI) P value 10.0 (7.4, 12.6) P <0.0001 Key Secondary Absolute change in sweat chloride from baseline at Week 4 (mmol/L) Treatment difference (95% CI) P value -45.1 (-50.1, -40.1) P <0.0001 Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points) Treatment difference (95% CI) P value 17.4 (11.8, 23.0) P <0.0001 14.2 Clinical Studies in Patients with Cystic Fibrosis with at Least One Qualifying Non- F508del Variant The efficacy of TRIKAFTA in patients with cystic fibrosis (CF) without an F508del variant was evaluated in Trial 5. Trial 5 (NCT05274269) was a 24-week, randomized, placebo-controlled, double-blind, parallel-group trial in 307 patients aged 6 years and older with CF (mean age 33.5 years). The mean baseline ppFEV1 was 67.7% (range: 34.0%, 108.7%). The trial included patients who had at least one qualifying non- F508del TRIKAFTA-responsive variant and did not have an exclusionary variant. Patients were randomized to TRIKAFTA or placebo. The dosage of TRIKAFTA was administered according to age and weight as follows: Patients aged 6 to less than 12 years, weighing less than 30 kg: total morning dose of elexacaftor 100 mg/ tezacaftor 50 mg/ ivacaftor 75 mg and evening dose of ivacaftor 75 mg Patients aged 6 to less than 12 years, weighing greater than or equal to 30 kg: total morning dose of elexacaftor 200 mg/ tezacaftor 100 mg/ ivacaftor 150 mg and evening dose of ivacaftor 150 mg Patients aged 12 years and older: total morning dose of elexacaftor 200 mg/ tezacaftor 100 mg/ ivacaftor 150 mg and evening dose of ivacaftor 150 mg Patients discontinued any previous CFTR modulator therapies but continued on their other standard-of-care CF therapies (e.g., bronchodilators, inhaled antibiotics, dornase alfa and hypertonic saline). Patients had a ppFEV 1 between 40-100% at screening. The mean ppFEV 1 at baseline was 68% (range: 34%, 109%). Patients with a history of colonization with organisms associated with a more rapid decline in pulmonary status, including but not limited to Burkholderia cenocepacia , Burkholderia dolosa , or Mycobacterium abscessus , or who had an abnormal liver function test at screening (ALT, AST, ALP, or GGT ≥3 × ULN, or total bilirubin ≥2 × ULN), were excluded from the trials. Patients in Trial 5 were eligible to roll over into an open-label extension study. In Trial 5, the primary efficacy endpoint was absolute change in ppFEV 1 from baseline through Week 24. Secondary efficacy endpoints were absolute change in sweat chloride through Week 24, absolute change in CFQ-R respiratory domain score through Week 24, absolute change in growth parameters (BMI, weight) at Week 24, and number of pulmonary exacerbation events through Week 24. Table 13 provides a summary of the primary and secondary efficacy results. Table 13: Primary and Secondary Efficacy Analyses, Full Analysis Set (Trial 5) Analysis Statistic Treatment Difference Treatment difference was provided as the outcome measure for changes in ppFEV 1 , sweat chloride, CFQ-R RD and BMI; Rate ratio provided as the outcome measure for the number of pulmonary exacerbations. for TRIKAFTA (N=205) vs Placebo (N=102) BMI: body mass index; CFQ-R: Cystic Fibrosis Questionnaire-Revised; CI: confidence interval; N: total sample size; P : probability; ppFEV 1 : percent predicted forced expiratory volume in 1 second. Primary Absolute change in ppFEV 1 from baseline through Week 24 (percentage points) Treatment difference (95% CI) P value 9.2 (7.2, 11.3) P <0.0001 Secondary Absolute change in sweat chloride from baseline through Week 24 (mmol/L) Treatment difference (95% CI) P value -28.3 (-32.1, -24.5) P <0.0001 Absolute change in CFQ-R respiratory domain score from baseline through Week 24 (points) Treatment difference (95% CI) P value 19.5 (15.5, 23.5) P <0.0001 Absolute change from baseline in BMI at Week 24 (kg/m 2 ) Treatment difference (95% CI) P value 0.47 (0.24, 0.69) P <0.0001 Absolute change from baseline in weight at Week 24 (kg) Treatment difference (95% CI) P value 1.3 (0.6, 1.9) P <0.0001 Number of pulmonary exacerbations through Week 24 Number of pulmonary exacerbation events (event rate per year calculated based on 48 weeks per year) in the TRIKAFTA group were 21 (0.17) and in the placebo group were 40 (0.63). Rate ratio (95% CI) P value 0.28 (0.15, 0.51) P <0.0001"],"pharmacodynamics":["12.2 Pharmacodynamics Sweat Chloride Evaluation In Trial 1 (patients with an F508del variant on one allele and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive ivacaftor and tezacaftor/ivacaftor), a reduction in sweat chloride was observed from baseline at Week 4 and sustained through the 24-week treatment period [see Clinical Studies (14.1) ] . In Trial 2 (patients homozygous for the F508del variant), a reduction in sweat chloride was observed from baseline at Week 4 [see Clinical Studies (14.2) ] . In Trial 3 (patients aged 6 to less than 12 years who are homozygous for the F508del variant or heterozygous for the F508del variant and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor), the mean absolute change in sweat chloride from baseline through Week 24 was -60.9 mmol/L (95% CI: -63.7, -58.2). In Trial 4 (patients aged 2 to less than 6 years who had at least one F508del variant or a variant known to be responsive to TRIKAFTA), the mean absolute change in sweat chloride from baseline through Week 24 was -57.9 mmol/L (95% CI: -61.3, -54.6). In Trial 5 (patients aged 6 years and older with at least one qualifying non- F508del elexacaftor/tezacaftor/ivacaftor-responsive CFTR variant), the mean absolute change in sweat chloride from baseline through Week 24 compared to placebo was -28.3 mmol/L (95% CI: -32.1, -24.5). Cardiac Electrophysiology At doses up to 2 times the maximum recommended dose of elexacaftor and 3 times the maximum recommended dose of tezacaftor and ivacaftor, the QT/QTc interval in healthy subjects was not prolonged to any clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of elexacaftor, tezacaftor and ivacaftor are similar between healthy adult subjects and patients with CF. The pharmacokinetic parameters for elexacaftor, tezacaftor and ivacaftor in patients with CF aged 12 years and older are shown in Table 7. Table 7: Pharmacokinetic Parameters of TRIKAFTA Components Elexacaftor Tezacaftor Ivacaftor AUC ss : area under the concentration versus time curve at steady state; SD: Standard Deviation; C max : maximum observed concentration; T max : time of maximum concentration; AUC: area under the concentration versus time curve. General Information AUC ss (SD), mcg∙h/mL Based on elexacaftor 200 mg and tezacaftor 100 mg once daily/ivacaftor 150 mg every 12 hours at steady state in patients with CF aged 12 years and older. 162 (47.5) AUC 0-24h . 89.3 (23.2) 11.7 (4.01) AUC 0-12h . C max (SD), mcg/mL 9.2 (2.1) 7.7 (1.7) 1.2 (0.3) Time to Steady State, days Within 7 days Within 8 days Within 3-5 days Accumulation Ratio 2.2 2.07 2.4 Absorption Absolute Bioavailability 80% Not determined Not determined Median T max (range), hours 6 (4 to 12) 3 (2 to 4) 4 (3 to 6) Effect of Food AUC increases 1.9- to 2.5-fold (moderate-fat meal) No clinically significant effect Exposure increases 2.5- to 4-fold Distribution Mean (SD) Apparent Volume of Distribution, L Elexacaftor, tezacaftor and ivacaftor do not partition preferentially into human red blood cells. 53.7 (17.7) 82.0 (22.3) 293 (89.8) Protein Binding Elexacaftor and tezacaftor bind primarily to albumin. Ivacaftor primarily bind to albumin, alpha 1-acid glycoprotein and human gamma-globulin. >99% approximately 99% approximately 99% Elimination Mean (SD) Effective Half-Life, hours Mean (SD) terminal half-lives of elexacaftor, tezacaftor and ivacaftor are approximately 24.7 (4.87) hours, 60.3 (15.7) hours and 13.1 (2.98) hours, respectively. 27.4 (9.31) 25.1 (4.93) 15.0 (3.92) Mean (SD) Apparent Clearance, L/hours 1.18 (0.29) 0.79 (0.10) 10.2 (3.13) Metabolism Primary Pathway CYP3A4/5 CYP3A4/5 CYP3A4/5 Active Metabolites M23-ELX M1-TEZ M1-IVA Metabolite Potency Relative to Parent Similar Similar approximately 1/6 th of parent Excretion Following radiolabeled doses. Primary Pathway Feces: 87.3% (primarily as metabolites) Urine: 0.23% Feces: 72% (unchanged or as M2-TEZ) Urine: 14% (0.79% unchanged) Feces: 87.8% Urine: 6.6% Specific Populations Pediatric Patients 2 to Less Than 12 Years of Age Elexacaftor, tezacaftor and ivacaftor exposures observed in patients aged 2 to less than 12 years as determined using population PK analysis are presented by age group and dose administered in Table 8. Elexacaftor, tezacaftor and ivacaftor exposures in this patient population are within the range observed in patients aged 12 years and older. Table 8: Mean (SD) Elexacaftor, Tezacaftor and Ivacaftor Exposures Observed at Steady State by Age Group and Dose Administered Age Group Dose Elexacaftor AUC 0-24h,ss (µg∙h/mL) Tezacaftor AUC 0-24h,ss (µg∙h/mL) Ivacaftor AUC 0-12h,ss (µg∙h/mL) SD: Standard Deviation; AUC ss : area under the concentration versus time curve at steady state. Patients aged 2 to less than 6 years weighing less than 14 kg (N = 16) elexacaftor 80 mg qd/tezacaftor 40 mg qd/ivacaftor 60 mg qAM and ivacaftor 59.5 mg qPM 128 (24.8) 87.3 (17.3) 11.9 (3.86) Patients aged 2 to less than 6 years weighing 14 kg or more (N = 59) elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h 138 (47.0) 90.2 (27.9) 13.0 (6.11) Patients aged 6 to less than 12 years weighing less than 30 kg (N = 36) elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h 116 (39.4) 67.0 (22.3) 9.78 (4.50) Patients aged 6 to less than 12 years weighing 30 kg or more (N = 30) elexacaftor 200 mg qd/ tezacaftor 100 mg qd/ ivacaftor 150 mg q12h 195 (59.4) 103 (23.7) 17.5 (4.97) Pediatric Patients 12 to Less Than 18 Years of Age The following conclusions about exposures between adults and the pediatric population are based on population pharmacokinetic (PK) analyses. Following oral administration of TRIKAFTA to patients 12 to less than 18 years of age (elexacaftor 200 mg qd/tezacaftor 100 mg qd/ivacaftor 150 mg q12h), the mean (±SD) AUC ss was 147 (36.8) mcg∙h/mL, 88.8 (21.8) mcg∙h/mL and 10.6 (3.35) mcg∙h/mL, respectively for elexacaftor, tezacaftor and ivacaftor, similar to the AUC ss in adult patients. Patients with Renal Impairment Renal excretion of elexacaftor, tezacaftor and ivacaftor is minimal. Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in subjects with severe (eGFR <30 mL/min/1.73 m 2 ) renal impairment or end-stage renal disease. Based on population PK analyses, the clearance of elexacaftor and tezacaftor was similar in subjects with mild (eGFR 60 to <90 mL/min/1.73 m 2 ) or moderate (eGFR 30 to <60 mL/min/1.73 m 2 ) renal impairment relative to patients with normal renal function [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in subjects with severe hepatic impairment (Child-Pugh Class C, score 10-15). In a clinical study, following multiple doses of elexacaftor, tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7-9) had 25% higher AUC and 12% higher C max for elexacaftor, 73% higher AUC and 70% higher C max for M23-ELX, 36% higher AUC and 24% higher C max for combined elexacaftor and M23-ELX, 20% higher AUC but similar C max for tezacaftor and 1.5-fold higher AUC and 10% higher C max for ivacaftor compared with healthy subjects matched for demographics [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Use in Specific Populations (8.7) ] . Tezacaftor and Ivacaftor Following multiple doses of tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function had an approximately 36% higher AUC and a 10% higher in C max for tezacaftor and a 1.5-fold higher AUC but similar C max for ivacaftor compared with healthy subjects matched for demographics. Ivacaftor In a study with ivacaftor alone, subjects with moderately impaired hepatic function had similar ivacaftor C max , but an approximately 2.0-fold higher ivacaftor AUC 0-∞ compared with healthy subjects matched for demographics. Male and Female Patients Based on population PK analysis, the exposures of elexacaftor, tezacaftor and ivacaftor are similar in males and females. Drug Interaction Studies Drug interaction studies were performed with elexacaftor, tezacaftor and/or ivacaftor and other drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interaction studies [see Drug Interactions (7) ] . Potential for Elexacaftor, Tezacaftor and/or Ivacaftor to Affect Other Drugs Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, whereas ivacaftor has the potential to inhibit CYP2C8, CYP2C9 and CYP3A. However, clinical studies showed that the combination regimen of tezacaftor/ivacaftor is not an inhibitor of CYP3A and ivacaftor is not an inhibitor of CYP2C8 or CYP2D6. Based on in vitro results, elexacaftor, tezacaftor and ivacaftor are not likely to induce CYP3A, CYP1A2 and CYP2B6. Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit the transporter P-gp, while ivacaftor has the potential to inhibit P-gp. Co-administration of tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold in a clinical study. Based on in vitro results, elexacaftor and M23-ELX may inhibit OATP1B1 and OATP1B3 uptake. Tezacaftor has a low potential to inhibit BCRP, OCT2, OAT1, or OAT3. Ivacaftor is not an inhibitor of the transporters OCT1, OCT2, OAT1, or OAT3. The effects of elexacaftor, tezacaftor and/or ivacaftor on the exposure of co-administered drugs are shown in Table 9 [see Drug Interactions (7) ] . Table 9: Impact of Elexacaftor, Tezacaftor and/or Ivacaftor on Other Drugs Dose and Schedule Effect on Other Drug PK Geometric Mean Ratio (90% CI) of Other Drug No Effect=1.0 AUC C max ↑ = increase, ↓ = decrease, ↔ = no change. AUC: area under the concentration versus time curve; CI: Confidence Interval; ELX: elexacaftor; C max : maximum observed concentration; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics. Midazolam 2 mg single oral dose TEZ 100 mg qd/IVA 150 mg q12h ↔ Midazolam 1.12 (1.01, 1.25) 1.13 (1.01, 1.25) Digoxin 0.5 mg single dose TEZ 100 mg qd/IVA 150 mg q12h ↑ Digoxin 1.30 (1.17, 1.45) 1.32 (1.07, 1.64) Oral Contraceptive Ethinyl estradiol 30 µg/Levonorgestrel 150 µg qd ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h ↑ Ethinyl estradiol Effect is not clinically significant [see Drug Interactions (7.3) ] . 1.33 (1.20, 1.49) 1.26 (1.14, 1.39) ↑ Levonorgestrel 1.23 (1.10, 1.37) 1.10 (0.985, 1.23) Rosiglitazone 4 mg single oral dose IVA 150 mg q12h ↔ Rosiglitazone 0.975 (0.897, 1.06) 0.928 (0.858, 1.00) Desipramine 50 mg single dose IVA 150 mg q12h ↔ Desipramine 1.04 (0.985, 1.10) 1.00 (0.939, 1.07) Potential for Other Drugs to Affect Elexacaftor, Tezacaftor and/or Ivacaftor In vitro studies showed that elexacaftor, tezacaftor and ivacaftor are all metabolized by CYP3A. Exposure to elexacaftor, tezacaftor and ivacaftor may be reduced by concomitant CYP3A inducers and increased by concomitant CYP3A inhibitors. In vitro studies showed that elexacaftor and tezacaftor are substrates for the efflux transporter P-gp, but ivacaftor is not. Elexacaftor and ivacaftor are not substrates for OATP1B1 or OATP1B3; tezacaftor is a substrate for OATP1B1, but not OATP1B3. Tezacaftor is a substrate for BCRP. The effects of co-administered drugs on the exposure of elexacaftor, tezacaftor and/or ivacaftor are shown in Table 10 [see Dosage and Administration (2.4) and Drug Interactions (7) ] . Table 10: Impact of Other Drugs on Elexacaftor, Tezacaftor and/or Ivacaftor Dose and Schedule Effect on ELX, TEZ and/or IVA PK Geometric Mean Ratio (90% CI) of Elexacaftor, Tezacaftor and Ivacaftor No Effect = 1.0 AUC C max ↑ = increase, ↓ = decrease, ↔ = no change. AUC: area under the concentration versus time curve; CI: Confidence Interval; C max : maximum observed concentration; ELX: elexacaftor; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics. Itraconazole 200 mg q12h on Day 1, followed by 200 mg qd TEZ 25 mg qd + IVA 50 mg qd ↑ Tezacaftor 4.02 (3.71, 4.63) 2.83 (2.62, 3.07) ↑ Ivacaftor 15.6 (13.4, 18.1) 8.60 (7.41, 9.98) Itraconazole 200 mg qd ELX 20 mg + TEZ 50 mg single dose ↑ Elexacaftor 2.83 (2.59, 3.10) 1.05 (0.977, 1.13) ↑ Tezacaftor 4.51 (3.85, 5.29) 1.48 (1.33, 1.65) Ketoconazole 400 mg qd IVA 150 mg single dose ↑ Ivacaftor 8.45 (7.14, 10.0) 2.65 (2.21, 3.18) Ciprofloxacin 750 mg q12h TEZ 50 mg q12h + IVA 150 mg q12h ↔ Tezacaftor 1.08 (1.03, 1.13) 1.05 (0.99, 1.11) ↑ Ivacaftor Effect is not clinically significant [see Drug Interactions (7.3) ] . 1.17 (1.06, 1.30) 1.18 (1.06, 1.31) Rifampin 600 mg qd IVA 150 mg single dose ↓ Ivacaftor 0.114 (0.097, 0.136) 0.200 (0.168, 0.239) Fluconazole 400 mg single dose on Day 1, followed by 200 mg qd IVA 150 mg q12h ↑ Ivacaftor 2.95 (2.27, 3.82) 2.47 (1.93, 3.17)"],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Drug-Induced Liver Injury and Liver Failure [see Warnings and Precautions (5.1) ] Hypersensitivity Reactions, Including Anaphylaxis [see Warnings and Precautions (5.2) ] Intracranial Hypertension [see Warnings and Precautions (5.3) ] Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors [see Warnings and Precautions (5.4) ] Cataracts [see Warnings and Precautions (5.7) ] The most common adverse drug reactions to TRIKAFTA (≥5% of patients and at a frequency higher than placebo by ≥1%) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vertex Pharmaceuticals Incorporated at 1-877-634-8789 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Patients with Cystic Fibrosis with at Least One F508del Variant The safety profile of TRIKAFTA in patients with CF with at least one F508del variant is based on data from 510 patients aged 12 years and older in two double-blind, controlled trials of 24 weeks and 4 weeks treatment duration (Trials 1 and 2, respectively). Eligible patients were also able to participate in an open-label extension safety study (up to 96 weeks of TRIKAFTA). In the two controlled trials, a total of 257 patients aged 12 years and older received at least one dose of TRIKAFTA. In Trial 1, the proportion of patients who discontinued study drug prematurely due to adverse events was 1% for TRIKAFTA-treated patients and 0% for placebo-treated patients. In Trial 1, serious adverse reactions that occurred more frequently in TRIKAFTA-treated patients compared to placebo were rash (1% vs <1%) and influenza (1% vs 0%). There were no deaths. Table 4 shows adverse reactions occurring in ≥5% of TRIKAFTA-treated patients and higher than placebo by ≥1% in the 24-week, placebo-controlled, parallel-group trial (Trial 1). Table 4: Adverse Reactions Occurring in ≥5% of TRIKAFTA-Treated Patients and Higher than Placebo by ≥1% in Trial 1 Adverse Reactions TRIKAFTA N=202 n (%) Placebo N=201 n (%) Headache 35 (17) 30 (15) Upper respiratory tract infection Includes upper respiratory tract infection and viral upper respiratory tract infection. 32 (16) 25 (12) Abdominal pain Includes abdominal pain, abdominal pain upper, abdominal pain lower. 29 (14) 18 (9) Diarrhea 26 (13) 14 (7) Rash Includes rash, rash generalized, rash erythematous, rash macular, rash pruritic. 21 (10) 10 (5) Alanine aminotransferase increased 20 (10) 7 (3) Nasal congestion 19 (9) 15 (7) Blood creatine phosphokinase increased 19 (9) 9 (4) Aspartate aminotransferase increased 19 (9) 4 (2) Rhinorrhea 17 (8) 6 (3) Rhinitis 15 (7) 11 (5) Influenza 14 (7) 3 (1) Sinusitis 11 (5) 8 (4) Blood bilirubin increased 10 (5) 2 (1) Additional adverse reactions that occurred in TRIKAFTA-treated patients at a frequency of 2% to <5% and higher than placebo by ≥1% include the following: flatulence, abdominal distension, conjunctivitis, pharyngitis, respiratory tract infection, tonsillitis, urinary tract infection, C-reactive protein increased, hypoglycemia, dizziness, dysmenorrhea, acne, eczema and pruritus. In addition, the following clinical trials have also been conducted [see Use in Specific Populations (8.4) , Clinical Pharmacology (12.3) and Clinical Studies (14) ]: a 24-week, open-label trial in 66 patients with CF aged 6 to less than 12 years who were either homozygous for the F508del variant or heterozygous for the F508del variant, and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor (Trial 3). a 24-week, open-label trial in 75 patients with CF aged 2 to less than 6 years. Patients who had at least one F508del variant or a variant known to be responsive to TRIKAFTA were eligible for the study (Trial 4). The safety profile for the CF patients enrolled in Trials 2, 3, and 4 was consistent to that observed in Trial 1. Patients with Cystic Fibrosis with at Least One Qualifying Non- F508del Variant The safety of TRIKAFTA in patients with CF with at least one non- F508del variant is based on data from 307 patients aged 6 years and older with at least one qualifying non- F508del CFTR variant that was TRIKAFTA-responsive. Trial 5 was a randomized, double blind, placebo-controlled trial for a 24-week treatment duration in which 205 patients received at least one dose of TRIKAFTA. Eligible patients were also able to participate in an open-label extension safety study. In Trial 5, the proportion of patients who discontinued study drug prematurely due to adverse reactions was 2% for TRIKAFTA-treated patients and 0% for placebo-treated patients. Table 5 shows adverse reactions occurring in ≥5% of TRIKAFTA-treated patients and higher than placebo by ≥1% in the 24-week, placebo-controlled, parallel-group trial (Trial 5). Table 5: Adverse Reactions Occurring in ≥5% of TRIKAFTA-Treated Patients and Higher than Placebo by ≥1% in Trial 5 Adverse Reactions TRIKAFTA N=205 n (%) Placebo N=102 n (%) Rash Includes rash, rash maculo-papular, rash erythematous, rash papular 48 (23) 2 (2) Headache 37 (18) 13 (13) Diarrhea 26 (13) 10 (10) Rhinitis 20 (10) 6 (6) Influenza 18 (9) 2 (2) Constipation 15 (7) 4 (4) Specific Adverse Reactions Liver Function Test Elevations In Trial 1, the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 × ULN was 1%, 2%, and 8% in TRIKAFTA-treated patients and 1%, 1%, and 5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations (AST and/or ALT) was 11% in TRIKAFTA-treated patients and 4% in placebo-treated patients. In Trial 1, the incidence of maximum total bilirubin elevation >2 × ULN was 4% in TRIKAFTA-treated patients and <1% in placebo-treated patients. Maximum indirect and direct bilirubin elevations >1.5 × ULN occurred in 11% and 3% of TRIKAFTA-treated patients, respectively. No TRIKAFTA-treated patients developed maximum direct bilirubin elevation >2 × ULN. During Trial 3, in patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT or AST) >8, >5, and >3 × ULN were 0%, 1.5%, and 10.6%, respectively. No TRIKAFTA-treated patients had transaminase elevation >3 × ULN associated with elevated total bilirubin >2 × ULN or discontinued treatment due to transaminase elevations. During Trial 4 in patients aged 2 to less than 6 years, the incidence of maximum transaminase (ALT or AST) >8, >5, and >3 × ULN were 1.3%, 2.7%, and 8.0%, respectively. No TRIKAFTA-treated patients had transaminase elevation >3 × ULN associated with elevated total bilirubin >2 × ULN. One patient required treatment interruption during Trial 4 and later discontinued TRIKAFTA during the open label extension due to transaminase elevations. In Trial 5, the incidence of maximum transaminase (ALT or AST) >8, >5, and >3 × ULN were 2.0%, 2.0%, and 6.3%, respectively, and led to treatment discontinuation in 0.5% and treatment interruptions in 1.5% of TRIKAFTA-treated patients. There were no transaminase elevations >3 × ULN in placebo-treated patients. Rash In Trial 1, the overall incidence of rash was 10% in TRIKAFTA-treated and 5% in placebo-treated patients (see Table 4 ). The incidence of rash was higher in female TRIKAFTA-treated patients (16%) than in male TRIKAFTA-treated patients (5%). In Trial 5, the overall incidence of rash was 23% in TRIKAFTA-treated and 2% in placebo-treated patients (see Table 5 ). The incidence of rash was higher in female TRIKAFTA-treated patients (27%) than in male TRIKAFTA-treated patients (20%). A role of hormonal contraceptives in the occurrence of rash cannot be excluded [see Drug Interactions (7.3) ] . Increased Creatine Phosphokinase In Trial 1, the incidence of maximum creatine phosphokinase elevation >5 × ULN was 10% in TRIKAFTA-treated and 5% in placebo-treated patients. Among the TRIKAFTA-treated patients with creatine phosphokinase elevation >5 × ULN, 14% (3/21) required treatment interruption and none discontinued treatment. In Trial 5, the incidence of maximum creatine phosphokinase elevation >5 × ULN was 5.4% (11/205) in TRIKAFTA-treated patients and 1% (1/102) in placebo-treated patients. The incidence of maximum creatine phosphokinase elevation >10 × ULN was 2.4% (5/205) in TRIKAFTA-treated patients and 1% (1/102) in placebo-treated patients. There were no interruptions or discontinuations among the TRIKAFTA-treated patients with creatine phosphokinase elevation >5 × ULN. Among the TRIKAFTA-treated patients with creatine phosphokinase elevation > 10 × ULN, two patients, who had exercised within the preceding 72 hours, developed rhabdomyolysis without evidence of renal involvement resulting in treatment interruption in 1 patient. Increased Blood Pressure In Trial 1, the maximum increase from baseline in mean systolic and diastolic blood pressure was 3.5 mmHg and 1.9 mmHg, respectively for TRIKAFTA-treated patients (baseline: 113 mmHg systolic and 69 mmHg diastolic) and 0.9 mmHg and 0.5 mmHg, respectively for placebo-treated patients (baseline: 114 mmHg systolic and 70 mmHg diastolic). The proportion of patients who had systolic blood pressure >140 mmHg and 10 mmHg increase from baseline on at least two occasions was 4% in TRIKAFTA-treated patients and 1% in placebo-treated patients. The proportion of patients who had diastolic blood pressure >90 mmHg and 5 mmHg increase from baseline on at least two occasions was 1% in TRIKAFTA-treated patients and 2% in placebo-treated patients. With the exception of sex differences in rash, the safety profile of TRIKAFTA was generally similar across all subgroups of patients, including analysis by age, sex, baseline percent predicted FEV 1 (ppFEV 1 ) and geographic regions. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of TRIKAFTA or drugs containing the same or similar active ingredients as TRIKAFTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hepatobiliary : liver injury, fatal liver failure, liver transplantation Immune System Disorders : anaphylaxis, angioedema Nervous System Disorders : intracranial hypertension Psychiatric Disorders : anxiety, depression, suicidal ideation and behavior, insomnia"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"middle\"/><tbody><tr><td><renderMultiMedia referencedObject=\"MM1\"/></td></tr></tbody></table>","<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"middle\"/><tbody><tr><td><renderMultiMedia referencedObject=\"MM2\"/></td></tr></tbody></table>","<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"middle\"/><tbody><tr><td><renderMultiMedia referencedObject=\"MM3\"/></td></tr></tbody></table>"],"drug_interactions":["7 DRUG INTERACTIONS Strong CYP3A inducers: Avoid concomitant use. ( 5.5 , 7.1 , 12.3 ) Strong or moderate CYP3A inhibitors: Reduce TRIKAFTA dosage when used concomitantly. Avoid food or drink containing grapefruit. ( 2.4 , 5.6 , 7.1 , 12.3 ) 7.1 Effect of Other Drugs and Grapefruit on TRIKAFTA Strong CYP3A Inducers Concomitant use of TRIKAFTA with strong CYP3A inducers is not recommended. Elexacaftor, tezacaftor and ivacaftor are substrates of CYP3A (ivacaftor is a sensitive substrate of CYP3A). Concomitant use of CYP3A inducers may result in reduced exposures and thus reduced TRIKAFTA efficacy [see Warnings and Precautions (5.5) ] . Concomitant use of ivacaftor with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor area under the curve (AUC) by 89%. Elexacaftor and tezacaftor exposures are expected to decrease during concomitant use with strong CYP3A inducers [see Clinical Pharmacology (12.3) ] . Examples of strong CYP3A inducers include: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John's wort ( Hypericum perforatum ) Strong or Moderate CYP3A Inhibitors The dosage of TRIKAFTA should be reduced when used concomitantly with strong CYP3A inhibitors [see Dosage and Administration (2.4) and Warnings and Precautions (5.6) ] . Concomitant use with itraconazole, a strong CYP3A inhibitor, increased elexacaftor AUC by 2.8-fold and tezacaftor AUC by 4.0- to 4.5-fold. When used concomitantly with itraconazole and ketoconazole, ivacaftor AUC increased by 15.6-fold and 8.5-fold, respectively [see Clinical Pharmacology (12.3) ] . Examples of strong CYP3A inhibitors include: ketoconazole, itraconazole, posaconazole and voriconazole telithromycin and clarithromycin The dosage of TRIKAFTA should be reduced when used concomitantly with moderate CYP3A inhibitors [see Dosage and Administration (2.4) and Warnings and Precautions (5.6) ]. Simulations indicated that concomitant use with moderate CYP3A inhibitors may increase elexacaftor and tezacaftor AUC by approximately 1.9- to 2.3-fold and 2.1-fold, respectively. Concomitant use of fluconazole increased ivacaftor AUC by 2.9-fold [see Clinical Pharmacology (12.3) ] . Examples of moderate CYP3A inhibitors include: fluconazole erythromycin Grapefruit Concomitant use of TRIKAFTA with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of elexacaftor, tezacaftor and ivacaftor; therefore, food or drink containing grapefruit should be avoided during treatment with TRIKAFTA [see Dosage and Administration (2.4) ] . 7.2 Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . Transporters Concomitant use of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. Administration of TRIKAFTA may increase systemic exposure of medicinal products that are sensitive substrates of P-gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . Elexacaftor and M23-ELX inhibit uptake by OATP1B1 and OATP1B3 in vitro. Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. When used concomitantly with substrates of OATP1B1 or OATP1B3, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . Bilirubin is an OATP1B1 and OATP1B3 substrate. 7.3 Drugs with No Clinically Significant Interactions with TRIKAFTA Ciprofloxacin Ciprofloxacin had no clinically relevant effect on the exposure of tezacaftor or ivacaftor and is not expected to affect the exposure of elexacaftor. Therefore, no dose adjustment is necessary during concomitant administration of TRIKAFTA with ciprofloxacin [see Clinical Pharmacology (12.3) ] . Hormonal Contraceptives TRIKAFTA has been studied with ethinyl estradiol/levonorgestrel and was found to have no clinically relevant effect on the exposures of the oral contraceptive. TRIKAFTA is not expected to have an impact on the efficacy of oral contraceptives. Hormonal contraceptives may play a role in the occurrence of rash and cannot be excluded [see Adverse Reactions (6.1) ] . For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. Following the resolution of rash, consider resuming TRIKAFTA without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered."],"how_supplied_table":["<table width=\"80%\"><caption>Table 14: TRIKAFTA Tablets and Package Configuration</caption><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Strengths</th><th styleCode=\"Rrule\" align=\"center\">Tablet Description</th><th styleCode=\"Rrule\" align=\"center\">Package Configuration</th><th styleCode=\"Rrule\" align=\"center\">NDC</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Elexacaftor 50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg tablets</td><td styleCode=\"Rrule\">light orange, oblong-shaped, debossed with &quot;T50&quot; on one side and plain on the other </td><td styleCode=\"Rrule\" rowspan=\"2\">84-count carton containing 4 wallets, each wallet containing 14 tablets of elexacaftor, tezacaftor and ivacaftor, and 7 tablets of ivacaftor</td><td styleCode=\"Rrule\" rowspan=\"2\">NDC 51167-106-02</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Ivacaftor 75 mg</td><td styleCode=\"Rrule\">light blue, film-coated, oblong-shaped, printed with the characters &quot;V 75&quot; in black ink on one side and plain on the other</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg</td><td styleCode=\"Rrule\">orange, oblong-shaped, debossed with &quot;T100&quot; on one side and plain on the other</td><td styleCode=\"Rrule\" rowspan=\"2\">84-count carton containing 4 wallets, each wallet containing 14 tablets of elexacaftor, tezacaftor and ivacaftor, and 7 tablets of ivacaftor</td><td styleCode=\"Rrule\" rowspan=\"2\">NDC 51167-331-01</td></tr><tr><td styleCode=\"Lrule Rrule\">Ivacaftor 150 mg</td><td styleCode=\"Rrule\">light blue, film-coated, oblong-shaped, printed with the characters &quot;V 150&quot; in black ink on one side and plain on the other</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 15: TRIKAFTA Oral Granules and Package Configuration</caption><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"left\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Strengths</th><th styleCode=\"Rrule\" align=\"center\">Granule Description</th><th styleCode=\"Rrule\" align=\"center\">Package Configuration</th><th styleCode=\"Rrule\" align=\"center\">NDC</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg</td><td styleCode=\"Rrule\">white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and blue unit-dose packets </td><td styleCode=\"Rrule\" rowspan=\"2\">56-count carton containing 4 wallets, each wallet containing 7 white and blue packets of elexacaftor, tezacaftor and ivacaftor, and 7 white and green packets of ivacaftor</td><td styleCode=\"Rrule\" rowspan=\"2\">NDC 51167-445-01</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Ivacaftor 59.5 mg</td><td styleCode=\"Rrule\">white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and green unit-dose packets</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg</td><td styleCode=\"Rrule\">white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and orange unit-dose packets</td><td styleCode=\"Rrule\" rowspan=\"2\">56-count carton containing 4 wallets, each wallet containing 7 white and orange packets of elexacaftor, tezacaftor and ivacaftor, and 7 white and pink packets of ivacaftor</td><td styleCode=\"Rrule\" rowspan=\"2\">NDC 51167-446-01</td></tr><tr><td styleCode=\"Lrule Rrule\">Ivacaftor 75 mg</td><td styleCode=\"Rrule\">white to off-white, sweetened, unflavored granules approximately 2 mm in diameter enclosed in white and pink unit-dose packets</td></tr></tbody></table>"],"spl_medguide_table":["<table width=\"100%\"><col width=\"1%\" align=\"left\" valign=\"top\"/><col width=\"60%\" align=\"left\" valign=\"top\"/><col width=\"39%\" align=\"left\" valign=\"top\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\" valign=\"top\">Revised: 03/2026 </td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\" align=\"center\"><content styleCode=\"bold\">MEDICATION GUIDE TRIKAFTA<sup>&#xAE;</sup> (tri-KAF-tuh)</content> (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use  (elexacaftor, tezacaftor, and ivacaftor oral granules; ivacaftor oral granules), co-packaged</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\"><paragraph ID=\"whatis\"><content styleCode=\"bold\">What is the most important information I should know about TRIKAFTA? TRIKAFTA can cause serious liver damage and liver failure.</content> Liver failure leading to transplantation and death have been seen in some people with or without a history of liver problems taking TRIKAFTA.</paragraph> Your healthcare provider will do blood tests to check your liver:<list listType=\"unordered\" styleCode=\"circle\"><item>before you start TRIKAFTA</item><item>then every month during your first 6 months of taking TRIKAFTA</item><item>then every 3 months during the next 12 months of taking TRIKAFTA</item><item>then at least every year while you are taking TRIKAFTA</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\">Your healthcare provider may do blood tests to check the liver more often if you have had high liver enzymes in your blood in the past or are experiencing signs or symptoms of liver injury. Stop taking TRIKAFTA and call your healthcare provider right away if you have any of the following symptoms of liver problems:</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"circle\"><item>pain, swelling, or discomfort in the upper right stomach (abdominal) area</item><item>yellowing of your skin or the white part of your eyes</item><item>mental changes</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>nausea or vomiting</item><item>dark, amber-colored urine</item><item>loss of appetite</item><item>have fluid in your stomach area (ascites)</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What is TRIKAFTA?</content><list listType=\"unordered\"><item>TRIKAFTA is a prescription medicine for people aged 2 years and older who have a diagnosis of cystic fibrosis (CF) and who have at least one genetic change (variant) in the cystic fibrosis transmembrane conductance regulator (<content styleCode=\"italics\">CFTR</content>) gene that is either responsive to TRIKAFTA or results in the production of protein.</item><item>Talk to your healthcare provider to learn if you have an indicated CF gene variant.</item></list>It is not known if TRIKAFTA is safe and effective in children under 2 years of age.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What should I tell my healthcare provider before taking TRIKAFTA? Before taking TRIKAFTA, tell your healthcare provider about all of your medical conditions, including if you:</content><list listType=\"unordered\"><item>have or have had liver problems.</item><item>are allergic to TRIKAFTA or any ingredients in TRIKAFTA. See the end of this Medication Guide for a complete list of ingredients in TRIKAFTA.</item><item>have kidney problems.</item><item>have or have had mental health problems.</item><item>are pregnant or plan to become pregnant. It is not known if TRIKAFTA will harm your unborn baby. You and your healthcare provider should decide if you will take TRIKAFTA while you are pregnant.</item><item>are breastfeeding or planning to breastfeed. It is not known if TRIKAFTA passes into your breast milk. You and your healthcare provider should decide if you will take TRIKAFTA while you are breastfeeding.</item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRIKAFTA may affect the way other medicines work and other medicines may affect how TRIKAFTA works. The dose of TRIKAFTA may need to be adjusted when taken with certain medicines. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Especially tell your healthcare provider if you take:<list listType=\"unordered\"><item>antibiotics such as rifampin (RIFAMATE, RIFATER) or rifabutin (MYCOBUTIN).</item><item>seizure medicines such as phenobarbital, carbamazepine (TEGRETOL, CARBATROL, EQUETRO), or phenytoin (DILANTIN, PHENYTEK).</item><item>St. John&apos;s wort</item><item>antifungal medicines including ketoconazole, itraconazole (such as SPORANOX), posaconazole (such as NOXAFIL), voriconazole (such as VFEND), or fluconazole (such as DIFLUCAN).</item><item>antibiotics including telithromycin, clarithromycin (such as BIAXIN), or erythromycin (such as ERY-TAB).</item></list>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">How should I take TRIKAFTA?</content><list listType=\"unordered\"><item>Take TRIKAFTA exactly as your healthcare provider tells you to take it.</item><item>Take TRIKAFTA by mouth only.</item><item>TRIKAFTA consists of 2 different doses (a morning dose and an evening dose taken about <content styleCode=\"bold\">12</content> hours apart). Each dose has different ingredients.</item><item><content styleCode=\"bold\">Always take TRIKAFTA oral granules or tablets with food that contains fat</content>. Examples of fat-containing foods include butter, oil, eggs, peanut butter, nuts, meat, and whole-milk dairy products such as whole milk, cheese, and yogurt.</item><item>TRIKAFTA oral granules (age 2 to less than 6 years weighing less than 31 pounds (14 kg)):<list listType=\"unordered\"><item>The white and blue packets each contain the medicines elexacaftor, tezacaftor, and ivacaftor. Take one morning dose packet in the morning.</item><item>The white and green color packets each contain the medicine ivacaftor. Take one evening dose packet in the evening.</item></list></item><item>TRIKAFTA oral granules (age 2 to less than 6 years weighing 31 pounds (14 kg) or more):<list listType=\"unordered\"><item>The white and orange packets each contain the medicines elexacaftor, tezacaftor, and ivacaftor. Take one morning dose packet in the morning.</item><item>The white and pink color packets each contain the medicine ivacaftor. Take one evening dose packet in the evening.</item></list></item><item>To prepare TRIKAFTA oral granules:<list listType=\"unordered\"><item>Hold the packet with the cut line on top.</item><item>Shake the packet gently to settle the TRIKAFTA oral granules.</item><item>Tear or cut the packet open along the cut line.</item><item>Carefully pour all the TRIKAFTA oral granules in the packet into 1 teaspoon (5 mL) of soft food or liquid in a small container (like an empty bowl). Look inside the sachet to make sure there are no granules left inside. The food or liquid should be at or below room temperature. Some examples of soft foods or liquids include pureed fruits or vegetables, yogurt, applesauce, water, milk, or juice.</item><item>Mix the TRIKAFTA granules with food or liquid.</item><item>After mixing, give TRIKAFTA within 1 hour. Make sure all the medicine is taken.</item></list></item><item>TRIKAFTA tablets (age 6 to less than 12 years weighing less than 66 pounds (30 kg)):<list listType=\"unordered\"><item>The light orange tablet is marked with &apos;T50&apos; and each tablet contains the medicines elexacaftor, tezacaftor and ivacaftor. Take 2 light orange tablets in the morning.</item><item>The light blue tablet is marked with &apos;V 75&apos; and contains the medicine ivacaftor. Take 1 light blue tablet in the evening.</item></list></item><item>TRIKAFTA tablets (age 6 to less than 12 years weighing 66 pounds (30 kg) or more, and age 12 years and older):<list listType=\"unordered\"><item>The orange tablet is marked with &apos;T100&apos; and each tablet contains the medicines elexacaftor, tezacaftor and ivacaftor. Take 2 orange tablets in the morning.</item><item>The light blue tablet is marked with &apos;V 150&apos; and contains the medicine ivacaftor. Take 1 light blue tablet in the evening.</item></list></item><item>Take TRIKAFTA tablets whole.</item><item>If you miss a dose of TRIKAFTA and:<list listType=\"unordered\"><item>it is <content styleCode=\"bold\">6 hours or less</content> from the time you usually take the morning dose or the evening dose, <content styleCode=\"bold\">take the missed dose</content> with food that contains fat as soon as you can. Then take your next dose at your usual time.</item><item>it is <content styleCode=\"bold\">more than 6 hours</content> from the time you usually take the morning dose, <content styleCode=\"bold\">take the missed dose</content> with food that contains fat as soon as you can. <content styleCode=\"bold\">Do not take the evening dose</content>.</item><item>it is <content styleCode=\"bold\">more than 6 hours</content> from the time you usually take the evening dose, <content styleCode=\"bold\">do not take the missed dose</content>. Take your next morning dose at the usual time with food that contains fat.</item><item><content styleCode=\"bold\">Do not</content> take more than your usual dose of TRIKAFTA to make up for a missed dose.</item><item><content styleCode=\"bold\">Do not</content> take the morning and evening doses at the same time.</item></list></item><item>If you have liver problems, your healthcare provider may tell you to take TRIKAFTA differently.</item></list>If you are not sure about your dosing, call your healthcare provider.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What should I avoid while taking TRIKAFTA?</content> Avoid food or drink that contains grapefruit while you are taking TRIKAFTA.</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What are the possible or reasonably likely side effects of TRIKAFTA? TRIKAFTA can cause serious side effects, including:</content><list listType=\"unordered\"><item><content styleCode=\"bold\">See &quot;<linkHtml href=\"#whatis\">What is the most important information I should know about TRIKAFTA?</linkHtml>&quot;</content></item><item><content styleCode=\"bold\">Serious Allergic Reactions</content> can happen to people who are treated with TRIKAFTA. Call your healthcare provider or go to the emergency room right away if you have any symptoms of an allergic reaction. Symptoms of an allergic reaction may include:<list listType=\"unordered\" styleCode=\"circle\"><item>rash or hives</item><item>tightness of the chest or throat or difficulty breathing</item><item>swelling of the face, lips and/or tongue, difficulty swallowing</item><item>light-headedness or dizziness</item></list></item><item><content styleCode=\"bold\">Increased pressure around the brain (intracranial hypertension)</content> has happened in people treated with TRIKAFTA. If you experience an unusual headache, blurred vision, double vision, or vision loss, call your healthcare provider right away.</item><item><content styleCode=\"bold\">Serious mental health problems</content> such as anxiety, depression, suicidal thoughts and behaviors, and trouble sleeping have happened in people treated with TRIKAFTA or medicines containing the same or similar ingredients as TRIKAFTA. If you experience new or worsening mental health problems, call your healthcare provider right away.</item><item><content styleCode=\"bold\">Abnormality of the eye lens (cataract)</content> has happened in some children and adolescents treated with TRIKAFTA. If you are a child or adolescent, your healthcare provider should perform eye examinations before and during treatment with TRIKAFTA to look for cataracts.</item></list><content styleCode=\"bold\">The most common side effects of TRIKAFTA include:</content></td></tr><tr><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"circle\"><item>headache</item><item>upper respiratory tract infection (common cold) including stuffy and runny nose</item><item>stomach (abdominal) pain</item><item>diarrhea</item><item>rash</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>increase in liver enzymes</item><item>increase in a certain blood enzyme called creatine phosphokinase</item><item>flu (influenza)</item><item>inflamed sinuses</item><item>increase in blood bilirubin</item><item>constipation</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\">Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TRIKAFTA. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">How should I store TRIKAFTA?</content><list listType=\"unordered\"><item>Store TRIKAFTA at room temperature between 68&#xBA;F to 77&#xBA;F (20&#xBA;C to 25&#xBA;C).</item></list><content styleCode=\"bold\">Keep TRIKAFTA and all medicines out of the reach of children.</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">General information about the safe and effective use of TRIKAFTA.</content> Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRIKAFTA for a condition for which it was not prescribed. Do not give TRIKAFTA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TRIKAFTA that is written for health professionals.</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">What are the ingredients in TRIKAFTA? Elexacaftor/tezacaftor/ivacaftor tablets: Active ingredients:</content> elexacaftor, tezacaftor and ivacaftor. <content styleCode=\"bold\">Inactive ingredients:</content> croscarmellose sodium, hypromellose, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The tablet film coat contains hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, talc, and titanium dioxide. <content styleCode=\"bold\">Ivacaftor tablets:</content> <content styleCode=\"bold\">Active ingredients:</content> ivacaftor. <content styleCode=\"bold\">Inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&amp;C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium oxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac. <content styleCode=\"bold\">Elexacaftor/tezacaftor/ivacaftor oral granules:</content> <content styleCode=\"bold\">Active ingredients:</content> elexacaftor, tezacaftor, and ivacaftor. <content styleCode=\"bold\">Inactive ingredients</content>: colloidal silicon dioxide, croscarmellose sodium, hypromellose, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. <content styleCode=\"bold\">Ivacaftor oral granules:</content> <content styleCode=\"bold\">Active ingredients</content>: ivacaftor. <content styleCode=\"bold\">Inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sodium lauryl sulfate, and sucralose. Manufactured for: Vertex Pharmaceuticals Incorporated; 50 Northern Avenue, Boston, MA 02210 TRIKAFTA, VERTEX and associated logos are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. &#xA9;2026 Vertex Pharmaceuticals Incorporated For more information, go to www.trikafta.com or call 1-877-752-5933.</td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Elexacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as measured both by CFTR-mediated chloride transport in vitro and by sweat chloride in patients with CF. CFTR Chloride Transport Assay in Fischer Rat Thyroid Cells Expressing Mutant CFTR Protein Effects of elexacaftor/tezacaftor/ivacaftor on chloride transport for mutant CFTR proteins was determined in Ussing chamber electrophysiology studies using a panel of Fischer Rat Thyroid (FRT) cell lines stably expressing individual mutant CFTR protein. Elexacaftor/tezacaftor/ivacaftor increased chloride transport in FRT cells expressing CFTR variants, as identified in Table 6. The threshold that the treatment-induced increase in chloride transport must exceed for the mutant CFTR protein to be considered responsive is ≥10% of normal over baseline. This threshold was used because it is expected to predict clinical benefit. For individual variants, the magnitude of the net change over baseline in CFTR-mediated chloride transport in vitro is not correlated with the magnitude of clinical response. CFTR Chloride Transport Assay in Human Bronchial Epithelial Cells Expressing Mutant CFTR Protein Homozygous and heterozygous N1303K -Human Bronchial Epithelial (HBE) cells showed greater chloride transport in the presence of elexacaftor/tezacaftor/ivacaftor than F508del/F508del -HBE cells treated with tezacaftor/ivacaftor (which has shown clinical benefit in people homozygous for F508del) . Patient Selection Select adult and pediatric patients 2 years of age and older for the treatment of CF with TRIKAFTA based on a clinical diagnosis of CF and the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein [see Indications and Usage (1) ] . TRIKAFTA should only be used in patients with a clinical diagnosis of CF. The presence of eligible CFTR variant(s) should not be the sole determinant for using TRIKAFTA. Table 6 lists CFTR variants responsive to TRIKAFTA based on clinical and/or in vitro data in FRT or HBE cells [see Clinical Studies (14) ] . Table 6: List of CFTR Gene Variants Responsive to TRIKAFTA The list of responsive CFTR variants is non-exhaustive. There may be protein-producing CFTR variants not listed that respond to treatment with TRIKAFTA. Variants responsive to TRIKAFTA based on clinical data Clinical data obtained from Trials 1, 2, and 5. 2789+5G→A D1152H This variant is also predicted to be responsive by FRT assay. L206W R1066H S945L 3272-26A→G F508del L997F R117C T338I 3849+10kbC→T G85E M1101K R347H V232D A455E L1077P P5L R347P Variants responsive to TRIKAFTA based on in vitro data The N1303K variant is predicted to be responsive by HBE assay. All other variants predicted to be responsive with in vitro data are supported by FRT assay. 1140-1151dup E264V H620P N396Y S1251N 1461insGAT E282D H620Q N418S S1255P 1507_1515del9 E292K H939R N900K S13F 2055del9 E384K H939R;H949L P1013H S13P 2183A→G E403D H954P P1013L S158N 2851A/G E474K I1023R P1021L S182R 293A→G E527G I1027T P1021T S18I 3007del6 E56K I105N P111L S18N 3132T→G E588V I1139V P1372T S308P 3141del9 E60K I1203V P140S S341P 3143del9 E822K I1234L P205S S364P 314del9 E92K I1234V del6aa P439S S434P 3331del6 F1016S I125T P499A S492F 3410T→C F1052V I1269N P574H S50P 3523A→G F1074L I1366N P67L S519G 3601A→C F1078S I1366T P750L S531P 3761T→G F1099L I148L P798S S549I 3791C/T F1107L I148N P988R S549N 3850G→A F191V I148T Q1012P S549R 3978G→C F200I I175V Q1209P S557F 546insCTA F311del I331N Q1291H S589I 548insTAC F311L I336K Q1291R S589N A1006E F312del I336L Q1313K S624R A1025D F433L I444S Q1352H S686Y A1067P F508C I497S Q151K S737F A1067T F508C;S1251N I502T Q179K S821G A1067V F508del;R1438W I506L Q237E S898R A107G F575Y I506V Q237H S912L A1081V F587I I506V;D1168G Q237P S912L;G1244V A1087P F587L I521S Q30P S912T A120T F693L(TTG) I530N Q359K/T360K S955P A1319E F87L I556V Q359R S977F A1374D F932S I586V Q372H S977F;R1438W A141D G1047D I601F Q493L T1036N A1466S G1047R I618N Q493R T1053I A155P G1061R I618T Q552P T1057R A234D G1069R I807M Q98P T1086A A234V G1123R I86M Q98R T1086I A238V G1173S I980K R1048G T1246I A309D G1237V K1060T R1066G T1299I A349V G1244E K162E R1070P T1299K A357T G1244R K464E R1070Q T351I A455V G1247R K464N R1070W T351S A457T G1249E K522E R1162L T351S;R851L A462P G1249R K522Q R1162Q T388M A46D G1265V K951E R117C;G576A;R668C T465I A534E G126D L1011S R117G T501A A554E G1298V L102R;F1016S R117H T582S A566D G1349D L1065R R117L T908N A62P G149R;G576A;R668C L1227S R117L;L997F T990I A872E G178E L1324P R117P V1008D c.1367_1369dupTTG G178R L1335P R1239S V1010D C225R G194R L137P R1283G V1153E C491R G194V L1388P R1283M V11I C590Y G213E L1480P R1283S V1240G C866Y G213E;R668C L159S R1438W V1293G D110E G213V L15P R170H V1293I D110H G226R L15P;L1253F R248K V1415F D110N G239R L165S R258G V201M D1152A G253R L167R R297Q V232A D1270N G27E L210P R31C V317A D1270Y G27R L293P R31L V322M D1312G G314E L320V R334L V392G D1377H G314R L327P R334Q V456A D1445N G424S L32P R347L V456F D192G G437D L333F R352Q V520I D192N G461R L333H R352W V562I D373N G461V L346P R516S V562I;A1006E D426N G463V L441P R553Q V562L D443Y G480C L453S R555G V591A D443Y;G576A;R668C G480D L467F R600S V603F D529G G480S L558F R668C V754M D565G G500D L619S R709Q V920L D567N G545R L633P R74Q V920M D579G G551A L636P R74Q;R297Q V93D D58H G551D L88S R74Q;V201M;D1270N W1098C D58V G551R L927P R74W W1282G D614G G551S L967F;L1096R R74W;D1270N W1282R D651H G576A L967S R74W;R1070W;D1270N W202C D651N G576A;R668C L973F R74W;S945L W361R D806G G576A;S1359Y M1137R R74W;V201M W496R D836Y G622D M1137V R74W;V201M;D1270N Y1014C D924N G622V M1210K R74W;V201M;L997F Y1032C D979A G628A M150K R751L Y1032N D979V G628R M150R R75L Y1073C D985H G930E M152L R75Q Y1092H D985Y G970D M152V R75Q;L1065P Y109H D993A G970S M265R R75Q;N1088D Y109N D993G G970V M348K R75Q;S549N Y122C D993Y H1054D M394L R792G Y1381H E1104K H1079P M469V R792Q Y161C E1104V H1085P M498I R810G Y161D E1126K H1085R M952I R851L Y161S E116K H1375N M952T R933G Y301C E116Q H1375P M961L S1045Y Y563N E1221V H139L N1088D S108F Y89C E1228K H139R N1195T S1118F Y913S E1409K H146R N1303I S1159F Y919C E1433K H199Q N1303K S1159P E193K H199Y N186K S1188L E217G H609L N187K S1235R"],"recent_major_changes":["Indications and Usage ( 1 ) 03/2026 Warnings and Precautions, Intracranial Hypertension ( 5.3 ) 09/2025 Warnings and Precautions, Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors ( 5.4 ) 03/2026"],"storage_and_handling":["Store at 20 ºC – 25 ºC (68 ºF – 77 ºF); excursions permitted to 15 ºC – 30 ºC (59 ºF – 86 ºF) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Elexacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as measured both by CFTR-mediated chloride transport in vitro and by sweat chloride in patients with CF. CFTR Chloride Transport Assay in Fischer Rat Thyroid Cells Expressing Mutant CFTR Protein Effects of elexacaftor/tezacaftor/ivacaftor on chloride transport for mutant CFTR proteins was determined in Ussing chamber electrophysiology studies using a panel of Fischer Rat Thyroid (FRT) cell lines stably expressing individual mutant CFTR protein. Elexacaftor/tezacaftor/ivacaftor increased chloride transport in FRT cells expressing CFTR variants, as identified in Table 6. The threshold that the treatment-induced increase in chloride transport must exceed for the mutant CFTR protein to be considered responsive is ≥10% of normal over baseline. This threshold was used because it is expected to predict clinical benefit. For individual variants, the magnitude of the net change over baseline in CFTR-mediated chloride transport in vitro is not correlated with the magnitude of clinical response. CFTR Chloride Transport Assay in Human Bronchial Epithelial Cells Expressing Mutant CFTR Protein Homozygous and heterozygous N1303K -Human Bronchial Epithelial (HBE) cells showed greater chloride transport in the presence of elexacaftor/tezacaftor/ivacaftor than F508del/F508del -HBE cells treated with tezacaftor/ivacaftor (which has shown clinical benefit in people homozygous for F508del) . Patient Selection Select adult and pediatric patients 2 years of age and older for the treatment of CF with TRIKAFTA based on a clinical diagnosis of CF and the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein [see Indications and Usage (1) ] . TRIKAFTA should only be used in patients with a clinical diagnosis of CF. The presence of eligible CFTR variant(s) should not be the sole determinant for using TRIKAFTA. Table 6 lists CFTR variants responsive to TRIKAFTA based on clinical and/or in vitro data in FRT or HBE cells [see Clinical Studies (14) ] . Table 6: List of CFTR Gene Variants Responsive to TRIKAFTA The list of responsive CFTR variants is non-exhaustive. There may be protein-producing CFTR variants not listed that respond to treatment with TRIKAFTA. Variants responsive to TRIKAFTA based on clinical data Clinical data obtained from Trials 1, 2, and 5. 2789+5G→A D1152H This variant is also predicted to be responsive by FRT assay. L206W R1066H S945L 3272-26A→G F508del L997F R117C T338I 3849+10kbC→T G85E M1101K R347H V232D A455E L1077P P5L R347P Variants responsive to TRIKAFTA based on in vitro data The N1303K variant is predicted to be responsive by HBE assay. All other variants predicted to be responsive with in vitro data are supported by FRT assay. 1140-1151dup E264V H620P N396Y S1251N 1461insGAT E282D H620Q N418S S1255P 1507_1515del9 E292K H939R N900K S13F 2055del9 E384K H939R;H949L P1013H S13P 2183A→G E403D H954P P1013L S158N 2851A/G E474K I1023R P1021L S182R 293A→G E527G I1027T P1021T S18I 3007del6 E56K I105N P111L S18N 3132T→G E588V I1139V P1372T S308P 3141del9 E60K I1203V P140S S341P 3143del9 E822K I1234L P205S S364P 314del9 E92K I1234V del6aa P439S S434P 3331del6 F1016S I125T P499A S492F 3410T→C F1052V I1269N P574H S50P 3523A→G F1074L I1366N P67L S519G 3601A→C F1078S I1366T P750L S531P 3761T→G F1099L I148L P798S S549I 3791C/T F1107L I148N P988R S549N 3850G→A F191V I148T Q1012P S549R 3978G→C F200I I175V Q1209P S557F 546insCTA F311del I331N Q1291H S589I 548insTAC F311L I336K Q1291R S589N A1006E F312del I336L Q1313K S624R A1025D F433L I444S Q1352H S686Y A1067P F508C I497S Q151K S737F A1067T F508C;S1251N I502T Q179K S821G A1067V F508del;R1438W I506L Q237E S898R A107G F575Y I506V Q237H S912L A1081V F587I I506V;D1168G Q237P S912L;G1244V A1087P F587L I521S Q30P S912T A120T F693L(TTG) I530N Q359K/T360K S955P A1319E F87L I556V Q359R S977F A1374D F932S I586V Q372H S977F;R1438W A141D G1047D I601F Q493L T1036N A1466S G1047R I618N Q493R T1053I A155P G1061R I618T Q552P T1057R A234D G1069R I807M Q98P T1086A A234V G1123R I86M Q98R T1086I A238V G1173S I980K R1048G T1246I A309D G1237V K1060T R1066G T1299I A349V G1244E K162E R1070P T1299K A357T G1244R K464E R1070Q T351I A455V G1247R K464N R1070W T351S A457T G1249E K522E R1162L T351S;R851L A462P G1249R K522Q R1162Q T388M A46D G1265V K951E R117C;G576A;R668C T465I A534E G126D L1011S R117G T501A A554E G1298V L102R;F1016S R117H T582S A566D G1349D L1065R R117L T908N A62P G149R;G576A;R668C L1227S R117L;L997F T990I A872E G178E L1324P R117P V1008D c.1367_1369dupTTG G178R L1335P R1239S V1010D C225R G194R L137P R1283G V1153E C491R G194V L1388P R1283M V11I C590Y G213E L1480P R1283S V1240G C866Y G213E;R668C L159S R1438W V1293G D110E G213V L15P R170H V1293I D110H G226R L15P;L1253F R248K V1415F D110N G239R L165S R258G V201M D1152A G253R L167R R297Q V232A D1270N G27E L210P R31C V317A D1270Y G27R L293P R31L V322M D1312G G314E L320V R334L V392G D1377H G314R L327P R334Q V456A D1445N G424S L32P R347L V456F D192G G437D L333F R352Q V520I D192N G461R L333H R352W V562I D373N G461V L346P R516S V562I;A1006E D426N G463V L441P R553Q V562L D443Y G480C L453S R555G V591A D443Y;G576A;R668C G480D L467F R600S V603F D529G G480S L558F R668C V754M D565G G500D L619S R709Q V920L D567N G545R L633P R74Q V920M D579G G551A L636P R74Q;R297Q V93D D58H G551D L88S R74Q;V201M;D1270N W1098C D58V G551R L927P R74W W1282G D614G G551S L967F;L1096R R74W;D1270N W1282R D651H G576A L967S R74W;R1070W;D1270N W202C D651N G576A;R668C L973F R74W;S945L W361R D806G G576A;S1359Y M1137R R74W;V201M W496R D836Y G622D M1137V R74W;V201M;D1270N Y1014C D924N G622V M1210K R74W;V201M;L997F Y1032C D979A G628A M150K R751L Y1032N D979V G628R M150R R75L Y1073C D985H G930E M152L R75Q Y1092H D985Y G970D M152V R75Q;L1065P Y109H D993A G970S M265R R75Q;N1088D Y109N D993G G970V M348K R75Q;S549N Y122C D993Y H1054D M394L R792G Y1381H E1104K H1079P M469V R792Q Y161C E1104V H1085P M498I R810G Y161D E1126K H1085R M952I R851L Y161S E116K H1375N M952T R933G Y301C E116Q H1375P M961L S1045Y Y563N E1221V H139L N1088D S108F Y89C E1228K H139R N1195T S1118F Y913S E1409K H146R N1303I S1159F Y919C E1433K H199Q N1303K S1159P E193K H199Y N186K S1188L E217G H609L N187K S1235R 12.2 Pharmacodynamics Sweat Chloride Evaluation In Trial 1 (patients with an F508del variant on one allele and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive ivacaftor and tezacaftor/ivacaftor), a reduction in sweat chloride was observed from baseline at Week 4 and sustained through the 24-week treatment period [see Clinical Studies (14.1) ] . In Trial 2 (patients homozygous for the F508del variant), a reduction in sweat chloride was observed from baseline at Week 4 [see Clinical Studies (14.2) ] . In Trial 3 (patients aged 6 to less than 12 years who are homozygous for the F508del variant or heterozygous for the F508del variant and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor), the mean absolute change in sweat chloride from baseline through Week 24 was -60.9 mmol/L (95% CI: -63.7, -58.2). In Trial 4 (patients aged 2 to less than 6 years who had at least one F508del variant or a variant known to be responsive to TRIKAFTA), the mean absolute change in sweat chloride from baseline through Week 24 was -57.9 mmol/L (95% CI: -61.3, -54.6). In Trial 5 (patients aged 6 years and older with at least one qualifying non- F508del elexacaftor/tezacaftor/ivacaftor-responsive CFTR variant), the mean absolute change in sweat chloride from baseline through Week 24 compared to placebo was -28.3 mmol/L (95% CI: -32.1, -24.5). Cardiac Electrophysiology At doses up to 2 times the maximum recommended dose of elexacaftor and 3 times the maximum recommended dose of tezacaftor and ivacaftor, the QT/QTc interval in healthy subjects was not prolonged to any clinically relevant extent. 12.3 Pharmacokinetics The pharmacokinetics of elexacaftor, tezacaftor and ivacaftor are similar between healthy adult subjects and patients with CF. The pharmacokinetic parameters for elexacaftor, tezacaftor and ivacaftor in patients with CF aged 12 years and older are shown in Table 7. Table 7: Pharmacokinetic Parameters of TRIKAFTA Components Elexacaftor Tezacaftor Ivacaftor AUC ss : area under the concentration versus time curve at steady state; SD: Standard Deviation; C max : maximum observed concentration; T max : time of maximum concentration; AUC: area under the concentration versus time curve. General Information AUC ss (SD), mcg∙h/mL Based on elexacaftor 200 mg and tezacaftor 100 mg once daily/ivacaftor 150 mg every 12 hours at steady state in patients with CF aged 12 years and older. 162 (47.5) AUC 0-24h . 89.3 (23.2) 11.7 (4.01) AUC 0-12h . C max (SD), mcg/mL 9.2 (2.1) 7.7 (1.7) 1.2 (0.3) Time to Steady State, days Within 7 days Within 8 days Within 3-5 days Accumulation Ratio 2.2 2.07 2.4 Absorption Absolute Bioavailability 80% Not determined Not determined Median T max (range), hours 6 (4 to 12) 3 (2 to 4) 4 (3 to 6) Effect of Food AUC increases 1.9- to 2.5-fold (moderate-fat meal) No clinically significant effect Exposure increases 2.5- to 4-fold Distribution Mean (SD) Apparent Volume of Distribution, L Elexacaftor, tezacaftor and ivacaftor do not partition preferentially into human red blood cells. 53.7 (17.7) 82.0 (22.3) 293 (89.8) Protein Binding Elexacaftor and tezacaftor bind primarily to albumin. Ivacaftor primarily bind to albumin, alpha 1-acid glycoprotein and human gamma-globulin. >99% approximately 99% approximately 99% Elimination Mean (SD) Effective Half-Life, hours Mean (SD) terminal half-lives of elexacaftor, tezacaftor and ivacaftor are approximately 24.7 (4.87) hours, 60.3 (15.7) hours and 13.1 (2.98) hours, respectively. 27.4 (9.31) 25.1 (4.93) 15.0 (3.92) Mean (SD) Apparent Clearance, L/hours 1.18 (0.29) 0.79 (0.10) 10.2 (3.13) Metabolism Primary Pathway CYP3A4/5 CYP3A4/5 CYP3A4/5 Active Metabolites M23-ELX M1-TEZ M1-IVA Metabolite Potency Relative to Parent Similar Similar approximately 1/6 th of parent Excretion Following radiolabeled doses. Primary Pathway Feces: 87.3% (primarily as metabolites) Urine: 0.23% Feces: 72% (unchanged or as M2-TEZ) Urine: 14% (0.79% unchanged) Feces: 87.8% Urine: 6.6% Specific Populations Pediatric Patients 2 to Less Than 12 Years of Age Elexacaftor, tezacaftor and ivacaftor exposures observed in patients aged 2 to less than 12 years as determined using population PK analysis are presented by age group and dose administered in Table 8. Elexacaftor, tezacaftor and ivacaftor exposures in this patient population are within the range observed in patients aged 12 years and older. Table 8: Mean (SD) Elexacaftor, Tezacaftor and Ivacaftor Exposures Observed at Steady State by Age Group and Dose Administered Age Group Dose Elexacaftor AUC 0-24h,ss (µg∙h/mL) Tezacaftor AUC 0-24h,ss (µg∙h/mL) Ivacaftor AUC 0-12h,ss (µg∙h/mL) SD: Standard Deviation; AUC ss : area under the concentration versus time curve at steady state. Patients aged 2 to less than 6 years weighing less than 14 kg (N = 16) elexacaftor 80 mg qd/tezacaftor 40 mg qd/ivacaftor 60 mg qAM and ivacaftor 59.5 mg qPM 128 (24.8) 87.3 (17.3) 11.9 (3.86) Patients aged 2 to less than 6 years weighing 14 kg or more (N = 59) elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h 138 (47.0) 90.2 (27.9) 13.0 (6.11) Patients aged 6 to less than 12 years weighing less than 30 kg (N = 36) elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h 116 (39.4) 67.0 (22.3) 9.78 (4.50) Patients aged 6 to less than 12 years weighing 30 kg or more (N = 30) elexacaftor 200 mg qd/ tezacaftor 100 mg qd/ ivacaftor 150 mg q12h 195 (59.4) 103 (23.7) 17.5 (4.97) Pediatric Patients 12 to Less Than 18 Years of Age The following conclusions about exposures between adults and the pediatric population are based on population pharmacokinetic (PK) analyses. Following oral administration of TRIKAFTA to patients 12 to less than 18 years of age (elexacaftor 200 mg qd/tezacaftor 100 mg qd/ivacaftor 150 mg q12h), the mean (±SD) AUC ss was 147 (36.8) mcg∙h/mL, 88.8 (21.8) mcg∙h/mL and 10.6 (3.35) mcg∙h/mL, respectively for elexacaftor, tezacaftor and ivacaftor, similar to the AUC ss in adult patients. Patients with Renal Impairment Renal excretion of elexacaftor, tezacaftor and ivacaftor is minimal. Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in subjects with severe (eGFR <30 mL/min/1.73 m 2 ) renal impairment or end-stage renal disease. Based on population PK analyses, the clearance of elexacaftor and tezacaftor was similar in subjects with mild (eGFR 60 to <90 mL/min/1.73 m 2 ) or moderate (eGFR 30 to <60 mL/min/1.73 m 2 ) renal impairment relative to patients with normal renal function [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in subjects with severe hepatic impairment (Child-Pugh Class C, score 10-15). In a clinical study, following multiple doses of elexacaftor, tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7-9) had 25% higher AUC and 12% higher C max for elexacaftor, 73% higher AUC and 70% higher C max for M23-ELX, 36% higher AUC and 24% higher C max for combined elexacaftor and M23-ELX, 20% higher AUC but similar C max for tezacaftor and 1.5-fold higher AUC and 10% higher C max for ivacaftor compared with healthy subjects matched for demographics [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Use in Specific Populations (8.7) ] . Tezacaftor and Ivacaftor Following multiple doses of tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function had an approximately 36% higher AUC and a 10% higher in C max for tezacaftor and a 1.5-fold higher AUC but similar C max for ivacaftor compared with healthy subjects matched for demographics. Ivacaftor In a study with ivacaftor alone, subjects with moderately impaired hepatic function had similar ivacaftor C max , but an approximately 2.0-fold higher ivacaftor AUC 0-∞ compared with healthy subjects matched for demographics. Male and Female Patients Based on population PK analysis, the exposures of elexacaftor, tezacaftor and ivacaftor are similar in males and females. Drug Interaction Studies Drug interaction studies were performed with elexacaftor, tezacaftor and/or ivacaftor and other drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interaction studies [see Drug Interactions (7) ] . Potential for Elexacaftor, Tezacaftor and/or Ivacaftor to Affect Other Drugs Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, whereas ivacaftor has the potential to inhibit CYP2C8, CYP2C9 and CYP3A. However, clinical studies showed that the combination regimen of tezacaftor/ivacaftor is not an inhibitor of CYP3A and ivacaftor is not an inhibitor of CYP2C8 or CYP2D6. Based on in vitro results, elexacaftor, tezacaftor and ivacaftor are not likely to induce CYP3A, CYP1A2 and CYP2B6. Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit the transporter P-gp, while ivacaftor has the potential to inhibit P-gp. Co-administration of tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold in a clinical study. Based on in vitro results, elexacaftor and M23-ELX may inhibit OATP1B1 and OATP1B3 uptake. Tezacaftor has a low potential to inhibit BCRP, OCT2, OAT1, or OAT3. Ivacaftor is not an inhibitor of the transporters OCT1, OCT2, OAT1, or OAT3. The effects of elexacaftor, tezacaftor and/or ivacaftor on the exposure of co-administered drugs are shown in Table 9 [see Drug Interactions (7) ] . Table 9: Impact of Elexacaftor, Tezacaftor and/or Ivacaftor on Other Drugs Dose and Schedule Effect on Other Drug PK Geometric Mean Ratio (90% CI) of Other Drug No Effect=1.0 AUC C max ↑ = increase, ↓ = decrease, ↔ = no change. AUC: area under the concentration versus time curve; CI: Confidence Interval; ELX: elexacaftor; C max : maximum observed concentration; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics. Midazolam 2 mg single oral dose TEZ 100 mg qd/IVA 150 mg q12h ↔ Midazolam 1.12 (1.01, 1.25) 1.13 (1.01, 1.25) Digoxin 0.5 mg single dose TEZ 100 mg qd/IVA 150 mg q12h ↑ Digoxin 1.30 (1.17, 1.45) 1.32 (1.07, 1.64) Oral Contraceptive Ethinyl estradiol 30 µg/Levonorgestrel 150 µg qd ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h ↑ Ethinyl estradiol Effect is not clinically significant [see Drug Interactions (7.3) ] . 1.33 (1.20, 1.49) 1.26 (1.14, 1.39) ↑ Levonorgestrel 1.23 (1.10, 1.37) 1.10 (0.985, 1.23) Rosiglitazone 4 mg single oral dose IVA 150 mg q12h ↔ Rosiglitazone 0.975 (0.897, 1.06) 0.928 (0.858, 1.00) Desipramine 50 mg single dose IVA 150 mg q12h ↔ Desipramine 1.04 (0.985, 1.10) 1.00 (0.939, 1.07) Potential for Other Drugs to Affect Elexacaftor, Tezacaftor and/or Ivacaftor In vitro studies showed that elexacaftor, tezacaftor and ivacaftor are all metabolized by CYP3A. Exposure to elexacaftor, tezacaftor and ivacaftor may be reduced by concomitant CYP3A inducers and increased by concomitant CYP3A inhibitors. In vitro studies showed that elexacaftor and tezacaftor are substrates for the efflux transporter P-gp, but ivacaftor is not. Elexacaftor and ivacaftor are not substrates for OATP1B1 or OATP1B3; tezacaftor is a substrate for OATP1B1, but not OATP1B3. Tezacaftor is a substrate for BCRP. The effects of co-administered drugs on the exposure of elexacaftor, tezacaftor and/or ivacaftor are shown in Table 10 [see Dosage and Administration (2.4) and Drug Interactions (7) ] . Table 10: Impact of Other Drugs on Elexacaftor, Tezacaftor and/or Ivacaftor Dose and Schedule Effect on ELX, TEZ and/or IVA PK Geometric Mean Ratio (90% CI) of Elexacaftor, Tezacaftor and Ivacaftor No Effect = 1.0 AUC C max ↑ = increase, ↓ = decrease, ↔ = no change. AUC: area under the concentration versus time curve; CI: Confidence Interval; C max : maximum observed concentration; ELX: elexacaftor; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics. Itraconazole 200 mg q12h on Day 1, followed by 200 mg qd TEZ 25 mg qd + IVA 50 mg qd ↑ Tezacaftor 4.02 (3.71, 4.63) 2.83 (2.62, 3.07) ↑ Ivacaftor 15.6 (13.4, 18.1) 8.60 (7.41, 9.98) Itraconazole 200 mg qd ELX 20 mg + TEZ 50 mg single dose ↑ Elexacaftor 2.83 (2.59, 3.10) 1.05 (0.977, 1.13) ↑ Tezacaftor 4.51 (3.85, 5.29) 1.48 (1.33, 1.65) Ketoconazole 400 mg qd IVA 150 mg single dose ↑ Ivacaftor 8.45 (7.14, 10.0) 2.65 (2.21, 3.18) Ciprofloxacin 750 mg q12h TEZ 50 mg q12h + IVA 150 mg q12h ↔ Tezacaftor 1.08 (1.03, 1.13) 1.05 (0.99, 1.11) ↑ Ivacaftor Effect is not clinically significant [see Drug Interactions (7.3) ] . 1.17 (1.06, 1.30) 1.18 (1.06, 1.31) Rifampin 600 mg qd IVA 150 mg single dose ↓ Ivacaftor 0.114 (0.097, 0.136) 0.200 (0.168, 0.239) Fluconazole 400 mg single dose on Day 1, followed by 200 mg qd IVA 150 mg q12h ↑ Ivacaftor 2.95 (2.27, 3.82) 2.47 (1.93, 3.17)"],"indications_and_usage":["1 INDICATIONS AND USAGE TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 6 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 , 12.1 ) If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Drug-induced liver injury and liver failure : TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Assess liver function tests (ALT, AST, alkaline phosphatase, bilirubin) in all patients prior to initiating and throughout treatment with TRIKAFTA. Interrupt TRIKAFTA in the event of significant elevations in liver function tests or signs or symptoms of liver injury. TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.1 , 2.3 , 5.1 , 6 , 8.7 , 12.3 ) Hypersensitivity reactions : Angioedema and anaphylaxis have been reported with TRIKAFTA in the postmarketing setting. Initiate appropriate therapy in the event of a hypersensitivity reaction. ( 5.2 ) Intracranial hypertension : Intracranial hypertension (IH) has been reported in the postmarketing setting with the use of TRIKAFTA. If an unusual headache or visual disturbances occur during treatment, and IH is suspected, interrupt TRIKAFTA and refer for prompt medical evaluation. ( 5.3 ) Neuropsychiatric events, including suicidal thoughts and behaviors : Serious neuropsychiatric events, including symptoms of anxiety, depression, suicidal ideation and behavior, and sleep disturbances, have been reported in the postmarketing setting for TRIKAFTA or drugs containing the same or similar active ingredients. Monitor patients closely for new or worsening symptoms. Consider the risks and benefits for the individual patient to determine if therapy with TRIKAFTA should be interrupted at the occurrence of neuropsychiatric symptoms. ( 5.4 ) Use with CYP3A inducers : Concomitant use with strong CYP3A inducers (e.g., rifampin, St. John's wort) significantly decrease ivacaftor exposure and are expected to decrease elexacaftor and tezacaftor exposure, which may reduce TRIKAFTA efficacy. Therefore, concomitant use is not recommended. ( 5.5 , 7.1 , 12.3 ) Cataracts : Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with ivacaftor-containing regimens. Baseline and follow-up examinations are recommended in pediatric patients initiating TRIKAFTA treatment. ( 5.7 , 8.4 ) 5.1 Drug-Induced Liver Injury and Liver Failure TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ] . Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA. Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating TRIKAFTA. Assess liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see Dosage and Administration (2.1) , Adverse Reactions (6) , and Use in Specific Populations (8.7) ] . Interrupt TRIKAFTA in the event of signs or symptoms of liver injury. These may include: Significant elevations in liver function tests (e.g., ALT or AST >5 × the upper limit of normal (ULN) or ALT or AST >3 × ULN with bilirubin >2 × ULN) Clinical symptoms suggestive of liver injury (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites). Consider referral to a hepatologist and follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve and if the benefit is expected to outweigh the risk, resume TRIKAFTA treatment with close monitoring. TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and the benefit outweighs the risk. If used, use with caution at a reduced dosage and monitor patients closely [see Dosage and Administration (2.3) , Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . 5.2 Hypersensitivity Reactions, Including Anaphylaxis Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported in the postmarketing setting [see Adverse Reactions (6.2) ] . If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue TRIKAFTA and institute appropriate therapy. Consider the benefits and risks for the individual patient to determine whether to resume treatment with TRIKAFTA . 5.3 Intracranial Hypertension Cases of intracranial hypertension (IH) have been reported in the postmarketing setting with the use of TRIKAFTA [see Adverse Reactions (6.2) ] . Clinical manifestations of IH include headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy. If an unusual headache or visual disturbances occur during treatment, and IH is suspected, interrupt TRIKAFTA and refer for prompt medical evaluation. Consider the benefits and risks for the individual patient to determine whether to resume treatment with TRIKAFTA. Patients should be monitored until IH resolution and for recurrence. Patients with elevated vitamin A levels may be at increased risk. 5.4 Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors Serious neuropsychiatric events, including symptoms of anxiety, depression, suicidal ideation and behavior, and sleep disturbances, have been reported in the postmarketing setting in patients taking TRIKAFTA or drugs containing the same or similar active ingredients [see Adverse Reactions (6.2) ] . The events were reported in adult and pediatric patients with and without a previous history of neuropsychiatric symptoms. Symptoms may occur within the first three months of treatment initiation. Assess patients for baseline neuropsychiatric symptoms and monitor for new or worsening symptoms of anxiety, depression, suicidal ideation or behavior, or sleep disturbances. Consider the benefits and risks for the individual patient to determine if therapy with TRIKAFTA should be interrupted at the occurrence of neuropsychiatric symptoms and whether to resume therapy with symptom improvement. 5.5 Concomitant Use with CYP3A Inducers Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by the concomitant use of strong CYP3A inducers, which may reduce the therapeutic effectiveness of TRIKAFTA. Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . 5.6 Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. Therefore, the dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors [see Dosage and Administration (2.4) , Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . 5.7 Cataracts Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow-up ophthalmological examinations are recommended in pediatric patients initiating treatment with TRIKAFTA [see Use in Specific Populations (8.4) ] ."],"clinical_studies_table":["<table width=\"90%\" ID=\"table11\"><caption>Table 11: Primary and Key Secondary Efficacy Analyses (Trial 1)</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"right\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Analysis</th><th styleCode=\"Rrule\" align=\"center\">Statistic</th><th styleCode=\"Rrule\" align=\"center\">Treatment Difference<footnote>Treatment difference provided as the outcome measure for changes in ppFEV<sub>1</sub>, sweat chloride, CFQ-R and BMI; Rate ratio provided as the outcome measure for the number of pulmonary exacerbations.</footnote> for TRIKAFTA (N=200) vs Placebo (N=203)</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"3\">ppFEV<sub>1</sub>: percent predicted Forced Expiratory Volume in 1 second; CI: Confidence Interval; CFQ-R: Cystic Fibrosis Questionnaire-Revised; BMI: Body Mass Index.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Primary (Interim Full Analysis Set)</content><footnote>Primary endpoint was based on interim analysis in 403 patients.</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in ppFEV<sub>1</sub> from baseline at Week 4 (percentage points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">13.8 (12.1, 15.4) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Key Secondary (Full Analysis Set)</content><footnote>Key secondary endpoints were tested at the final analysis in 403 patients.</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in ppFEV<sub>1</sub> from baseline through Week 24 (percentage points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">14.3 (12.7, 15.8) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Number of pulmonary exacerbations from baseline through Week 24<footnote>A pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sino-pulmonary signs/symptoms.</footnote><footnote>Number of pulmonary exacerbation events (event rate per year calculated based on 48 weeks per year) in the TRIKAFTA group were 41 (0.37) and 113 (0.98) in the placebo group.</footnote></td><td styleCode=\"Rrule\">Rate ratio (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">0.37 (0.25, 0.55) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in sweat chloride from baseline through Week 24 (mmol/L)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">-41.8 (-44.4, -39.3) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in CFQ-R respiratory domain score from baseline through Week 24 (points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">20.2 (17.5, 23.0) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in BMI from baseline at Week 24 (kg/m<sup>2</sup>)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">1.04 (0.85, 1.23) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in sweat chloride from baseline at Week 4 (mmol/L)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">-41.2 (-44.0, -38.5) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr><td styleCode=\"Lrule Rrule\">Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">20.1 (16.9, 23.2) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr></tbody></table>","<table width=\"90%\" ID=\"table12\"><caption>Table 12: Primary and Key Secondary Efficacy Analyses, Full Analysis Set (Trial 2)</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"right\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" align=\"center\">Analysis<footnote>Baseline for primary and key secondary endpoints is defined as the end of the 4-week tezacaftor/ivacaftor run-in period.</footnote></th><th styleCode=\"Rrule\" align=\"center\">Statistic</th><th styleCode=\"Rrule\" align=\"center\">Treatment Difference for TRIKAFTA (N=55) vs Tezacaftor/Ivacaftor<footnote>Regimen of tezacaftor 100 mg qd/ivacaftor 150 mg q12h.</footnote> (N=52)</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\" valign=\"top\">ppFEV<sub>1</sub>: percent predicted Forced Expiratory Volume in 1 second; CI: Confidence Interval; CFQ-R: Cystic Fibrosis Questionnaire-Revised.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Primary</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in ppFEV<sub>1</sub> from baseline at Week 4 (percentage points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">10.0 (7.4, 12.6) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Key Secondary</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in sweat chloride from baseline at Week 4 (mmol/L)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">-45.1 (-50.1, -40.1) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr><td styleCode=\"Lrule Rrule\">Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">17.4 (11.8, 23.0) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 13: Primary and Secondary Efficacy Analyses, Full Analysis Set (Trial 5)</caption><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"right\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">Analysis</th><th styleCode=\"Rrule\" align=\"center\" valign=\"middle\">Statistic</th><th styleCode=\"Rrule\">Treatment Difference<footnote>Treatment difference was provided as the outcome measure for changes in ppFEV<sub>1</sub>, sweat chloride, CFQ-R RD and BMI; Rate ratio provided as the outcome measure for the number of pulmonary exacerbations.</footnote> for TRIKAFTA (N=205) vs Placebo (N=102)</th></tr></thead><tfoot><tr><td colspan=\"3\">BMI: body mass index; CFQ-R: Cystic Fibrosis Questionnaire-Revised; CI: confidence interval; N: total sample size; <content styleCode=\"italics\">P</content>: probability; ppFEV<sub>1</sub>: percent predicted forced expiratory volume in 1 second.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Primary</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in ppFEV<sub>1</sub> from baseline through Week 24 (percentage points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">9.2 (7.2, 11.3) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Secondary</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in sweat chloride from baseline through Week 24 (mmol/L)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">-28.3 (-32.1, -24.5) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change in CFQ-R respiratory domain score from baseline through Week 24 (points)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">19.5 (15.5, 23.5) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change from baseline in BMI at Week 24 (kg/m<sup>2</sup>)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">0.47 (0.24, 0.69) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Absolute change from baseline in weight at Week 24 (kg)</td><td styleCode=\"Rrule\">Treatment difference (95% CI) <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">1.3 (0.6, 1.9) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr><tr><td styleCode=\"Lrule Rrule\">Number of pulmonary exacerbations through Week 24<footnote>Number of pulmonary exacerbation events (event rate per year calculated based on 48 weeks per year) in the TRIKAFTA group were 21 (0.17) and in the placebo group were 40 (0.63).</footnote></td><td styleCode=\"Rrule\">Rate ratio (95% CI)  <content styleCode=\"italics\">P</content> value</td><td styleCode=\"Rrule\">0.28 (0.15, 0.51) <content styleCode=\"italics\">P</content>&lt;0.0001</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with the combination of elexacaftor, tezacaftor and ivacaftor; however, separate studies of elexacaftor, tezacaftor and ivacaftor are described below. Elexacaftor A 6-month study in Tg.rasH2 transgenic mice showed no evidence of tumorigenicity at 50 mg/kg/day dose, the highest dose tested. A two-year study was conducted in rats to assess the carcinogenic potential of elexacaftor. No evidence of tumorigenicity was observed in rats at elexacaftor oral doses up to 10 mg/kg/day (approximately 2 and 5 times the MRHD based on summed AUCs of elexacaftor and its metabolite in male and female rats, respectively). Elexacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro mammalian cell micronucleus assay in TK6 cells, and in vivo mouse micronucleus test. Elexacaftor did not cause reproductive system toxicity in male rats at 55 mg/kg/day and female rats at 25 mg/kg/day, equivalent to approximately 6 times and 4 times the MRHD, respectively (based on summed AUCs of elexacaftor and its metabolite). Elexacaftor did not cause embryonic toxicity at 35 mg/kg/day which was the highest dose tested, equivalent to approximately 7 times the MRHD (based on summed AUCs of elexacaftor and its metabolite). Lower male and female fertility, male copulation and female conception indices were observed in males at 75 mg/kg/day and females at 35 mg/kg/day, equivalent to approximately 6 times and 7 times, respectively, the MRHD (based on summed AUCs of elexacaftor and its metabolite). Tezacaftor A two-year study in Sprague-Dawley rats and a 6-month study in Tg.rasH2 transgenic mice were conducted to assess the carcinogenic potential of tezacaftor. No evidence of tumorigenicity from tezacaftor was observed in male and female rats at oral doses up to 50 and 75 mg/kg/day (approximately 1 and 2 times the MRHD based on summed AUCs of tezacaftor and its metabolites in males and females, respectively). No evidence of tumorigenicity was observed in male and female Tg.rasH2 transgenic mice at tezacaftor doses up to 500 mg/kg/day. Tezacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro chromosomal aberration assay in Chinese hamster ovary cells and in vivo mouse micronucleus test. There were no effects on male or female fertility and early embryonic development in rats at oral tezacaftor doses up to 100 mg/kg/day (approximately 3 times the MRHD based on summed AUC of tezacaftor and M1-TEZ). Ivacaftor Two-year studies were conducted in CD-1 mice and Sprague-Dawley rats to assess the carcinogenic potential of ivacaftor. No evidence of tumorigenicity from ivacaftor was observed in mice or rats at oral doses up to 200 mg/kg/day and 50 mg/kg/day, respectively (approximately equivalent to 2 and 7 times the MRHD, respectively, based on summed AUCs of ivacaftor and its metabolites). Ivacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro chromosomal aberration assay in Chinese hamster ovary cells and in vivo mouse micronucleus test. Ivacaftor impaired fertility and reproductive performance indices in male and female rats at 200 mg/kg/day (approximately 7 and 5 times, respectively, the MRHD based on summed AUCs of ivacaftor and its metabolites). Increases in prolonged diestrus were observed in females at 200 mg/kg/day. Ivacaftor also increased the number of females with all nonviable embryos and decreased corpora lutea, implantations and viable embryos in rats at 200 mg/kg/day (approximately 5 times the MRHD based on summed AUCs of ivacaftor and its metabolites) when dams were dosed prior to and during early pregnancy. These impairments of fertility and reproductive performance in male and female rats at 200 mg/kg/day were attributed to severe toxicity."],"pharmacokinetics_table":["<table width=\"90%\" ID=\"table7\"><caption>Table 7: Pharmacokinetic Parameters of TRIKAFTA Components</caption><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Elexacaftor</th><th styleCode=\"Rrule\">Tezacaftor</th><th styleCode=\"Rrule\">Ivacaftor</th></tr></thead><tfoot><tr><td colspan=\"4\">AUC<sub>ss</sub>: area under the concentration versus time curve at steady state; SD: Standard Deviation; C<sub>max</sub>: maximum observed concentration; T<sub>max</sub>: time of maximum concentration; AUC: area under the concentration versus time curve.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">General Information</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> AUC<sub>ss</sub> (SD), mcg&#x2219;h/mL<footnote ID=\"fn5a\">Based on elexacaftor 200 mg and tezacaftor 100 mg once daily/ivacaftor 150 mg every 12 hours at steady state in patients with CF aged 12 years and older.</footnote></td><td styleCode=\"Rrule\">162 (47.5)<footnote ID=\"fn5b\">AUC<sub>0-24h</sub>.</footnote></td><td styleCode=\"Rrule\">89.3 (23.2)<footnoteRef IDREF=\"fn5b\"/></td><td styleCode=\"Rrule\">11.7 (4.01)<footnote ID=\"fn5c\">AUC<sub>0-12h</sub>.</footnote></td></tr><tr><td styleCode=\"Lrule Rrule\"> C<sub>max</sub> (SD), mcg/mL<footnoteRef IDREF=\"fn5a\"/></td><td styleCode=\"Rrule\">9.2 (2.1)</td><td styleCode=\"Rrule\">7.7 (1.7)</td><td styleCode=\"Rrule\">1.2 (0.3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule Toprule\"> Time to Steady State, days</td><td styleCode=\"Rrule Toprule\">Within 7 days</td><td styleCode=\"Rrule Toprule\">Within 8 days</td><td styleCode=\"Rrule Toprule\">Within 3-5 days</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Accumulation Ratio</td><td styleCode=\"Rrule\">2.2</td><td styleCode=\"Rrule\">2.07</td><td styleCode=\"Rrule\">2.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Absorption</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Absolute Bioavailability</td><td styleCode=\"Rrule\">80%</td><td styleCode=\"Rrule\">Not determined</td><td styleCode=\"Rrule\">Not determined</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Median T<sub>max</sub> (range), hours</td><td styleCode=\"Rrule\">6 (4 to 12)</td><td styleCode=\"Rrule\">3 (2 to 4)</td><td styleCode=\"Rrule\">4 (3 to 6)</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Effect of Food</td><td valign=\"middle\" styleCode=\"Rrule\">AUC increases 1.9- to 2.5-fold (moderate-fat meal)</td><td valign=\"middle\" styleCode=\"Rrule\">No clinically significant effect</td><td valign=\"middle\" styleCode=\"Rrule\">Exposure increases 2.5- to 4-fold</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Distribution</content></td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Apparent Volume of Distribution, L<footnote ID=\"fn5d\">Elexacaftor, tezacaftor and ivacaftor do not partition preferentially into human red blood cells.</footnote></td><td valign=\"middle\" styleCode=\"Rrule\">53.7 (17.7)</td><td valign=\"middle\" styleCode=\"Rrule\">82.0 (22.3)</td><td valign=\"middle\" styleCode=\"Rrule\">293 (89.8)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Protein Binding<footnote ID=\"fn5e\">Elexacaftor and tezacaftor bind primarily to albumin. Ivacaftor primarily bind to albumin, alpha 1-acid glycoprotein and human gamma-globulin.</footnote></td><td styleCode=\"Rrule\">&gt;99%</td><td styleCode=\"Rrule\">approximately 99%</td><td styleCode=\"Rrule\">approximately 99%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Elimination</content></td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Effective Half-Life, hours<footnote ID=\"fn5f\">Mean (SD) terminal half-lives of elexacaftor, tezacaftor and ivacaftor are approximately 24.7 (4.87) hours, 60.3 (15.7) hours and 13.1 (2.98) hours, respectively.</footnote></td><td valign=\"middle\" styleCode=\"Rrule\">27.4 (9.31)</td><td valign=\"middle\" styleCode=\"Rrule\">25.1 (4.93)</td><td valign=\"middle\" styleCode=\"Rrule\">15.0 (3.92)</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Apparent Clearance, L/hours</td><td valign=\"middle\" styleCode=\"Rrule\">1.18 (0.29)</td><td valign=\"middle\" styleCode=\"Rrule\">0.79 (0.10)</td><td valign=\"middle\" styleCode=\"Rrule\">10.2 (3.13)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"italics\">Metabolism</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Primary Pathway</td><td styleCode=\"Rrule\">CYP3A4/5</td><td styleCode=\"Rrule\">CYP3A4/5</td><td styleCode=\"Rrule\">CYP3A4/5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Active Metabolites</td><td styleCode=\"Rrule\">M23-ELX</td><td styleCode=\"Rrule\">M1-TEZ </td><td styleCode=\"Rrule\">M1-IVA</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Metabolite Potency Relative to Parent</td><td valign=\"middle\" styleCode=\"Rrule\">Similar</td><td valign=\"middle\" styleCode=\"Rrule\">Similar</td><td valign=\"middle\" styleCode=\"Rrule\">approximately 1/6<sup>th</sup> of parent</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"italics\">Excretion<footnote>Following radiolabeled doses.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"middle\"> Primary Pathway</td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 87.3% (primarily as metabolites)</item><item>Urine: 0.23%</item></list></td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 72% (unchanged or as M2-TEZ)</item><item>Urine: 14% (0.79% unchanged)</item></list></td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 87.8%</item><item>Urine: 6.6%</item></list></td></tr></tbody></table>","<table width=\"100%\" ID=\"table8\"><caption>Table 8: Mean (SD) Elexacaftor, Tezacaftor and Ivacaftor Exposures Observed at Steady State by Age Group and Dose Administered</caption><col width=\"23%\" align=\"left\" valign=\"middle\"/><col width=\"26%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"16%\" align=\"center\" valign=\"middle\"/><col width=\"16%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" align=\"center\">Age Group</th><th styleCode=\"Rrule\" align=\"center\">Dose</th><th styleCode=\"Rrule\" align=\"center\">Elexacaftor AUC<sub>0-24h,ss</sub> (&#xB5;g&#x2219;h/mL)</th><th styleCode=\"Rrule\" align=\"center\">Tezacaftor AUC<sub>0-24h,ss</sub> (&#xB5;g&#x2219;h/mL)</th><th styleCode=\"Rrule\" align=\"center\">Ivacaftor AUC<sub>0-12h,ss</sub> (&#xB5;g&#x2219;h/mL)</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">SD: Standard Deviation; AUC<sub>ss</sub>: area under the concentration versus time curve at steady state.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 2 to less than 6 years weighing less than 14 kg (N = 16)</td><td styleCode=\"Rrule\">elexacaftor 80 mg qd/tezacaftor 40 mg qd/ivacaftor 60 mg qAM and ivacaftor 59.5 mg qPM</td><td styleCode=\"Rrule\">128 (24.8)</td><td styleCode=\"Rrule\">87.3 (17.3)</td><td styleCode=\"Rrule\">11.9 (3.86)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 2 to less than 6 years weighing 14 kg or more (N = 59)</td><td styleCode=\"Rrule\">elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h</td><td styleCode=\"Rrule\">138 (47.0)</td><td styleCode=\"Rrule\">90.2 (27.9)</td><td styleCode=\"Rrule\">13.0 (6.11)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 6 to less than 12 years weighing less than 30 kg  (N = 36)</td><td styleCode=\"Rrule\">elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h</td><td styleCode=\"Rrule\">116 (39.4)</td><td styleCode=\"Rrule\">67.0 (22.3)</td><td styleCode=\"Rrule\">9.78 (4.50)</td></tr><tr><td styleCode=\"Lrule Rrule\">Patients aged 6 to less than 12 years weighing 30 kg or more (N = 30)</td><td styleCode=\"Rrule\">elexacaftor 200 mg qd/ tezacaftor 100 mg qd/ ivacaftor 150 mg q12h</td><td styleCode=\"Rrule\">195 (59.4)</td><td styleCode=\"Rrule\">103 (23.7)</td><td styleCode=\"Rrule\">17.5 (4.97)</td></tr></tbody></table>","<table width=\"90%\" ID=\"table9\"><caption>Table 9: Impact of Elexacaftor, Tezacaftor and/or Ivacaftor on Other Drugs</caption><col width=\"32%\" align=\"center\" valign=\"middle\"/><col width=\"22%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" colspan=\"2\">Dose and Schedule</th><th styleCode=\"Rrule\" rowspan=\"2\">Effect on Other Drug PK</th><th styleCode=\"Rrule Botrule\" colspan=\"2\">Geometric Mean Ratio (90% CI) of Other Drug No Effect=1.0</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" colspan=\"2\"/><th styleCode=\"Rrule\">AUC</th><th styleCode=\"Rrule\">C<sub>max</sub></th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">&#x2191; = increase, &#x2193; = decrease, &#x2194; = no change.</td></tr><tr><td align=\"left\" valign=\"top\" colspan=\"5\">AUC: area under the concentration versus time curve; CI: Confidence Interval; ELX: elexacaftor; C<sub>max</sub>: maximum observed concentration; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam 2 mg single oral dose</td><td valign=\"top\" styleCode=\"Rrule\">TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Midazolam</td><td styleCode=\"Rrule\">1.12 (1.01, 1.25)</td><td styleCode=\"Rrule\">1.13 (1.01, 1.25)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Digoxin 0.5 mg single dose</td><td styleCode=\"Rrule\">TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2191; Digoxin</td><td styleCode=\"Rrule\">1.30 (1.17, 1.45)</td><td styleCode=\"Rrule\">1.32 (1.07, 1.64)</td></tr><tr><td styleCode=\"Lrule Rrule Botrule\" rowspan=\"2\">Oral Contraceptive Ethinyl estradiol 30 &#xB5;g/Levonorgestrel 150 &#xB5;g qd</td><td styleCode=\"Rrule Botrule\" rowspan=\"2\">ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\" valign=\"top\">&#x2191; Ethinyl estradiol<footnote ID=\"t7f1\"> Effect is not clinically significant <content styleCode=\"italics\">[see </content><content styleCode=\"italics\"><linkHtml href=\"#S7.3\">Drug Interactions (7.3)</linkHtml>]</content>.</footnote></td><td styleCode=\"Rrule\" valign=\"top\">1.33 (1.20, 1.49)</td><td styleCode=\"Rrule\" valign=\"top\">1.26 (1.14, 1.39)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"top\">&#x2191; Levonorgestrel<footnoteRef IDREF=\"t7f1\"/></td><td styleCode=\"Rrule\" valign=\"top\">1.23 (1.10, 1.37)</td><td styleCode=\"Rrule\" valign=\"top\">1.10 (0.985, 1.23)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rosiglitazone 4 mg single oral dose</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Rosiglitazone</td><td styleCode=\"Rrule\">0.975 (0.897, 1.06)</td><td styleCode=\"Rrule\">0.928 (0.858, 1.00)</td></tr><tr><td styleCode=\"Lrule Rrule\">Desipramine 50 mg single dose</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Desipramine</td><td styleCode=\"Rrule\">1.04 (0.985, 1.10)</td><td styleCode=\"Rrule\">1.00 (0.939, 1.07)</td></tr></tbody></table>","<table width=\"90%\" ID=\"table10\"><caption>Table 10: Impact of Other Drugs on Elexacaftor, Tezacaftor and/or Ivacaftor</caption><col width=\"32%\" align=\"center\" valign=\"middle\"/><col width=\"22%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" rowspan=\"2\" colspan=\"2\">Dose and Schedule</th><th styleCode=\"Rrule\" rowspan=\"2\">Effect on ELX, TEZ and/or IVA PK</th><th styleCode=\"Rrule\" colspan=\"2\">Geometric Mean Ratio (90% CI) of Elexacaftor, Tezacaftor and Ivacaftor No Effect = 1.0</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Rrule Toprule\">AUC</th><th styleCode=\"Rrule Toprule\">C<sub>max</sub></th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">&#x2191; = increase, &#x2193; = decrease, &#x2194; = no change.</td></tr><tr><td align=\"left\" valign=\"top\" colspan=\"5\">AUC: area under the concentration versus time curve; CI: Confidence Interval; C<sub>max</sub>: maximum observed concentration; ELX: elexacaftor; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Itraconazole 200 mg q12h on Day 1, followed by 200 mg qd</td><td styleCode=\"Rrule\" rowspan=\"2\">TEZ 25 mg qd + IVA 50 mg qd</td><td styleCode=\"Rrule\">&#x2191; Tezacaftor</td><td styleCode=\"Rrule\">4.02 (3.71, 4.63)</td><td styleCode=\"Rrule\">2.83 (2.62, 3.07)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">15.6 (13.4, 18.1)</td><td styleCode=\"Rrule\">8.60 (7.41, 9.98)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Itraconazole 200 mg qd</td><td styleCode=\"Rrule\" rowspan=\"2\">ELX 20 mg + TEZ 50 mg single dose</td><td styleCode=\"Rrule\">&#x2191; Elexacaftor</td><td styleCode=\"Rrule\">2.83 (2.59, 3.10)</td><td styleCode=\"Rrule\">1.05 (0.977, 1.13)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Tezacaftor</td><td styleCode=\"Rrule\">4.51 (3.85, 5.29)</td><td styleCode=\"Rrule\">1.48 (1.33, 1.65)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Ketoconazole 400 mg qd</td><td styleCode=\"Rrule\" valign=\"middle\">IVA 150 mg single dose</td><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">8.45 (7.14, 10.0)</td><td styleCode=\"Rrule\">2.65 (2.21, 3.18)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Ciprofloxacin 750 mg q12h</td><td styleCode=\"Rrule\" rowspan=\"2\">TEZ 50 mg q12h + IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Tezacaftor</td><td styleCode=\"Rrule\">1.08 (1.03, 1.13)</td><td styleCode=\"Rrule\">1.05 (0.99, 1.11)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">&#x2191; Ivacaftor<footnote>Effect is not clinically significant <content styleCode=\"italics\">[see </content><content styleCode=\"italics\"><linkHtml href=\"#S7.3\">Drug Interactions (7.3)</linkHtml>]</content>.</footnote></td><td styleCode=\"Rrule\">1.17 (1.06, 1.30)</td><td styleCode=\"Rrule\">1.18 (1.06, 1.31)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rifampin 600 mg qd</td><td styleCode=\"Rrule\">IVA 150 mg single dose</td><td styleCode=\"Rrule\">&#x2193; Ivacaftor</td><td styleCode=\"Rrule\">0.114 (0.097, 0.136)</td><td styleCode=\"Rrule\">0.200 (0.168, 0.239)</td></tr><tr><td styleCode=\"Lrule Rrule\">Fluconazole 400 mg single dose on Day 1, followed by 200 mg qd</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">2.95 (2.27, 3.82)</td><td styleCode=\"Rrule\">2.47 (1.93, 3.17)</td></tr></tbody></table>"],"adverse_reactions_table":["<table width=\"90%\" ID=\"table4\"><caption>Table 4: Adverse Reactions Occurring in &#x2265;5% of TRIKAFTA-Treated Patients and Higher than Placebo by &#x2265;1% in Trial 1</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><thead><tr><th align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Adverse Reactions</th><th styleCode=\"Rrule\">TRIKAFTA N=202 n (%)</th><th styleCode=\"Rrule\">Placebo N=201 n (%)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Headache</td><td styleCode=\"Rrule Toprule\">35 (17)</td><td styleCode=\"Rrule Toprule\">30 (15)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Upper respiratory tract infection<footnote>Includes upper respiratory tract infection and viral upper respiratory tract infection.</footnote></td><td styleCode=\"Rrule\">32 (16)</td><td styleCode=\"Rrule\">25 (12)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Abdominal pain<footnote>Includes abdominal pain, abdominal pain upper, abdominal pain lower.</footnote></td><td styleCode=\"Rrule\">29 (14)</td><td styleCode=\"Rrule\">18 (9)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Diarrhea</td><td styleCode=\"Rrule\">26 (13)</td><td styleCode=\"Rrule\">14 (7)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rash<footnote>Includes rash, rash generalized, rash erythematous, rash macular, rash pruritic.</footnote></td><td styleCode=\"Rrule\">21 (10)</td><td styleCode=\"Rrule\">10 (5)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Alanine aminotransferase increased</td><td styleCode=\"Rrule\">20 (10)</td><td styleCode=\"Rrule\">7 (3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Nasal congestion</td><td styleCode=\"Rrule\">19 (9)</td><td styleCode=\"Rrule\">15 (7)</td></tr><tr><td styleCode=\"Lrule Rrule\">Blood creatine phosphokinase increased</td><td valign=\"middle\" styleCode=\"Rrule\">19 (9)</td><td valign=\"middle\" styleCode=\"Rrule\">9 (4)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule Toprule\">Aspartate aminotransferase increased</td><td styleCode=\"Rrule Toprule\" valign=\"middle\">19 (9)</td><td styleCode=\"Rrule Toprule\" valign=\"middle\">4 (2)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rhinorrhea</td><td styleCode=\"Rrule\">17 (8)</td><td styleCode=\"Rrule\">6 (3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rhinitis</td><td styleCode=\"Rrule\">15 (7)</td><td styleCode=\"Rrule\">11 (5)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Influenza</td><td styleCode=\"Rrule\">14 (7)</td><td styleCode=\"Rrule\">3 (1)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Sinusitis</td><td styleCode=\"Rrule\">11 (5)</td><td styleCode=\"Rrule\">8 (4)</td></tr><tr><td styleCode=\"Lrule Rrule\">Blood bilirubin increased</td><td styleCode=\"Rrule\">10 (5)</td><td styleCode=\"Rrule\">2 (1)</td></tr></tbody></table>","<table width=\"75%\" ID=\"table5\"><caption>Table 5: Adverse Reactions Occurring in &#x2265;5% of TRIKAFTA-Treated Patients and Higher than Placebo by &#x2265;1% in Trial 5</caption><col width=\"33%\" align=\"left\" valign=\"middle\"/><col width=\"33%\" align=\"center\" valign=\"middle\"/><col width=\"34%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Adverse Reactions</th><th styleCode=\"Rrule\">TRIKAFTA N=205 n (%)</th><th styleCode=\"Rrule\">Placebo N=102 n (%)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rash<footnote>Includes rash, rash maculo-papular, rash erythematous, rash papular</footnote></td><td styleCode=\"Rrule\">48 (23)</td><td styleCode=\"Rrule\">2 (2)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Headache</td><td styleCode=\"Rrule\">37 (18)</td><td styleCode=\"Rrule\">13 (13)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Diarrhea</td><td styleCode=\"Rrule\">26 (13)</td><td styleCode=\"Rrule\">10 (10)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rhinitis</td><td styleCode=\"Rrule\">20 (10)</td><td styleCode=\"Rrule\">6 (6)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Influenza</td><td styleCode=\"Rrule\">18 (9)</td><td styleCode=\"Rrule\">2 (2)</td></tr><tr><td styleCode=\"Lrule Rrule\">Constipation</td><td styleCode=\"Rrule\">15 (7)</td><td styleCode=\"Rrule\">4 (4)</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Drug-Induced Liver Injury and Liver Failure Inform patients that TRIKAFTA is associated with a serious risk for drug-induced liver injury and that liver injury resulting in liver failure leading to liver transplantation or death have occurred, including in patients without a history of liver disease. Advise all patients that liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) should be assessed prior to initiating TRIKAFTA and then assessed every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Inform patients with a history of liver disease or liver function test elevations at baseline that more frequent monitoring may be necessary. Instruct patients to interrupt treatment with TRIKAFTA if symptoms of liver injury occur (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites) and to notify their healthcare provider immediately. [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ] . Drug Interactions with CYP3A Inducers and Inhibitors Ask patients to tell you all the medications they are taking including any herbal supplements or vitamins. Inform patients that concomitant use of TRIKAFTA with strong CYP3A inducers (e.g., rifampin, St. John's wort) is not recommended, as they may reduce the efficacy of TRIKAFTA. Dose reduction to two elexacaftor/tezacaftor/ivacaftor tablets or one elexacaftor/tezacaftor/ivacaftor oral granules packet twice a week, taken approximately 3 to 4 days apart is recommended when used concomitantly with strong CYP3A inhibitors, such as ketoconazole. Advise the patient not to take the evening dose of ivacaftor. Dose reduction to two elexacaftor/tezacaftor/ivacaftor tablets or one elexacaftor/tezacaftor/ivacaftor oral granules packet and one ivacaftor tablet or ivacaftor oral granules packet, taken on alternate days, is recommended when used concomitantly with moderate CYP3A inhibitors, such as fluconazole. Advise the patient not to take the evening dose of ivacaftor. Food or drink containing grapefruit should be avoided [see Dosage and Administration (2.4) , Warnings and Precautions (5.5 , 5.6 ), Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . Hypersensitivity Reactions, Including Anaphylaxis Hypersensitivity reactions including angioedema and anaphylaxis are possible with use of TRIKAFTA. Inform patients of the early signs of hypersensitivity reactions including rash, hives, itching, facial swelling, tightness of the chest and wheezing. Advise patients to discontinue use of TRIKAFTA immediately and contact their physician or go to the emergency department if these symptoms occur [see Warnings and Precautions (5.2) ] . Intracranial Hypertension Inform patients that intracranial hypertension has occurred with the use of TRIKAFTA. Instruct patients to notify their healthcare provider right away if they experience signs and symptoms of intracranial hypertension, including headache, blurred vision, diplopia, and vision loss [see Warnings and Precautions (5.3) ] . Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors Inform patients that neuropsychiatric symptoms, including anxiety, depression, suicidal thoughts and behaviors, and sleep disturbances (e.g., insomnia), have been reported with the use of TRIKAFTA or drugs containing the same or similar active ingredients as TRIKAFTA. The symptoms have been observed in patients with and without a history of similar symptoms and may occur within three months of TRIKAFTA initiation. Instruct patients to contact their healthcare provider immediately if changes in behavior or thinking that are not typical for the patient occur, or if the patient develops suicidal ideation or behavior [see Warnings and Precautions (5.4) ] . Cataracts Inform patients that abnormality of the eye lens (cataract) has been noted in some children and adolescents receiving ivacaftor-containing regimens. Baseline and follow-up ophthalmological examinations should be performed in pediatric patients initiating treatment with TRIKAFTA [see Warnings and Precautions (5.7) and Use in Specific Populations (8.4) ] . Administration Inform patients that TRIKAFTA is best absorbed by the body when taken with food that contains fat. A typical CF diet will satisfy this requirement. Examples include eggs, butter, peanut butter, whole-milk dairy products (such as whole milk, cheese and yogurt), etc. [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) ] . Patients should be informed about what to do in the event they miss a dose [see Dosage and Administration (2.5) ] of TRIKAFTA: If 6 hours or less have passed since the missed morning or evening dose is usually taken, patients should be instructed to take the prescribed dose with fat-containing food as soon as possible. If more than 6 hours have passed since: the time the morning dose is usually taken, patients should be instructed to take the morning dose as soon as possible, and not take the evening dose. Patients should take the next scheduled morning dose at the usual time. the time the evening dose is usually taken, patients should be instructed to not take the missed evening dose. Patients should take the next scheduled morning dose at the usual time. Patients should be instructed to not take the morning and evening doses at the same time. Patients should be advised to contact their health care provider if they have questions."],"spl_unclassified_section":["Manufactured for Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 TRIKAFTA, VERTEX and Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. ©2026 Vertex Pharmaceuticals Incorporated All Rights Reserved"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Prior to initiating TRIKAFTA obtain liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients. Monitor liver function tests every month during the first 6 months of treatment, then every 3 months during the next 12 months, then at least annually thereafter. ( 2.1 , 5.1) Recommended Dosage for Adult and Pediatric Patients Aged 2 Years and Older (with fat-containing food ( 2.2 , 12.3 )) Age Weight Morning Dose Evening Dose 2 to less than 6 years Less than 14 kg One packet containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg oral granules One packet containing ivacaftor 59.5 mg oral granules 14 kg or more One packet containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg oral granules One packet containing ivacaftor 75 mg oral granules 6 to less than 12 years Less than 30 kg Two tablets, each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg One tablet of ivacaftor 75 mg 30 kg or more Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg One tablet of ivacaftor 150 mg 12 years and older - Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg One tablet of ivacaftor 150 mg Should not be used in patients with severe hepatic impairment. Use not recommended in patients with moderate hepatic impairment unless the benefit outweighs the risk. Reduce dose if used in patients with moderate hepatic impairment. Liver function tests should be closely monitored. ( 2.3 , 5.1 , 6 , 8.7 , 12.3 ) See full prescribing information for dosage modifications due to drug interactions with TRIKAFTA. ( 2.4 , 5.6 , 7.1 , 12.3 ) 2.1 Recommended Laboratory Testing Prior to TRIKAFTA Initiation and During Treatment Prior to initiating TRIKAFTA, obtain liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) for all patients. Monitor liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see Warnings and Precautions (5.1) and Use in Specific Populations (8.7) ] . 2.2 Recommended Dosage in Adults and Pediatric Patients Aged 2 Years and Older Recommended dosage for adult and pediatric patients aged 2 years and older is provided in Table 1. Administer TRIKAFTA tablets (swallow the tablets whole) or oral granules orally with fat-containing food, in the morning and in the evening approximately 12 hours apart. Examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs, peanut butter, cheeses, nuts, whole milk, or meats [see Clinical Pharmacology (12.3) ] . Administer each dose of TRIKAFTA oral granules immediately before or after ingestion of fat-containing food. Mix entire contents of each packet of oral granules with one teaspoon (5 mL) of age-appropriate soft food or liquid that is at or below room temperature. Some examples of soft food or liquids include pureed fruits or vegetables, yogurt, applesauce, water, milk, or juice. Once mixed, the product should be consumed completely within one hour. Table 1: Recommended Dosage of TRIKAFTA for Adult and Pediatric Patients Aged 2 Years and Older Age Weight Oral Morning Dose Oral Evening Dose 2 to less than 6 years Less than 14 kg One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules One packet (containing ivacaftor 59.5 mg) oral granules 14 kg or more One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules One packet (containing ivacaftor 75 mg) oral granules 6 to less than 12 years Less than 30 kg Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) One tablet of ivacaftor 75 mg 30 kg or more Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) One tablet of ivacaftor 150 mg 12 years and older — Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) One tablet of ivacaftor 150 mg 2.3 Recommended Dosage for Patients with Hepatic Impairment Severe Hepatic Impairment (Child-Pugh Class C): Should not be used. TRIKAFTA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), but the exposure is expected to be higher than in patients with moderate hepatic impairment [see Warnings and Precautions (5.1) , Adverse Reactions (6) , Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . Moderate Hepatic Impairment (Child-Pugh Class B) : Treatment is not recommended. Use of TRIKAFTA in patients with moderate hepatic impairment should only be considered when there is a clear medical need, and the benefit outweighs the risk. If used, TRIKAFTA should be used with caution at a reduced dose (see Table 2 ) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . Liver function tests should be closely monitored [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Recommended dosage for patients with moderate hepatic impairment (Child-Pugh Class B) is provided in Table 2. Table 2: Recommended Dosage of TRIKAFTA, if used, in Patients with Moderate Hepatic Impairment (Child-Pugh Class B) Age Weight Oral Morning Dose Oral Evening Dose 2 to less than 6 years Less than 14 kg Weekly dosing schedule is as follows: Days 1-3: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules each day Day 4: no dose Days 5-6: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules each day Day 7: no dose No evening dose of ivacaftor oral granules. 14 kg or more Weekly dosing schedule is as follows: Days 1-3: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules each day Day 4: no dose Days 5-6: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules each day Day 7: no dose No evening dose of ivacaftor oral granules. 6 to less than 12 years Less than 30 kg Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) Day 2: One tablet of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg No evening ivacaftor tablet dose. 30 kg or more Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) Day 2: One tablet of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg No evening ivacaftor tablet dose. 12 years and older — Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) Day 2: One tablet of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg No evening ivacaftor tablet dose. Mild Hepatic Impairment (Child-Pugh Class A): No dose adjustment is recommended [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . See Table 1 for recommended dosage of TRIKAFTA. Liver function tests should be closely monitored [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. 2.4 Dosage Modification for Patients Taking Drugs that are CYP3A Inhibitors Table 3 describes the recommended dosage modification for TRIKAFTA when used concomitantly with strong (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin) or moderate (e.g., fluconazole, erythromycin) CYP3A inhibitors. Administer TRIKAFTA orally with fat-containing food [see Dosage and Administration (2.2) ]. Avoid food or drink containing grapefruit during TRIKAFTA treatment [see Warnings and Precautions (5.6) , Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . Table 3: Dosage Modification for Concomitant Use of TRIKAFTA with Moderate and Strong CYP3A Inhibitors Age Weight Moderate CYP3A Inhibitors Strong CYP3A Inhibitors 2 to less than 6 years Less than 14 kg Alternating daily dosing schedule is as follows: Day 1: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning Day 2: One packet (containing ivacaftor 59.5 mg) oral granules in the morning No evening packet of ivacaftor oral granules. One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening packet of ivacaftor oral granules. 14 kg or more Alternating daily dosing schedule is as follows: Day 1: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning Day 2: One packet (containing ivacaftor 75 mg) oral granules in the morning No evening packet of ivacaftor oral granules. One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening packet of ivacaftor oral granules. 6 to less than 12 years Less than 30 kg Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning Day 2: One tablet of ivacaftor 75 mg in the morning No evening ivacaftor tablet dose. Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening ivacaftor tablet dose. 30 kg or more Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor100 mg/ivacaftor 150 mg) in the morning Day 2: One tablet of ivacaftor 150 mg in the morning No evening ivacaftor tablet dose. Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening ivacaftor tablet dose. 12 years and older — Alternating daily dosing schedule is as follows: Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning Day 2: One tablet of ivacaftor 150 mg in the morning No evening ivacaftor tablet dose. Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening ivacaftor tablet dose. 2.5 Recommendations Regarding Missed Dose(s) If 6 hours or less have passed since the missed morning or evening dose, the patient should take the missed dose as soon as possible and continue on the original schedule. If more than 6 hours have passed since: the missed morning dose, the patient should take the missed dose as soon as possible and should not take the evening dose. The next scheduled morning dose should be taken at the usual time. the missed evening dose, the patient should not take the missed dose. The next scheduled morning dose should be taken at the usual time. Morning and evening doses should not be taken at the same time."],"mechanism_of_action_table":["<table width=\"100%\" ID=\"table6\"><caption>Table 6: List of CFTR Gene Variants Responsive to TRIKAFTA </caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><tfoot><tr><td colspan=\"5\">The list of responsive CFTR variants is non-exhaustive. There may be protein-producing CFTR variants not listed that respond to treatment with TRIKAFTA.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Variants responsive to TRIKAFTA based on clinical data<footnote>Clinical data obtained from Trials 1, 2, and 5.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2789+5G&#x2192;A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">D1152H<footnote ID=\"t6f2\">This variant is also predicted to be responsive by FRT assay.</footnote></content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L206W</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1066H</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S945L</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3272-26A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508del</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L997F</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117C</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T338I</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3849+10kbC&#x2192;T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G85E</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1101K</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347H</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V232D</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A455E</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1077P</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P5L</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347P</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Variants responsive to TRIKAFTA based on in vitro data<footnote>The N1303K variant is predicted to be responsive by HBE assay. All other variants predicted to be responsive with in vitro data are supported by FRT assay.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1140-1151dup</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E264V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H620P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N396Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1251N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1461insGAT</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E282D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H620Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N418S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1255P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1507_1515del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E292K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H939R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N900K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S13F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2055del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E384K </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H939R;H949L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1013H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S13P </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2183A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E403D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H954P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1013L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S158N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2851A/G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E474K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1023R </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1021L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S182R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">293A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E527G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1027T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1021T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S18I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3007del6</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E56K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I105N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P111L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S18N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3132T&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E588V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1139V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1372T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S308P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3141del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E60K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1203V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P140S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S341P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3143del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E822K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1234L </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P205S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S364P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">314del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E92K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1234V del6aa</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P439S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S434P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3331del6</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1016S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I125T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P499A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S492F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3410T&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1052V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1269N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P574H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S50P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3523A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1074L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1366N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P67L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S519G </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3601A&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1078S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1366T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P750L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S531P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3761T&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1099L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P798S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3791C/T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1107L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P988R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3850G&#x2192;A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F191V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1012P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3978G&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F200I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I175V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1209P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S557F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">546insCTA</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F311del</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I331N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1291H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S589I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">548insTAC</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F311L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I336K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1291R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S589N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1006E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F312del</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I336L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1313K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S624R </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1025D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F433L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I444S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1352H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S686Y</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I497S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q151K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S737F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508C;S1251N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I502T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q179K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S821G </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508del;R1438W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S898R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A107G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F575Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1081V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F587I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506V;D1168G </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912L;G1244V</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1087P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F587L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I521S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q30P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912T</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A120T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F693L(TTG)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I530N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q359K/T360K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S955P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1319E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F87L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I556V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q359R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S977F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1374D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F932S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I586V </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q372H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S977F;R1438W</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A141D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1047D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I601F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q493L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1036N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1466S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1047R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I618N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q493R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1053I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A155P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1061R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I618T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q552P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1057R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A234D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1069R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I807M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q98P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1086A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A234V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1123R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I86M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q98R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1086I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A238V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1173S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I980K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1048G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1246I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A309D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1237V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K1060T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1066G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1299I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A349V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1244E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K162E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1299K</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A357T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1244R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K464E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A455V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1247R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K464N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A457T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1249E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K522E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1162L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351S;R851L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A462P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1249R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K522Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1162Q </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T388M </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A46D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1265V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K951E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117C;G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T465I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A534E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G126D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1011S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T501A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A554E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1298V </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L102R;F1016S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T582S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A566D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1349D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1065R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T908N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A62P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G149R;G576A;R668C </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1227S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117L;L997F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T990I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A872E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G178E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1324P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1008D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">c.1367_1369dupTTG</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G178R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1335P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1239S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1010D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C225R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G194R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L137P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1153E</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C491R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G194V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1388P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V11I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C590Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1480P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1240G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C866Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213E;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L159S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1438W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1293G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L15P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R170H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1293I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G226R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L15P;L1253F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R248K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1415F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G239R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L165S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R258G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V201M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1152A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G253R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L167R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R297Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V232A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G27E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L210P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R31C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V317A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1270Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G27R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L293P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R31L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V322M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1312G </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G314E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L320V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R334L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V392G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1377H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G314R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L327P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R334Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V456A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1445N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G424S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L32P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V456F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D192G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G437D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L333F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R352Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V520I </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D192N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G461R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L333H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R352W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D373N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G461V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L346P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R516S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562I;A1006E</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D426N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G463V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L441P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R553Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D443Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L453S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R555G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V591A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D443Y;G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L467F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R600S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V603F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D529G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L558F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V754M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D565G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G500D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L619S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R709Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V920L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D567N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G545R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L633P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V920M </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D579G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L636P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q;R297Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V93D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D58H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L88S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q;V201M;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1098C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D58V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L927P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1282G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D614G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L967F;L1096R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1282R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D651H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L967S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;R1070W;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W202C </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D651N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L973F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;S945L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W361R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D806G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A;S1359Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1137R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W496R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D836Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G622D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1137V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1014C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D924N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G622V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1210K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M;L997F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1032C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D979A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G628A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M150K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R751L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1032N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D979V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G628R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M150R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1073C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D985H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G930E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M152L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1092H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D985Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M152V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;L1065P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y109H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M265R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;N1088D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y109N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M348K </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;S549N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y122C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1054D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M394L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R792G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1381H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1104K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1079P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M469V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R792Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1104V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1085P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M498I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R810G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1126K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1085R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M952I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R851L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E116K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1375N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M952T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R933G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y301C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E116Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1375P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M961L </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1045Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y563N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1221V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H139L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1088D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S108F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y89C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1228K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H139R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1195T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1118F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y913S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1409K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H146R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1303I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1159F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y919C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1433K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H199Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1303K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1159P</content></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E193K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H199Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N186K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1188L</content></td><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E217G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H609L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N187K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1235R</content></td><td styleCode=\"Rrule\"/></tr></tbody></table>"],"spl_product_data_elements":["Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor Elexacaftor Tezacaftor Tezacaftor Ivacaftor Ivacaftor HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) HYPROMELLOSE, UNSPECIFIED sodium lauryl sulfate croscarmellose sodium microcrystalline cellulose magnesium stearate hypromellose 2910 (6 mpa.s) hydroxypropyl cellulose, unspecified titanium dioxide talc ferric oxide yellow ferric oxide red Oblong T100 Ivacaftor Ivacaftor Ivacaftor Ivacaftor silicon dioxide HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate Magnesium stearate microcrystalline cellulose sodium lauryl sulfate carnauba wax FD&C Blue No. 2 polyethylene glycol 3350 polyvinyl alcohol, unspecified talc titanium dioxide Ammonia ferrosoferric oxide propylene glycol shellac Croscarmellose sodium light blue Oblong V;150 Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor Elexacaftor Tezacaftor Tezacaftor Ivacaftor Ivacaftor HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) HYPROMELLOSE, UNSPECIFIED sodium lauryl sulfate croscarmellose sodium microcrystalline cellulose magnesium stearate hypromellose 2910 (6 mpa.s) hydroxypropyl cellulose, unspecified titanium dioxide talc ferric oxide yellow ferric oxide red light orange Oblong T50 Ivacaftor Ivacaftor Ivacaftor Ivacaftor silicon dioxide Croscarmellose sodium HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate Magnesium stearate microcrystalline cellulose sodium lauryl sulfate carnauba wax FD&C Blue No. 2 polyethylene glycol 3350 polyvinyl alcohol, unspecified talc titanium dioxide Ammonia ferrosoferric oxide propylene glycol shellac light blue Oblong V;75 Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor Elexacaftor Tezacaftor Tezacaftor Ivacaftor Ivacaftor silicon dioxide croscarmellose sodium HYPROMELLOSE, UNSPECIFIED HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate magnesium stearate mannitol sodium lauryl sulfate sucralose Trikafta Ivacaftor Ivacaftor Ivacaftor silicon dioxide Croscarmellose sodium HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate Magnesium stearate sucralose sodium lauryl sulfate mannitol Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Trikafta Elexacaftor, Tezacaftor, and Ivacaftor Elexacaftor Elexacaftor Tezacaftor Tezacaftor Ivacaftor Ivacaftor silicon dioxide croscarmellose sodium HYPROMELLOSE, UNSPECIFIED HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate magnesium stearate mannitol sodium lauryl sulfate sucralose Trikafta Ivacaftor Ivacaftor Ivacaftor silicon dioxide Croscarmellose sodium HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S) lactose monohydrate Magnesium stearate sucralose sodium lauryl sulfate mannitol"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: Fixed-dose combination containing elexacaftor 50 mg, tezacaftor 25 mg and ivacaftor 37.5 mg co-packaged with ivacaftor 75 mg; Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 150 mg. ( 3 ) Oral granules: Unit-dose packets of elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg co-packaged with unit-dose packets of ivacaftor 75 mg; Unit-dose packets of elexacaftor 80 mg, tezacaftor 40 mg and ivacaftor 60 mg co-packaged with unit-dose packets of ivacaftor 59.5 mg. ( 3 ) Tablets : Fixed-dose combination containing elexacaftor 50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg co-packaged with ivacaftor 75 mg: Elexacaftor, tezacaftor and ivacaftor tablets are light orange, oblong-shaped and debossed with \"T50\" on one side and plain on the other Ivacaftor tablets are light blue, oblong-shaped, and printed with \"V 75\" in black ink on one side and plain on the other Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 150 mg: Elexacaftor, tezacaftor and ivacaftor tablets are orange, oblong-shaped and debossed with \"T100\" on one side and plain on the other Ivacaftor tablets are light blue, oblong-shaped, and printed with \"V 150\" in black ink on one side and plain on the other Oral Granules : Fixed-dose combination oral granules containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 75 mg oral granules: Elexacaftor, tezacaftor, and ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and orange unit-dose packet Ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and pink unit-dose packet Fixed-dose combination oral granules containing elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg co-packaged with ivacaftor 59.5 mg oral granules: Elexacaftor, tezacaftor, and ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and blue unit-dose packet Ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and green unit-dose packet"],"recent_major_changes_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"80%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"right\" valign=\"top\"/><tbody><tr><td>Indications and Usage (<linkHtml href=\"#S1\">1</linkHtml>)</td><td>03/2026</td></tr><tr><td>Warnings and Precautions, Intracranial Hypertension (<linkHtml href=\"#S5.3\">5.3</linkHtml>)</td><td>09/2025</td></tr><tr><td>Warnings and Precautions, Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors (<linkHtml href=\"#S5.4\">5.4</linkHtml>)</td><td>03/2026</td></tr></tbody></table>"],"clinical_pharmacology_table":["<table width=\"100%\" ID=\"table6\"><caption>Table 6: List of CFTR Gene Variants Responsive to TRIKAFTA </caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><tfoot><tr><td colspan=\"5\">The list of responsive CFTR variants is non-exhaustive. There may be protein-producing CFTR variants not listed that respond to treatment with TRIKAFTA.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Variants responsive to TRIKAFTA based on clinical data<footnote>Clinical data obtained from Trials 1, 2, and 5.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2789+5G&#x2192;A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">D1152H<footnote ID=\"t6f2\">This variant is also predicted to be responsive by FRT assay.</footnote></content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L206W</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1066H</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S945L</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3272-26A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508del</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L997F</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117C</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T338I</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3849+10kbC&#x2192;T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G85E</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1101K</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347H</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V232D</content><footnoteRef IDREF=\"t6f2\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A455E</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1077P</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P5L</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347P</content><footnoteRef IDREF=\"t6f2\"/></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Variants responsive to TRIKAFTA based on in vitro data<footnote>The N1303K variant is predicted to be responsive by HBE assay. All other variants predicted to be responsive with in vitro data are supported by FRT assay.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1140-1151dup</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E264V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H620P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N396Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1251N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1461insGAT</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E282D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H620Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N418S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1255P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">1507_1515del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E292K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H939R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N900K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S13F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2055del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E384K </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H939R;H949L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1013H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S13P </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2183A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E403D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H954P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1013L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S158N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">2851A/G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E474K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1023R </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1021L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S182R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">293A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E527G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1027T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1021T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S18I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3007del6</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E56K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I105N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P111L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S18N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3132T&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E588V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1139V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P1372T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S308P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3141del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E60K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1203V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P140S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S341P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3143del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E822K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1234L </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P205S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S364P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">314del9</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">E92K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1234V del6aa</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P439S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S434P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3331del6</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1016S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I125T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P499A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S492F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3410T&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1052V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1269N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P574H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S50P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3523A&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1074L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1366N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P67L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S519G </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3601A&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1078S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I1366T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P750L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S531P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3761T&#x2192;G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1099L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P798S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3791C/T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F1107L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">P988R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3850G&#x2192;A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F191V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I148T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1012P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S549R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">3978G&#x2192;C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F200I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I175V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1209P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S557F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">546insCTA</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F311del</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I331N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1291H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S589I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">548insTAC</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F311L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I336K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1291R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S589N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1006E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F312del</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I336L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1313K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S624R </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1025D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F433L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I444S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q1352H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S686Y</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I497S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q151K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S737F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508C;S1251N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I502T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q179K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S821G </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1067V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F508del;R1438W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S898R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A107G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F575Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1081V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F587I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I506V;D1168G </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q237P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912L;G1244V</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1087P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F587L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I521S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q30P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S912T</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A120T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F693L(TTG)</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I530N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q359K/T360K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S955P</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1319E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F87L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I556V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q359R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S977F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1374D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">F932S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I586V </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q372H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S977F;R1438W</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A141D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1047D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I601F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q493L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1036N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A1466S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1047R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I618N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q493R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1053I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A155P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1061R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I618T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q552P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1057R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A234D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1069R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I807M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q98P </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1086A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A234V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1123R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I86M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Q98R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1086I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A238V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1173S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">I980K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1048G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1246I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A309D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1237V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K1060T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1066G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1299I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A349V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1244E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K162E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T1299K</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A357T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1244R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K464E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A455V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1247R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K464N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1070W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A457T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1249E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K522E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1162L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T351S;R851L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A462P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1249R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K522Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1162Q </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T388M </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A46D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1265V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">K951E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117C;G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T465I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A534E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G126D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1011S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T501A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A554E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1298V </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L102R;F1016S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T582S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A566D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G1349D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1065R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T908N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A62P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G149R;G576A;R668C </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1227S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117L;L997F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">T990I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">A872E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G178E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1324P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R117P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1008D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">c.1367_1369dupTTG</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G178R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1335P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1239S </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1010D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C225R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G194R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L137P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1153E</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C491R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G194V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1388P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V11I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C590Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L1480P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1283S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1240G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">C866Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213E;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L159S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R1438W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1293G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G213V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L15P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R170H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1293I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G226R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L15P;L1253F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R248K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V1415F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D110N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G239R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L165S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R258G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V201M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1152A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G253R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L167R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R297Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V232A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G27E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L210P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R31C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V317A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1270Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G27R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L293P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R31L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V322M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1312G </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G314E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L320V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R334L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V392G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1377H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G314R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L327P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R334Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V456A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D1445N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G424S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L32P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R347L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V456F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D192G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G437D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L333F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R352Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V520I </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D192N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G461R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L333H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R352W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562I</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D373N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G461V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L346P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R516S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562I;A1006E</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D426N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G463V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L441P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R553Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V562L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D443Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L453S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R555G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V591A</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D443Y;G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L467F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R600S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V603F</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D529G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G480S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L558F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V754M</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D565G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G500D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L619S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R709Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V920L</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D567N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G545R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L633P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V920M </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D579G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L636P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q;R297Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">V93D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D58H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L88S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74Q;V201M;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1098C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D58V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L927P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1282G</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D614G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G551S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L967F;L1096R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W1282R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D651H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L967S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;R1070W;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W202C </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D651N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A;R668C</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">L973F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;S945L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W361R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D806G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G576A;S1359Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1137R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">W496R</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D836Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G622D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1137V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M;D1270N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1014C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D924N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G622V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M1210K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R74W;V201M;L997F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1032C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D979A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G628A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M150K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R751L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1032N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D979V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G628R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M150R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1073C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D985H</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G930E</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M152L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1092H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D985Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M152V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;L1065P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y109H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993A</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970S</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M265R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;N1088D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y109N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">G970V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M348K </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R75Q;S549N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y122C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">D993Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1054D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M394L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R792G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y1381H</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1104K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1079P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M469V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R792Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1104V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1085P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M498I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R810G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161D</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1126K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1085R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M952I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R851L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y161S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E116K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1375N</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M952T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">R933G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y301C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E116Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H1375P</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">M961L </content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1045Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y563N</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1221V</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H139L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1088D</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S108F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y89C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1228K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H139R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1195T</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1118F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y913S</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1409K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H146R</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1303I</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1159F</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">Y919C</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E1433K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H199Q</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N1303K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1159P</content></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E193K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H199Y</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N186K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1188L</content></td><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"italics\">E217G</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">H609L</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">N187K</content></td><td styleCode=\"Rrule\"><content styleCode=\"italics\">S1235R</content></td><td styleCode=\"Rrule\"/></tr></tbody></table>","<table width=\"90%\" ID=\"table7\"><caption>Table 7: Pharmacokinetic Parameters of TRIKAFTA Components</caption><col width=\"25%\" align=\"left\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Elexacaftor</th><th styleCode=\"Rrule\">Tezacaftor</th><th styleCode=\"Rrule\">Ivacaftor</th></tr></thead><tfoot><tr><td colspan=\"4\">AUC<sub>ss</sub>: area under the concentration versus time curve at steady state; SD: Standard Deviation; C<sub>max</sub>: maximum observed concentration; T<sub>max</sub>: time of maximum concentration; AUC: area under the concentration versus time curve.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">General Information</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> AUC<sub>ss</sub> (SD), mcg&#x2219;h/mL<footnote ID=\"fn5a\">Based on elexacaftor 200 mg and tezacaftor 100 mg once daily/ivacaftor 150 mg every 12 hours at steady state in patients with CF aged 12 years and older.</footnote></td><td styleCode=\"Rrule\">162 (47.5)<footnote ID=\"fn5b\">AUC<sub>0-24h</sub>.</footnote></td><td styleCode=\"Rrule\">89.3 (23.2)<footnoteRef IDREF=\"fn5b\"/></td><td styleCode=\"Rrule\">11.7 (4.01)<footnote ID=\"fn5c\">AUC<sub>0-12h</sub>.</footnote></td></tr><tr><td styleCode=\"Lrule Rrule\"> C<sub>max</sub> (SD), mcg/mL<footnoteRef IDREF=\"fn5a\"/></td><td styleCode=\"Rrule\">9.2 (2.1)</td><td styleCode=\"Rrule\">7.7 (1.7)</td><td styleCode=\"Rrule\">1.2 (0.3)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule Toprule\"> Time to Steady State, days</td><td styleCode=\"Rrule Toprule\">Within 7 days</td><td styleCode=\"Rrule Toprule\">Within 8 days</td><td styleCode=\"Rrule Toprule\">Within 3-5 days</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Accumulation Ratio</td><td styleCode=\"Rrule\">2.2</td><td styleCode=\"Rrule\">2.07</td><td styleCode=\"Rrule\">2.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Absorption</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Absolute Bioavailability</td><td styleCode=\"Rrule\">80%</td><td styleCode=\"Rrule\">Not determined</td><td styleCode=\"Rrule\">Not determined</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Median T<sub>max</sub> (range), hours</td><td styleCode=\"Rrule\">6 (4 to 12)</td><td styleCode=\"Rrule\">3 (2 to 4)</td><td styleCode=\"Rrule\">4 (3 to 6)</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Effect of Food</td><td valign=\"middle\" styleCode=\"Rrule\">AUC increases 1.9- to 2.5-fold (moderate-fat meal)</td><td valign=\"middle\" styleCode=\"Rrule\">No clinically significant effect</td><td valign=\"middle\" styleCode=\"Rrule\">Exposure increases 2.5- to 4-fold</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Distribution</content></td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Apparent Volume of Distribution, L<footnote ID=\"fn5d\">Elexacaftor, tezacaftor and ivacaftor do not partition preferentially into human red blood cells.</footnote></td><td valign=\"middle\" styleCode=\"Rrule\">53.7 (17.7)</td><td valign=\"middle\" styleCode=\"Rrule\">82.0 (22.3)</td><td valign=\"middle\" styleCode=\"Rrule\">293 (89.8)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Protein Binding<footnote ID=\"fn5e\">Elexacaftor and tezacaftor bind primarily to albumin. Ivacaftor primarily bind to albumin, alpha 1-acid glycoprotein and human gamma-globulin.</footnote></td><td styleCode=\"Rrule\">&gt;99%</td><td styleCode=\"Rrule\">approximately 99%</td><td styleCode=\"Rrule\">approximately 99%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Elimination</content></td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Effective Half-Life, hours<footnote ID=\"fn5f\">Mean (SD) terminal half-lives of elexacaftor, tezacaftor and ivacaftor are approximately 24.7 (4.87) hours, 60.3 (15.7) hours and 13.1 (2.98) hours, respectively.</footnote></td><td valign=\"middle\" styleCode=\"Rrule\">27.4 (9.31)</td><td valign=\"middle\" styleCode=\"Rrule\">25.1 (4.93)</td><td valign=\"middle\" styleCode=\"Rrule\">15.0 (3.92)</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Mean (SD) Apparent Clearance, L/hours</td><td valign=\"middle\" styleCode=\"Rrule\">1.18 (0.29)</td><td valign=\"middle\" styleCode=\"Rrule\">0.79 (0.10)</td><td valign=\"middle\" styleCode=\"Rrule\">10.2 (3.13)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"italics\">Metabolism</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Primary Pathway</td><td styleCode=\"Rrule\">CYP3A4/5</td><td styleCode=\"Rrule\">CYP3A4/5</td><td styleCode=\"Rrule\">CYP3A4/5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Active Metabolites</td><td styleCode=\"Rrule\">M23-ELX</td><td styleCode=\"Rrule\">M1-TEZ </td><td styleCode=\"Rrule\">M1-IVA</td></tr><tr styleCode=\"Botrule\"><td valign=\"middle\" styleCode=\"Lrule Rrule\"> Metabolite Potency Relative to Parent</td><td valign=\"middle\" styleCode=\"Rrule\">Similar</td><td valign=\"middle\" styleCode=\"Rrule\">Similar</td><td valign=\"middle\" styleCode=\"Rrule\">approximately 1/6<sup>th</sup> of parent</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"italics\">Excretion<footnote>Following radiolabeled doses.</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"middle\"> Primary Pathway</td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 87.3% (primarily as metabolites)</item><item>Urine: 0.23%</item></list></td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 72% (unchanged or as M2-TEZ)</item><item>Urine: 14% (0.79% unchanged)</item></list></td><td styleCode=\"Rrule\" align=\"left\"><list listType=\"unordered\"><item>Feces: 87.8%</item><item>Urine: 6.6%</item></list></td></tr></tbody></table>","<table width=\"100%\" ID=\"table8\"><caption>Table 8: Mean (SD) Elexacaftor, Tezacaftor and Ivacaftor Exposures Observed at Steady State by Age Group and Dose Administered</caption><col width=\"23%\" align=\"left\" valign=\"middle\"/><col width=\"26%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"16%\" align=\"center\" valign=\"middle\"/><col width=\"16%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" align=\"center\">Age Group</th><th styleCode=\"Rrule\" align=\"center\">Dose</th><th styleCode=\"Rrule\" align=\"center\">Elexacaftor AUC<sub>0-24h,ss</sub> (&#xB5;g&#x2219;h/mL)</th><th styleCode=\"Rrule\" align=\"center\">Tezacaftor AUC<sub>0-24h,ss</sub> (&#xB5;g&#x2219;h/mL)</th><th styleCode=\"Rrule\" align=\"center\">Ivacaftor AUC<sub>0-12h,ss</sub> (&#xB5;g&#x2219;h/mL)</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">SD: Standard Deviation; AUC<sub>ss</sub>: area under the concentration versus time curve at steady state.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 2 to less than 6 years weighing less than 14 kg (N = 16)</td><td styleCode=\"Rrule\">elexacaftor 80 mg qd/tezacaftor 40 mg qd/ivacaftor 60 mg qAM and ivacaftor 59.5 mg qPM</td><td styleCode=\"Rrule\">128 (24.8)</td><td styleCode=\"Rrule\">87.3 (17.3)</td><td styleCode=\"Rrule\">11.9 (3.86)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 2 to less than 6 years weighing 14 kg or more (N = 59)</td><td styleCode=\"Rrule\">elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h</td><td styleCode=\"Rrule\">138 (47.0)</td><td styleCode=\"Rrule\">90.2 (27.9)</td><td styleCode=\"Rrule\">13.0 (6.11)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Patients aged 6 to less than 12 years weighing less than 30 kg  (N = 36)</td><td styleCode=\"Rrule\">elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h</td><td styleCode=\"Rrule\">116 (39.4)</td><td styleCode=\"Rrule\">67.0 (22.3)</td><td styleCode=\"Rrule\">9.78 (4.50)</td></tr><tr><td styleCode=\"Lrule Rrule\">Patients aged 6 to less than 12 years weighing 30 kg or more (N = 30)</td><td styleCode=\"Rrule\">elexacaftor 200 mg qd/ tezacaftor 100 mg qd/ ivacaftor 150 mg q12h</td><td styleCode=\"Rrule\">195 (59.4)</td><td styleCode=\"Rrule\">103 (23.7)</td><td styleCode=\"Rrule\">17.5 (4.97)</td></tr></tbody></table>","<table width=\"90%\" ID=\"table9\"><caption>Table 9: Impact of Elexacaftor, Tezacaftor and/or Ivacaftor on Other Drugs</caption><col width=\"32%\" align=\"center\" valign=\"middle\"/><col width=\"22%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" colspan=\"2\">Dose and Schedule</th><th styleCode=\"Rrule\" rowspan=\"2\">Effect on Other Drug PK</th><th styleCode=\"Rrule Botrule\" colspan=\"2\">Geometric Mean Ratio (90% CI) of Other Drug No Effect=1.0</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" colspan=\"2\"/><th styleCode=\"Rrule\">AUC</th><th styleCode=\"Rrule\">C<sub>max</sub></th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">&#x2191; = increase, &#x2193; = decrease, &#x2194; = no change.</td></tr><tr><td align=\"left\" valign=\"top\" colspan=\"5\">AUC: area under the concentration versus time curve; CI: Confidence Interval; ELX: elexacaftor; C<sub>max</sub>: maximum observed concentration; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam 2 mg single oral dose</td><td valign=\"top\" styleCode=\"Rrule\">TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Midazolam</td><td styleCode=\"Rrule\">1.12 (1.01, 1.25)</td><td styleCode=\"Rrule\">1.13 (1.01, 1.25)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Digoxin 0.5 mg single dose</td><td styleCode=\"Rrule\">TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2191; Digoxin</td><td styleCode=\"Rrule\">1.30 (1.17, 1.45)</td><td styleCode=\"Rrule\">1.32 (1.07, 1.64)</td></tr><tr><td styleCode=\"Lrule Rrule Botrule\" rowspan=\"2\">Oral Contraceptive Ethinyl estradiol 30 &#xB5;g/Levonorgestrel 150 &#xB5;g qd</td><td styleCode=\"Rrule Botrule\" rowspan=\"2\">ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h</td><td styleCode=\"Rrule\" valign=\"top\">&#x2191; Ethinyl estradiol<footnote ID=\"t7f1\"> Effect is not clinically significant <content styleCode=\"italics\">[see </content><content styleCode=\"italics\"><linkHtml href=\"#S7.3\">Drug Interactions (7.3)</linkHtml>]</content>.</footnote></td><td styleCode=\"Rrule\" valign=\"top\">1.33 (1.20, 1.49)</td><td styleCode=\"Rrule\" valign=\"top\">1.26 (1.14, 1.39)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"top\">&#x2191; Levonorgestrel<footnoteRef IDREF=\"t7f1\"/></td><td styleCode=\"Rrule\" valign=\"top\">1.23 (1.10, 1.37)</td><td styleCode=\"Rrule\" valign=\"top\">1.10 (0.985, 1.23)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rosiglitazone 4 mg single oral dose</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Rosiglitazone</td><td styleCode=\"Rrule\">0.975 (0.897, 1.06)</td><td styleCode=\"Rrule\">0.928 (0.858, 1.00)</td></tr><tr><td styleCode=\"Lrule Rrule\">Desipramine 50 mg single dose</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Desipramine</td><td styleCode=\"Rrule\">1.04 (0.985, 1.10)</td><td styleCode=\"Rrule\">1.00 (0.939, 1.07)</td></tr></tbody></table>","<table width=\"90%\" ID=\"table10\"><caption>Table 10: Impact of Other Drugs on Elexacaftor, Tezacaftor and/or Ivacaftor</caption><col width=\"32%\" align=\"center\" valign=\"middle\"/><col width=\"22%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" rowspan=\"2\" colspan=\"2\">Dose and Schedule</th><th styleCode=\"Rrule\" rowspan=\"2\">Effect on ELX, TEZ and/or IVA PK</th><th styleCode=\"Rrule\" colspan=\"2\">Geometric Mean Ratio (90% CI) of Elexacaftor, Tezacaftor and Ivacaftor No Effect = 1.0</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Rrule Toprule\">AUC</th><th styleCode=\"Rrule Toprule\">C<sub>max</sub></th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"5\">&#x2191; = increase, &#x2193; = decrease, &#x2194; = no change.</td></tr><tr><td align=\"left\" valign=\"top\" colspan=\"5\">AUC: area under the concentration versus time curve; CI: Confidence Interval; C<sub>max</sub>: maximum observed concentration; ELX: elexacaftor; TEZ: tezacaftor; IVA: ivacaftor; PK: Pharmacokinetics.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Itraconazole 200 mg q12h on Day 1, followed by 200 mg qd</td><td styleCode=\"Rrule\" rowspan=\"2\">TEZ 25 mg qd + IVA 50 mg qd</td><td styleCode=\"Rrule\">&#x2191; Tezacaftor</td><td styleCode=\"Rrule\">4.02 (3.71, 4.63)</td><td styleCode=\"Rrule\">2.83 (2.62, 3.07)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">15.6 (13.4, 18.1)</td><td styleCode=\"Rrule\">8.60 (7.41, 9.98)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Itraconazole 200 mg qd</td><td styleCode=\"Rrule\" rowspan=\"2\">ELX 20 mg + TEZ 50 mg single dose</td><td styleCode=\"Rrule\">&#x2191; Elexacaftor</td><td styleCode=\"Rrule\">2.83 (2.59, 3.10)</td><td styleCode=\"Rrule\">1.05 (0.977, 1.13)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Tezacaftor</td><td styleCode=\"Rrule\">4.51 (3.85, 5.29)</td><td styleCode=\"Rrule\">1.48 (1.33, 1.65)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Ketoconazole 400 mg qd</td><td styleCode=\"Rrule\" valign=\"middle\">IVA 150 mg single dose</td><td styleCode=\"Rrule\" valign=\"middle\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">8.45 (7.14, 10.0)</td><td styleCode=\"Rrule\">2.65 (2.21, 3.18)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Ciprofloxacin 750 mg q12h</td><td styleCode=\"Rrule\" rowspan=\"2\">TEZ 50 mg q12h + IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2194; Tezacaftor</td><td styleCode=\"Rrule\">1.08 (1.03, 1.13)</td><td styleCode=\"Rrule\">1.05 (0.99, 1.11)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">&#x2191; Ivacaftor<footnote>Effect is not clinically significant <content styleCode=\"italics\">[see </content><content styleCode=\"italics\"><linkHtml href=\"#S7.3\">Drug Interactions (7.3)</linkHtml>]</content>.</footnote></td><td styleCode=\"Rrule\">1.17 (1.06, 1.30)</td><td styleCode=\"Rrule\">1.18 (1.06, 1.31)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rifampin 600 mg qd</td><td styleCode=\"Rrule\">IVA 150 mg single dose</td><td styleCode=\"Rrule\">&#x2193; Ivacaftor</td><td styleCode=\"Rrule\">0.114 (0.097, 0.136)</td><td styleCode=\"Rrule\">0.200 (0.168, 0.239)</td></tr><tr><td styleCode=\"Lrule Rrule\">Fluconazole 400 mg single dose on Day 1, followed by 200 mg qd</td><td styleCode=\"Rrule\">IVA 150 mg q12h</td><td styleCode=\"Rrule\">&#x2191; Ivacaftor</td><td styleCode=\"Rrule\">2.95 (2.27, 3.82)</td><td styleCode=\"Rrule\">2.47 (1.93, 3.17)</td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are limited and incomplete human data from clinical trials on the use of TRIKAFTA or its individual components, elexacaftor, tezacaftor and ivacaftor, in pregnant women to inform a drug-associated risk. Although there are no animal reproduction studies with the concomitant administration of elexacaftor, tezacaftor and ivacaftor, separate reproductive and developmental studies were conducted with each active component of TRIKAFTA in pregnant rats and rabbits. In animal embryo fetal development (EFD) studies oral administration of elexacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 2 times the exposure at the maximum recommended human dose (MRHD) in rats and 4 times the MRHD in rabbits [based on summed AUCs of elexacaftor and its metabolite (for rat) and AUC of elexacaftor (for rabbit)]. Oral administration of tezacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 3 times the exposure at the MRHD in rats and 0.2 times the MRHD in rabbits (based on summed AUCs of tezacaftor and M1-TEZ). Oral administration of ivacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 5 and 14 times the exposure at the MRHD, respectively [based on summed AUCs of ivacaftor and its metabolites (for rat) and AUC of ivacaftor (for rabbit)]. No adverse developmental effects were observed after oral administration of elexacaftor, tezacaftor or ivacaftor to pregnant rats from the period of organogenesis through lactation at doses that produced maternal exposures approximately 1 time, approximately 1 time and 3 times the exposures at the MRHD, respectively [based on summed AUCs of parent and metabolite(s)] (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Elexacaftor In an EFD study, pregnant rats were administered oral doses of elexacaftor at 15, 25, and 40 mg/kg/day during the period of organogenesis from gestation Days 6-17. Elexacaftor did not cause adverse developmental outcomes at exposures up to 9 times the MRHD (based on summed AUCs for elexacaftor and its metabolite at maternal doses up to 40 mg/kg/day). Lower mean fetal body weights were observed at doses ≥25 mg/kg/day that produced maternal exposures ≥4 times the MRHD. Maternal toxicity was observed at 40 mg/kg/day (9 times the MRHD). In an EFD study, pregnant rabbits were administered oral doses of elexacaftor at 50, 100, or 125 mg/kg/day during the period of organogenesis from gestation Days 7-20. Elexacaftor was not teratogenic at exposures up to 4 times the MRHD (based on AUC of elexacaftor at maternal doses up to 125 mg/kg/day). Maternal toxicity was observed at 125 mg/kg/day (4 times the MRHD). In a pre- and postnatal development (PPND), pregnant rats were administered elexacaftor at oral doses of 5, 7.5, and 10 mg/kg/day from gestation Day 6 through lactation Day 18. Elexacaftor did not cause adverse developmental outcomes in pups at maternal doses up to 10 mg/kg/day (approximately 1 time the MRHD based on summed AUCs of elexacaftor and its metabolite). Placental transfer of elexacaftor was observed in pregnant rats. Tezacaftor In an EFD study, pregnant rats were administered tezacaftor at oral doses of 25, 50, or 100 mg/kg/day during the period of organogenesis from gestation Days 6-17. Tezacaftor did not cause adverse developmental effects at exposures up to 3 times the MRHD (based on summed AUCs of tezacaftor and M1-TEZ). Maternal toxicity in rats was observed at greater than or equal to 50 mg/kg/day (approximately greater than or equal to 1 time the MRHD). In an EFD study, pregnant rabbits were administered tezacaftor at oral doses of 10, 25, or 50 mg/kg/day during the period of organogenesis from gestation Days 7-20. Tezacaftor did not affect fetal developmental outcomes at exposures up to 0.2 times the MRHD (based on summed AUCs of tezacaftor and M1-TEZ). Lower fetal body weights were observed in rabbits at a maternally toxic dose that produced exposures approximately 1 time the MRHD (based on summed AUCs of tezacaftor and M1-TEZ at a maternal dose of 50 mg/kg/day). In a PPND study, pregnant rats were administered tezacaftor at oral doses of 25, 50, or 100 mg/kg/day from gestation Day 6 through lactation Day 18. Tezacaftor had no adverse developmental effects on pups at an exposure of approximately 1 time the MRHD (based on summed AUCs for tezacaftor and M1-TEZ at a maternal dose of 25 mg/kg/day). Decreased fetal body weights and early developmental delays in pinna detachment, eye opening, and righting reflex occurred at a maternally toxic dose (based on maternal weight loss) that produced exposures approximately 2 times the exposure at the MRHD (based on summed AUCs for tezacaftor and M1-TEZ). Placental transfer of tezacaftor was observed in pregnant rats. Ivacaftor In an EFD study, pregnant rats were administered ivacaftor at oral doses of 50, 100, or 200 mg/kg/day during the period of organogenesis from gestation Days 7-17. Ivacaftor did not affect fetal survival at exposures up to 5 times the MRHD (based on summed AUCs of ivacaftor and its metabolites at maternal oral doses up to 200 mg/kg/day). Maternal toxicity was observed at 100 and 200 mg/kg/day (3 and 5 times the exposure at the MRHD) and was associated with a decrease in fetal body weights at a maternal dose of 200 mg/kg/day (5 times the MRHD). In an EFD study, pregnant rabbits were administered ivacaftor at oral doses of 25, 50, or 100 mg/kg/day during the period of organogenesis from gestation Days 7-19. Ivacaftor did not affect fetal development or survival at exposures up to 14 times the MRHD (on an ivacaftor AUC basis at maternal oral doses up to 100 mg/kg/day). Maternal toxicity (i.e., death, decreased food consumption, decreased mean body weight and body weight gain, decreased clinical condition, abortions) was observed at doses greater than or equal to 50 mg/kg/day (approximately 5 times the MRHD). In a PPND study, pregnant rats were administered ivacaftor at oral doses of 50, 100, or 200 mg/kg/day from gestation Day 7 through lactation Day 20. Ivacaftor had no effects on delivery or growth and development of offspring at exposures up to 3 times the MRHD (based on summed AUCs for ivacaftor and its metabolites at maternal oral doses up to 100 mg/kg/day). Decreased fetal body weights were observed at a maternally toxic dose that produced exposures 5 times the MRHD (based on summed AUCs of ivacaftor and its metabolites). Placental transfer of ivacaftor was observed in pregnant rats and rabbits. 8.2 Lactation Risk Summary There is no information regarding the presence of elexacaftor, tezacaftor, or ivacaftor in human milk, the effects on the breastfed infant, or the effects on milk production. Elexacaftor, tezacaftor, and ivacaftor are excreted into the milk of lactating rats (see Data ) . The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TRIKAFTA and any potential adverse effects on the breastfed child from TRIKAFTA or from the underlying maternal condition. Data Elexacaftor: Lacteal excretion of elexacaftor in rats was demonstrated following a single oral dose (10 mg/kg) of 14 C-elexacaftor administered 6 to 10 days postpartum to lactating dams. Exposure of 14 C-elexacaftor in milk was approximately 0.4 times the value observed in plasma (based on AUC 0-72h ). Tezacaftor: Lacteal excretion of tezacaftor in rats was demonstrated following a single oral dose (30 mg/kg) of 14 C-tezacaftor administered 6 to 10 days postpartum to lactating dams. Exposure of 14 C-tezacaftor in milk was approximately 3 times higher than in plasma (based on AUC 0-72h ). Ivacaftor: Lacteal excretion of ivacaftor in rats was demonstrated following a single oral dose (100 mg/kg) of 14 C-ivacaftor administered 9 to 10 days postpartum to lactating dams. Exposure of 14 C-ivacaftor in milk was approximately 1.5 times higher than in plasma (based on AUC 0-24h ). 8.4 Pediatric Use The safety and effectiveness of TRIKAFTA for the treatment of CF have been established in pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Use of TRIKAFTA for this indication for pediatric patients 12 years of age and older was supported by evidence from two adequate and well-controlled studies (Trials 1 and 2) in CF patients aged 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14) ]. Use of TRIKAFTA for this indication in pediatric patients 2 to less than 12 years of age is based on the following: Trial 1, 56 pediatric patients aged 12 to less than 18 years who had an F508del variant on one allele and a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor [see Adverse Reactions (6) and Clinical Studies (14) ] . Trial 2, 16 pediatric patients aged 12 to less than 18 years who were homozygous for the F508del variant [see Adverse Reactions (6) and Clinical Studies (14) ] . Trial 3, 66 pediatric patients aged 6 to less than 12 years who were homozygous for the F508del variant or heterozygous for the F508del variant with a variant on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor [see Adverse Reactions (6) and Clinical Pharmacology (12.3) ] . Trial 4, 75 pediatric patients aged 2 to less than 6 years who had at least one F508del variant or a variant known to be responsive to TRIKAFTA [see Adverse Reactions (6) and Clinical Pharmacology (12.3) ]. Trial 5, 64 pediatric patients aged 6 years to less than 18 years who had at least one qualifying non- F508del TRIKAFTA-responsive variant and did not have an exclusionary variant [see Adverse Reactions (6) and Clinical Studies (14.2) ]. The effectiveness of TRIKAFTA in patients aged 2 to less than 12 years was extrapolated from patients aged 12 years and older with support from population pharmacokinetic analyses showing elexacaftor, tezacaftor, and ivacaftor exposure levels in patients aged 2 to less than 12 years within the range of exposures observed in patients aged 12 years and older [see Clinical Pharmacology (12.3) ] . Safety of TRIKAFTA in patients aged 6 to less than 12 years was derived from a 24-week, open-label, clinical trial in 66 patients aged 6 to less than 12 years (mean age at baseline 9.3 years) administered either a total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening (for patients weighing less than 30 kg) or a total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150 mg in the evening (for patients weighing 30 kg or more) (Trial 3). Safety of TRIKAFTA in patients aged 2 to less than 6 years was derived from a 24-week, open-label, clinical trial in 75 patients aged 2 to less than 6 years (mean age at baseline 4.1 years) administered either a total dose of elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg in the morning and ivacaftor 59.5 mg in the evening (for patients weighing 10 kg to less than 14 kg) or a total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening (for patients weighing 14 kg or more) (Trial 4). The safety profile of patients in these trials was similar to that observed in Trial 1 [see Adverse Reactions (6) ]. The safety and effectiveness of TRIKAFTA in patients with CF younger than 2 years of age have not been established. Juvenile Animal Toxicity Data Findings of cataracts were observed in juvenile rats dosed from postnatal Day 7 through 35 with ivacaftor dose levels of 10 mg/kg/day and higher (0.21 times the MRHD based on systemic exposure of ivacaftor and its metabolites). This finding has not been observed in older animals [see Warnings and Precautions (5.7) ] . Studies were conducted with tezacaftor in juvenile rats starting at postnatal day (PND) 21 and ranging up to PNDs 35 to 49. Findings of convulsions and death were observed in juvenile rats that received a tezacaftor dose level of 100 mg/kg/day (approximately equivalent to 1.9 times the MRHD based on summed AUCs of tezacaftor and its metabolite, M1-TEZ). A no-effect dose level was identified at 30 mg/kg/day (approximately equivalent to 0.8 times the MRHD based on summed AUCs of tezacaftor and its metabolite, M1-TEZ). Findings were dose related and generally more severe when dosing with tezacaftor was initiated earlier in the postnatal period (PND 7, which would be approximately equivalent to a human neonate). Tezacaftor and its metabolite, M1-TEZ, are substrates for P-glycoprotein. Lower brain levels of P-glycoprotein activity in younger rats resulted in higher brain levels of tezacaftor and M1-TEZ. These findings are not relevant for the indicated pediatric population, 2 years of age and older, for whom levels of P-glycoprotein activity are equivalent to levels observed in adults. 8.5 Geriatric Use Clinical studies of TRIKAFTA did not include any patients aged 65 years and older. 8.6 Renal Impairment TRIKAFTA has not been studied in patients with severe renal impairment or end-stage renal disease. No dosage adjustment is recommended in patients with mild (eGFR 60 to <90 mL/min/1.73 m 2 ) or moderate (eGFR 30 to <60 mL/min/1.73 m 2 ) renal impairment. Use with caution in patients with severe (eGFR <30 mL/min/1.73 m 2 ) renal impairment or end-stage renal disease [see Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment Severe Hepatic Impairment (Child-Pugh Class C): Should not be used. TRIKAFTA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), but the exposure is expected to be higher than in patients with moderate hepatic impairment [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Clinical Pharmacology (12.3) ] . Moderate Hepatic Impairment (Child-Pugh Class B): Treatment is not recommended. Use of TRIKAFTA in patients with moderate hepatic impairment should only be considered when there is a clear medical need, and the benefit outweighs the risk. If used in patients with moderate hepatic impairment, TRIKAFTA should be used at a reduced dose. Liver function tests should be closely monitored [see Dosage and Administration (2.1 , 2.3) and Warnings and Precautions (5.1) ] . In a clinical study of 11 subjects with moderate hepatic impairment, one subject developed total and direct bilirubin elevations >2 × ULN, and a second subject developed direct bilirubin elevation >4.5 × ULN [see Clinical Pharmacology (12.3) ] . Mild Hepatic Impairment (Child-Pugh Class A): No dose modification is recommended. Liver function tests should be closely monitored [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ] . 8.8 Patients with Severe Lung Dysfunction Trial 1 included a total of 18 patients receiving TRIKAFTA with ppFEV 1 <40 at baseline. The safety and efficacy in this subgroup were comparable to those observed in the overall population."],"dosage_and_administration_table":["<table width=\"100%\"><col width=\"18%\" align=\"left\" valign=\"middle\"/><col width=\"13%\" align=\"left\" valign=\"middle\"/><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"29%\" align=\"left\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" colspan=\"4\" align=\"center\">Recommended Dosage for Adult and Pediatric Patients Aged 2 Years and Older (with fat-containing food (<linkHtml href=\"#S2.2\">2.2</linkHtml>, <linkHtml href=\"#S12.3\">12.3</linkHtml>))</th></tr><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Age</th><th styleCode=\"Rrule\" align=\"center\">Weight</th><th styleCode=\"Rrule\" align=\"center\">Morning Dose</th><th styleCode=\"Rrule\" align=\"center\">Evening Dose</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">2 to less than 6 years </td><td styleCode=\"Rrule\">Less than 14 kg</td><td styleCode=\"Rrule\">One packet containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg oral granules</td><td styleCode=\"Rrule\">One packet containing ivacaftor 59.5 mg oral granules</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">14 kg or more</td><td styleCode=\"Rrule\">One packet containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg oral granules</td><td styleCode=\"Rrule\">One packet containing ivacaftor 75 mg oral granules</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\">6 to less than 12 years</td><td styleCode=\"Rrule\" valign=\"top\">Less than 30 kg</td><td styleCode=\"Rrule\">Two tablets, each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg</td><td styleCode=\"Rrule\">One tablet of ivacaftor 75 mg</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">30 kg or more</td><td styleCode=\"Rrule\">Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg</td><td styleCode=\"Rrule\">One tablet of ivacaftor 150 mg</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">12 years and older</td><td styleCode=\"Rrule\">-</td><td styleCode=\"Rrule\" valign=\"top\">Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg</td><td styleCode=\"Rrule\">One tablet of ivacaftor 150 mg</td></tr></tbody></table>","<table width=\"90%\" ID=\"table1\"><caption>Table 1: Recommended Dosage of TRIKAFTA for Adult and Pediatric Patients Aged 2 Years and Older</caption><col width=\"15%\" align=\"left\" valign=\"middle\"/><col width=\"15%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"left\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Age</th><th styleCode=\"Rrule\" align=\"center\">Weight</th><th styleCode=\"Rrule\" align=\"center\">Oral Morning Dose</th><th styleCode=\"Rrule\" align=\"center\">Oral Evening Dose</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">2 to less than 6 years</td><td styleCode=\"Rrule\">Less than 14 kg</td><td styleCode=\"Rrule\">One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules</td><td styleCode=\"Rrule\">One packet (containing ivacaftor 59.5 mg) oral granules</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">14 kg or more</td><td styleCode=\"Rrule\">One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules</td><td styleCode=\"Rrule\">One packet (containing ivacaftor 75 mg) oral granules</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">6 to less than 12 years</td><td styleCode=\"Rrule\">Less than 30 kg</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg)</td><td styleCode=\"Rrule\">One tablet of ivacaftor 75 mg</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">30 kg or more</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg)</td><td styleCode=\"Rrule\">One tablet of ivacaftor 150 mg</td></tr><tr><td styleCode=\"Lrule Rrule\">12 years and older</td><td styleCode=\"Rrule\" align=\"center\">&#x2014;</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg)</td><td styleCode=\"Rrule\">One tablet of ivacaftor 150 mg</td></tr></tbody></table>","<table width=\"75%\" ID=\"table2\"><caption>Table 2: Recommended Dosage of TRIKAFTA, if used, in Patients with Moderate Hepatic Impairment (Child-Pugh Class B)</caption><col width=\"10%\" align=\"left\" valign=\"middle\"/><col width=\"10%\" align=\"left\" valign=\"middle\"/><col width=\"60%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"left\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Age</th><th styleCode=\"Rrule\" align=\"center\">Weight</th><th styleCode=\"Rrule\" align=\"center\">Oral Morning Dose</th><th styleCode=\"Rrule\" align=\"center\">Oral Evening Dose</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\"><content styleCode=\"bold\">2 to less than 6 years</content></td><td styleCode=\"Rrule\">Less than 14 kg</td><td styleCode=\"Rrule\">Weekly dosing schedule is as follows:<list styleCode=\"disc\" listType=\"unordered\"><item>Days 1-3: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules each day</item><item>Day 4: no dose</item><item>Days 5-6: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules each day</item><item>Day 7: no dose</item></list></td><td styleCode=\"Rrule\">No evening dose of ivacaftor oral granules.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">14 kg or more</td><td styleCode=\"Rrule\">Weekly dosing schedule is as follows:<list styleCode=\"disc\" listType=\"unordered\"><item>Days 1-3: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules each day</item><item>Day 4: no dose</item><item>Days 5-6: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules each day</item><item>Day 7: no dose</item></list></td><td styleCode=\"Rrule\">No evening dose of ivacaftor oral granules.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\"><content styleCode=\"bold\">6 to less than 12 years</content></td><td styleCode=\"Rrule\">Less than 30 kg</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list styleCode=\"disc\" listType=\"unordered\"><item>Day 1: Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg)</item><item>Day 2: One tablet of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg</item></list></td><td styleCode=\"Rrule\">No evening ivacaftor tablet dose.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">30 kg or more</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list styleCode=\"disc\" listType=\"unordered\"><item>Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg)</item><item>Day 2: One tablet of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg</item></list></td><td styleCode=\"Rrule\">No evening ivacaftor tablet dose.</td></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">12 years and older</content></td><td styleCode=\"Rrule\" align=\"center\">&#x2014;</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list styleCode=\"disc\" listType=\"unordered\"><item>Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg)</item><item>Day 2: One tablet of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg</item></list></td><td styleCode=\"Rrule\">No evening ivacaftor tablet dose.</td></tr></tbody></table>","<table width=\"90%\" ID=\"table3\"><caption>Table 3: Dosage Modification for Concomitant Use of TRIKAFTA with Moderate and Strong CYP3A Inhibitors</caption><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"10%\" align=\"left\" valign=\"middle\"/><col width=\"37%\" align=\"left\" valign=\"top\"/><col width=\"38%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Age</th><th styleCode=\"Rrule\">Weight</th><th styleCode=\"Rrule\">Moderate CYP3A Inhibitors</th><th styleCode=\"Rrule\">Strong CYP3A Inhibitors</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"middle\"><content styleCode=\"bold\">2 to less than 6 years</content></td><td styleCode=\"Rrule\">Less than 14 kg</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list listType=\"unordered\" styleCode=\"disc\"><item>Day 1: One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning</item><item>Day 2: One packet (containing ivacaftor 59.5 mg) oral granules in the morning</item></list>No evening packet of ivacaftor oral granules.</td><td styleCode=\"Rrule\">One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning twice a week, approximately 3 to 4 days apart.  No evening packet of ivacaftor oral granules.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">14 kg or more</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list listType=\"unordered\" styleCode=\"disc\"><item>Day 1: One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning</item><item>Day 2: One packet (containing ivacaftor 75 mg) oral granules in the morning</item></list>No evening packet of ivacaftor oral granules.</td><td styleCode=\"Rrule\">One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning twice a week, approximately 3 to 4 days apart.  No evening packet of ivacaftor oral granules.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"middle\"><content styleCode=\"bold\">6 to less than 12 years</content></td><td styleCode=\"Rrule\">Less than 30 kg</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list listType=\"unordered\" styleCode=\"disc\"><item>Day 1: Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning</item><item>Day 2: One tablet of ivacaftor 75 mg in the morning</item></list>No evening ivacaftor tablet dose.</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning twice a week, approximately 3 to 4 days apart. No evening ivacaftor tablet dose.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">30 kg or more</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list listType=\"unordered\" styleCode=\"disc\"><item>Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor100 mg/ivacaftor 150 mg) in the morning</item><item>Day 2: One tablet of ivacaftor 150 mg in the morning</item></list>No evening ivacaftor tablet dose.</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning twice a week, approximately 3 to 4 days apart.  No evening ivacaftor tablet dose.</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">12 years and older</content></td><td styleCode=\"Rrule\" align=\"center\">&#x2014;</td><td styleCode=\"Rrule\">Alternating daily dosing schedule is as follows:<list listType=\"unordered\" styleCode=\"disc\"><item>Day 1: Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning</item><item>Day 2: One tablet of ivacaftor 150 mg in the morning</item></list>No evening ivacaftor tablet dose.</td><td styleCode=\"Rrule\">Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning twice a week, approximately 3 to 4 days apart.  No evening ivacaftor tablet dose.</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - Kit Carton NDC 51167-331-01 Rx Only trikafta ® (elexacaftor, tezacaftor and ivacaftor) 100 mg, 50 mg and 75 mg; (ivacaftor) 150 mg tablets ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient. 84 Tablets 4-wallets (each containing 14 tablets of elexacaftor, tezacaftor, and ivacaftor and 7 tablets of ivacaftor) LIFT HERE TO OPEN ► PRINCIPAL DISPLAY PANEL - Kit Carton","PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-106-02 NDC 51167-106-02 Rx Only trikafta ® (elexacaftor, tezacaftor and ivacaftor) 50 mg, 25 mg and 37.5 mg; (ivacaftor) 75 mg tablets ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient. 84 Tablets 4-wallets (each containing 14 tablets of elexacaftor, tezacaftor, and ivacaftor and 7 tablets of ivacaftor) LIFT HERE TO OPEN → PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-106-02","PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-445-01 NDC 51167-445-01 Rx only trikafta ® (elexacaftor, tezacaftor, ivacaftor) oral granules 80 mg/40 mg/60 mg Co-packaged with (ivacaftor) oral granules 59.5 mg 80 mg 40 mg 60 mg and 59.5 mg 56 packets Carton contains: 4 individual wallets with 14 packets per wallet ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient. Lift here to open PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-445-01","PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-446-01 NDC 51167-446-01 Rx only trikafta ® (elexacaftor, tezacaftor, ivacaftor) oral granules 100 mg/50 mg/75 mg Co-packaged with (ivacaftor) oral granules 75 mg 100 mg 50 mg 75 mg and 75 mg 56 packets Carton contains: 4 individual wallets with 14 packets per wallet ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient. Lift here to open PRINCIPAL DISPLAY PANEL - Kit Carton - 51167-446-01"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with the combination of elexacaftor, tezacaftor and ivacaftor; however, separate studies of elexacaftor, tezacaftor and ivacaftor are described below. Elexacaftor A 6-month study in Tg.rasH2 transgenic mice showed no evidence of tumorigenicity at 50 mg/kg/day dose, the highest dose tested. A two-year study was conducted in rats to assess the carcinogenic potential of elexacaftor. No evidence of tumorigenicity was observed in rats at elexacaftor oral doses up to 10 mg/kg/day (approximately 2 and 5 times the MRHD based on summed AUCs of elexacaftor and its metabolite in male and female rats, respectively). Elexacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro mammalian cell micronucleus assay in TK6 cells, and in vivo mouse micronucleus test. Elexacaftor did not cause reproductive system toxicity in male rats at 55 mg/kg/day and female rats at 25 mg/kg/day, equivalent to approximately 6 times and 4 times the MRHD, respectively (based on summed AUCs of elexacaftor and its metabolite). Elexacaftor did not cause embryonic toxicity at 35 mg/kg/day which was the highest dose tested, equivalent to approximately 7 times the MRHD (based on summed AUCs of elexacaftor and its metabolite). Lower male and female fertility, male copulation and female conception indices were observed in males at 75 mg/kg/day and females at 35 mg/kg/day, equivalent to approximately 6 times and 7 times, respectively, the MRHD (based on summed AUCs of elexacaftor and its metabolite). Tezacaftor A two-year study in Sprague-Dawley rats and a 6-month study in Tg.rasH2 transgenic mice were conducted to assess the carcinogenic potential of tezacaftor. No evidence of tumorigenicity from tezacaftor was observed in male and female rats at oral doses up to 50 and 75 mg/kg/day (approximately 1 and 2 times the MRHD based on summed AUCs of tezacaftor and its metabolites in males and females, respectively). No evidence of tumorigenicity was observed in male and female Tg.rasH2 transgenic mice at tezacaftor doses up to 500 mg/kg/day. Tezacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro chromosomal aberration assay in Chinese hamster ovary cells and in vivo mouse micronucleus test. There were no effects on male or female fertility and early embryonic development in rats at oral tezacaftor doses up to 100 mg/kg/day (approximately 3 times the MRHD based on summed AUC of tezacaftor and M1-TEZ). Ivacaftor Two-year studies were conducted in CD-1 mice and Sprague-Dawley rats to assess the carcinogenic potential of ivacaftor. No evidence of tumorigenicity from ivacaftor was observed in mice or rats at oral doses up to 200 mg/kg/day and 50 mg/kg/day, respectively (approximately equivalent to 2 and 7 times the MRHD, respectively, based on summed AUCs of ivacaftor and its metabolites). Ivacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro chromosomal aberration assay in Chinese hamster ovary cells and in vivo mouse micronucleus test. Ivacaftor impaired fertility and reproductive performance indices in male and female rats at 200 mg/kg/day (approximately 7 and 5 times, respectively, the MRHD based on summed AUCs of ivacaftor and its metabolites). Increases in prolonged diestrus were observed in females at 200 mg/kg/day. Ivacaftor also increased the number of females with all nonviable embryos and decreased corpora lutea, implantations and viable embryos in rats at 200 mg/kg/day (approximately 5 times the MRHD based on summed AUCs of ivacaftor and its metabolites) when dams were dosed prior to and during early pregnancy. These impairments of fertility and reproductive performance in male and female rats at 200 mg/kg/day were attributed to severe toxicity."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Cystic fibrosis transmembrane conductance regulator","category":"target"},{"label":"CFTR","category":"gene"},{"label":"R07AX32","category":"atc"},{"label":"Active","category":"status"},{"label":"Cystic fibrosis","category":"indication"},{"label":"Vertex Pharms Inc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Chloride Channel Agonists","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ]. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA . Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating TRIKAFTA. Assess liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Use in Specific Populations (8.7) ] . Interrupt TRIKAFTA for significant elevations in liver function tests or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve, resume treatment only if the benefit is expected to outweigh the risk. Closer monitoring is advised after resuming TRIKAFTA [see Warnings and Precautions (5.1) ] . TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). If used, use with caution at a reduced dosage and monitor patients closely [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , Adverse Reactions (6) , Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] . WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE See full prescribing information for complete boxed warning. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Liver failure leading to transplantation and death has been reported. ( 5.1 , 6 ) Assess liver function tests (ALT, AST, alkaline phosphatase, bilirubin) in all patients prior to initiating TRIKAFTA. ( 2.1 , 5.1 ) Monitor liver function tests (ALT, AST, alkaline phosphatase, bilirubin) every month for the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually. ( 2.1 , 5.1 ) Interrupt TRIKAFTA for significant elevations in liver function tests or signs or symptoms of liver injury. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. ( 5.1 ) Resume TRIKAFTA if abnormalities resolve and only if the benefit is expected to outweigh the risk. ( 5.1 ) TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.3 , 5.1 , 8.7 , 12.3 )"],"safetySignals":[{"date":"","signal":"INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS","source":"FDA FAERS","actionTaken":"777 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"747 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"579 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"575 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"560 reports"},{"date":"","signal":"PRODUCTIVE COUGH","source":"FDA FAERS","actionTaken":"519 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"513 reports"},{"date":"","signal":"WEIGHT INCREASED","source":"FDA FAERS","actionTaken":"494 reports"},{"date":"","signal":"CYSTIC FIBROSIS","source":"FDA FAERS","actionTaken":"475 reports"},{"date":"","signal":"ABDOMINAL PAIN UPPER","source":"FDA FAERS","actionTaken":"460 reports"}],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Alanine aminotransferase increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Nasal congestion","drugRate":"","severity":"common","organSystem":""},{"effect":"Blood creatine phosphokinase increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Aspartate aminotransferase increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinorrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Influenza","drugRate":"","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Blood bilirubin increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Abdominal distension","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Conjunctivitis","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Respiratory tract infection","drugRate":"2%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Rash","drugRate":"1%","severity":"serious"},{"effect":"Influenza","drugRate":"1%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Vertex Pharms Inc","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2037-12-08","territory":"US","patentNumber":"10793547"},{"source":"FDA Orange Book via DrugCentral","expires":"2037-12-08","territory":"US","patentNumber":"11179367"},{"source":"FDA Orange Book via DrugCentral","expires":"2037-12-08","territory":"US","patentNumber":"11453655"},{"source":"FDA Orange Book via DrugCentral","expires":"2037-12-08","territory":"US","patentNumber":"11517564"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-10-06","territory":"US","patentNumber":"10758534"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-10-06","territory":"US","patentNumber":"11426407"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-07-15","territory":"US","patentNumber":"9012496"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-02-27","territory":"US","patentNumber":"10272046"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-02-27","territory":"US","patentNumber":"11147770"},{"source":"FDA Orange Book via DrugCentral","expires":"2033-02-27","territory":"US","patentNumber":"8883206"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-03-25","territory":"US","patentNumber":"10081621"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-03-25","territory":"US","patentNumber":"11578062"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-08-13","territory":"US","patentNumber":"10646481"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-08-13","territory":"US","patentNumber":"11564916"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-11-12","territory":"US","patentNumber":"8415387"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-08-05","territory":"US","patentNumber":"8324242"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-06-03","territory":"US","patentNumber":"7776905"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-05-20","territory":"US","patentNumber":"7495103"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-05-01","territory":"US","patentNumber":"7645789"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-05-01","territory":"US","patentNumber":"8598181"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-05-01","territory":"US","patentNumber":"8623905"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-04-09","territory":"US","patentNumber":"10022352"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-04-09","territory":"US","patentNumber":"10239867"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-04-09","territory":"US","patentNumber":"11639347"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-04-09","territory":"US","patentNumber":"9974781"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-12-28","territory":"US","patentNumber":"8410274"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-12-28","territory":"US","patentNumber":"8754224"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-12-28","territory":"US","patentNumber":"9670163"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-12-28","territory":"US","patentNumber":"9931334"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-07-06","territory":"US","patentNumber":"8354427"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-06-24","territory":"US","patentNumber":"8629162"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ELEXACAFTOR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:48:41.508571+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:48:41.508126+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:48:48.841420+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:48:41.523577+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:48:39.599692+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELEXACAFTOR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:48:49.626749+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ]. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA . Assess liver fu","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:38.383244+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:48:51.100546+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cystic fibrosis transmembrane conductance regulator positive modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:48:50.199948+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298128/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:48:50.100128+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA212273, NDA217660","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:38.383286+00:00"}},"allNames":"trikafta (copackaged)","offLabel":[],"synonyms":["elexacaftor"],"timeline":[{"date":"2019-10-10","type":"positive","source":"DrugCentral","milestone":"FDA approval (Vertex Pharms Inc)"},{"date":"2020-08-21","type":"positive","source":"DrugCentral","milestone":"EMA approval (Vertex Pharmaceuticals (Ireland) Limited)"}],"approvals":[{"date":"2019-10-10","orphan":false,"company":"VERTEX PHARMS INC","regulator":"FDA"},{"date":"2020-08-21","orphan":true,"company":"Vertex Pharmaceuticals (Ireland) Limited","regulator":"EMA"}],"brandName":"Trikafta (Copackaged)","ecosystem":[{"indication":"Cystic fibrosis","otherDrugs":[{"name":"dornase alfa","slug":"dornase-alfa","company":"Genentech"},{"name":"mannitol","slug":"mannitol","company":"Baxter Hlthcare"}],"globalPrevalence":890552}],"mechanism":{"target":"Cystic fibrosis transmembrane conductance regulator","novelty":"Follow-on","targets":[{"gene":"CFTR","source":"DrugCentral","target":"Cystic fibrosis transmembrane conductance regulator","protein":"Cystic fibrosis transmembrane conductance regulator"}],"modality":"Small Molecule","explanation":"In people with cystic fibrosis, the protein that regulates mucus production is defective. This leads to thick, sticky mucus that clogs the lungs and digestive system. Trikafta helps to correct this defect, allowing the body to produce normal amounts of mucus that can be easily cleared from the lungs and digestive system.","oneSentence":"Trikafta works by correcting the faulty protein that causes cystic fibrosis, allowing the body to produce normal amounts of mucus.","technicalDetail":"Elexacaftor is a corrector that stabilizes the cystic fibrosis transmembrane conductance regulator (CFTR) protein, allowing it to reach the cell surface and function properly, thereby increasing chloride ion transport and improving mucus clearance.","_target_confidence":0.5},"commercial":{"launchDate":"2019","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2019-10-10, VERTEX PHARMS INC)","annualRevenue":11100,"revenueSource":"Verified: Vertex 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5372","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ELEXACAFTOR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELEXACAFTOR","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:54:06.121647","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:48:55.873812+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"nitric oxide","drugSlug":"nitric-oxide","fdaApproval":"1999-12-23","patentExpiry":"Sep 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivacaftor","drugSlug":"ivacaftor","fdaApproval":"2012-01-31","patentExpiry":"Nov 20, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lumacaftor","drugSlug":"lumacaftor","fdaApproval":"2015-07-02","relationship":"same-class"},{"drugName":"tezacaftor","drugSlug":"tezacaftor","fdaApproval":"2018-02-12","relationship":"same-class"}],"genericName":"elexacaftor","indications":{"approved":[{"name":"Cystic fibrosis","source":"DrugCentral","snomedId":190905008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":890552,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nitric-oxide","brandName":"nitric oxide","genericName":"nitric oxide","approvalYear":"1999","relationship":"same-class"},{"drugId":"ivacaftor","brandName":"ivacaftor","genericName":"ivacaftor","approvalYear":"2012","relationship":"same-class"},{"drugId":"lumacaftor","brandName":"lumacaftor","genericName":"lumacaftor","approvalYear":"2015","relationship":"same-class"},{"drugId":"tezacaftor","brandName":"tezacaftor","genericName":"tezacaftor","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":["Cystic Fibrosis"],"enrollment":71,"completionDate":"2026-01-29"},{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":["Cystic Fibrosis"],"enrollment":500,"completionDate":"2027-12-31"},{"nctId":"NCT07303621","phase":"","title":"Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-09","conditions":["Cystic Fibrosis (CF)"],"enrollment":150,"completionDate":"2027-08-09"},{"nctId":"NCT05743946","phase":"PHASE4","title":"Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-04-18","conditions":["Non-cystic Fibrosis Bronchiectasis"],"enrollment":32,"completionDate":"2025-12-23"},{"nctId":"NCT07363304","phase":"","title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-12-02","conditions":["Cystic Fibrosis (CF)"],"enrollment":150,"completionDate":"2029-04-30"},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":["Cystic Fibrosis"],"enrollment":297,"completionDate":"2027-04-06"},{"nctId":"NCT07102043","phase":"","title":"Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":["Cystic Fibrosis Related Diabetes"],"enrollment":30,"completionDate":"2028-12-01"},{"nctId":"NCT07314229","phase":"NA","title":"Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-01-01","conditions":["Cystic Fibrosis (CF)","Mucoviscidosis"],"enrollment":130,"completionDate":"2027-01-26"},{"nctId":"NCT06457451","phase":"NA","title":"Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial","status":"RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-25","conditions":["Cystic Fibrosis"],"enrollment":100,"completionDate":"2027-11"},{"nctId":"NCT06507956","phase":"","title":"Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-17","conditions":["Cystic Fibrosis"],"enrollment":270,"completionDate":"2027-03-03"},{"nctId":"NCT06683092","phase":"","title":"Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-01","conditions":["Cystic Fibrosis"],"enrollment":200,"completionDate":"2028-06"},{"nctId":"NCT04613128","phase":"","title":"The PROMISE Pediatric Study 6 to 11 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicole Hamblett","startDate":"2021-06-11","conditions":["Cystic Fibrosis","Cystic Fibrosis in Children"],"enrollment":180,"completionDate":"2026-01-31"},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":["Cystic Fibrosis"],"enrollment":70,"completionDate":"2025-09-04"},{"nctId":"NCT06460506","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-11-21","conditions":["Cystic Fibrosis"],"enrollment":50,"completionDate":"2027-09-30"},{"nctId":"NCT06191640","phase":"","title":"Sinus Disease in Young Children With Cystic Fibrosis","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-04-12","conditions":["Cystic Fibrosis in Children","Cystic Fibrosis","Chronic Rhinosinusitis (Diagnosis)","Olfactory Disorder","Olfactory Impairment"],"enrollment":80,"completionDate":"2026-04"},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":["Cystic Fibrosis"],"enrollment":82,"completionDate":"2022-07-26"},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":["Cystic Fibrosis"],"enrollment":507,"completionDate":"2023-01-09"},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":["Cystic Fibrosis"],"enrollment":47,"completionDate":"2025-01-08"},{"nctId":"NCT03506061","phase":"PHASE2","title":"Trikafta in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":["Cystic Fibrosis"],"enrollment":42,"completionDate":"2024-02-13"},{"nctId":"NCT07148739","phase":"PHASE4","title":"Ensuring Access to Optimal Therapy in CF: The ENACT Study","status":"RECRUITING","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2025-06-10","conditions":["Cystic Fibrosis (CF)"],"enrollment":95,"completionDate":"2030-12"},{"nctId":"NCT05752019","phase":"","title":"TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-03-21","conditions":["Cystic Fibrosis","Lung Inflammation","Lung Infection","Lung Disease; Cystic","Lung Diseases","Lung Disease; Cystic, Congenital","Inflammation Lungs","Congenital Disorders","Exacerbation, Symptom","Infections, Bacterial"],"enrollment":103,"completionDate":"2024-12-31"},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":["Cystic Fibrosis"],"enrollment":64,"completionDate":"2024-02-24"},{"nctId":"NCT06331000","phase":"","title":"Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-04-08","conditions":["Cystic Fibrosis"],"enrollment":184,"completionDate":"2025-02-24"},{"nctId":"NCT05279040","phase":"","title":"Trikafta Exercise Study in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-10","conditions":["Cystic Fibrosis","Lung Diseases"],"enrollment":20,"completionDate":"2025-12"},{"nctId":"NCT05519020","phase":"","title":"Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2022-07-27","conditions":["Cystic Fibrosis"],"enrollment":1385,"completionDate":"2024-10-31"},{"nctId":"NCT05818319","phase":"NA","title":"Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-01","conditions":["Cystic Fibrosis (CF)","CFTR Gene Mutation"],"enrollment":30,"completionDate":"2025-12"},{"nctId":"NCT04038047","phase":"","title":"A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2019-10-22","conditions":["Cystic Fibrosis"],"enrollment":490,"completionDate":"2024-12-23"},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":["Cystic Fibrosis"],"enrollment":435,"completionDate":"2023-11-21"},{"nctId":"NCT04509050","phase":"","title":"Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children","status":"RECRUITING","sponsor":"Sonya Heltshe","startDate":"2020-11-18","conditions":["Cystic Fibrosis"],"enrollment":210,"completionDate":"2029-12-01"},{"nctId":"NCT04840862","phase":"PHASE4","title":"Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-05-09","conditions":["Drug Drug Interaction"],"enrollment":6,"completionDate":"2024-05-30"},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":["Cystic Fibrosis"],"enrollment":307,"completionDate":"2023-07-05"},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":["Cystic Fibrosis"],"enrollment":597,"completionDate":"2023-11-30"},{"nctId":"NCT06284577","phase":"NA","title":"Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-01-02","conditions":["Cystic Fibrosis in Children"],"enrollment":40,"completionDate":"2027-07-01"},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":["Cystic Fibrosis"],"enrollment":120,"completionDate":"2023-03-24"},{"nctId":"NCT04602468","phase":"PHASE4","title":"Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal College of Surgeons, Ireland","startDate":"2020-09-03","conditions":["Cystic Fibrosis","Cystic Fibrosis Liver Disease","Cystic Fibrosis in Children","Adherence, Medication","Cystic Fibrosis Gastrointestinal Disease"],"enrollment":237,"completionDate":"2029-07-01"},{"nctId":"NCT06302270","phase":"","title":"CFTR Modulators in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2024-03-15","conditions":["Cystic Fibrosis"],"enrollment":75,"completionDate":"2039-01-31"},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":["Cystic Fibrosis"],"enrollment":251,"completionDate":"2022-12-16"},{"nctId":"NCT06184763","phase":"","title":"Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":["Cystic Fibrosis"],"enrollment":73,"completionDate":"2024-11-01"},{"nctId":"NCT06072365","phase":"","title":"Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2021-10-21","conditions":["Cystic Fibrosis"],"enrollment":120,"completionDate":"2023-01-15"},{"nctId":"NCT04599465","phase":"PHASE3","title":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-15","conditions":["Cystic Fibrosis"],"enrollment":69,"completionDate":"2022-07-14"},{"nctId":"NCT04362761","phase":"PHASE3","title":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-05-04","conditions":["Cystic Fibrosis"],"enrollment":172,"completionDate":"2022-12-21"},{"nctId":"NCT05822102","phase":"","title":"Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY","status":"UNKNOWN","sponsor":"National Jewish Health","startDate":"2023-02-09","conditions":["Cystic Fibrosis"],"enrollment":100,"completionDate":"2023-09"},{"nctId":"NCT05111145","phase":"PHASE3","title":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-14","conditions":["Cystic Fibrosis"],"enrollment":86,"completionDate":"2022-12-20"},{"nctId":"NCT05937815","phase":"NA","title":"Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-13","conditions":["Cystic Fibrosis"],"enrollment":253,"completionDate":"2024-09-13"},{"nctId":"NCT04043806","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-09","conditions":["Cystic Fibrosis"],"enrollment":458,"completionDate":"2022-12-14"},{"nctId":"NCT04537793","phase":"PHASE3","title":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-11-19","conditions":["Cystic Fibrosis"],"enrollment":83,"completionDate":"2022-06-03"},{"nctId":"NCT05699148","phase":"","title":"Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-04-01","conditions":["Cystic Fibrosis"],"enrollment":17,"completionDate":"2023-04-01"},{"nctId":"NCT05675592","phase":"","title":"Trikafta/Kaftrio and Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2022-02-22","conditions":["Cystic Fibrosis"],"enrollment":20,"completionDate":"2025-05-16"},{"nctId":"NCT05599230","phase":"","title":"Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.","status":"UNKNOWN","sponsor":"CHC Montlegia","startDate":"2022-09-01","conditions":["Cystic Fibrosis"],"enrollment":20,"completionDate":"2022-11-30"},{"nctId":"NCT05576324","phase":"","title":"Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-12-30","conditions":["Cystic Fibrosis"],"enrollment":130,"completionDate":"2023-10-18"},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":["Cystic Fibrosis"],"enrollment":121,"completionDate":"2021-05-17"},{"nctId":"NCT05200429","phase":"","title":"Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":["Cystic Fibrosis"],"enrollment":500,"completionDate":"2027-12-31"},{"nctId":"NCT04923464","phase":"","title":"A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-06-30","conditions":["Cystic Fibrosis"],"enrollment":51,"completionDate":"2021-12-20"},{"nctId":"NCT03227471","phase":"PHASE1,PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":["Cystic Fibrosis"],"enrollment":225,"completionDate":"2018-03-27"},{"nctId":"NCT04684823","phase":"NA","title":"The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-01-15","conditions":["Cystic Fibrosis","Adherence, Medication"],"enrollment":12,"completionDate":"2021-12-27"},{"nctId":"NCT03691779","phase":"PHASE3","title":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-02","conditions":["Cystic Fibrosis"],"enrollment":71,"completionDate":"2020-08-07"},{"nctId":"NCT04105972","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-10-03","conditions":["Cystic Fibrosis"],"enrollment":176,"completionDate":"2020-07-24"},{"nctId":"NCT04702360","phase":"","title":"ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":""},{"nctId":"NCT04058353","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-28","conditions":["Cystic Fibrosis"],"enrollment":271,"completionDate":"2020-06-12"},{"nctId":"NCT04056702","phase":"","title":"Impact of Triple Combination CFTR Therapy on Sinus Disease.","status":"UNKNOWN","sponsor":"Jennifer Taylor-Cousar","startDate":"2019-09-05","conditions":["Cystic Fibrosis"],"enrollment":31,"completionDate":"2022-07"},{"nctId":"NCT04058210","phase":"","title":"VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":""}],"_emaApprovals":[{"date":"2020-08-21","status":"Authorised","company":"Vertex Pharmaceuticals (Ireland) Limited"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"37631","NDDF":"018170","UNII":"RRN67GMB0V","VANDF":"4038884","INN_ID":"11180","RXNORM":"2256951","UMLSCUI":"C5139717","chemblId":"CHEMBL4298128","ChEMBL_ID":"CHEMBL4298128","KEGG_DRUG":"D11700","DRUGBANK_ID":"DB15444","PDB_CHEM_ID":" WJX","PUBCHEM_CID":"134587348","SNOMEDCT_US":"827070004","IUPHAR_LIGAND_ID":"10552","MESH_SUPPLEMENTAL_RECORD_UI":"C000629074"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2019-","companyName":"Vertex Pharms Inc","relationship":"Original Developer"},{"period":"2020","companyName":"Vertex Pharmaceuticals (Ireland) Limited","relationship":"EMA Licensee"}],"pharmacokinetics":{"tmax":"Not provided in text","halfLife":"Not provided in text","metabolism":"Not provided in text","elimination":"Not provided in text","bioavailability":"Not provided in text"},"publicationCount":1140,"therapeuticAreas":["Respiratory"],"_revenueScrapedAt":"2026-04-08 13:58:03.526462+00","atcClassification":{"source":"DrugCentral","atcCode":"R07AX32","allCodes":["R07AX32"]},"biosimilarFilings":[],"originalDeveloper":"Vertex Pharms Inc","recentPublications":[{"date":"2026 Feb 26","pmid":"41892019","title":"Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes.","journal":"International journal of neonatal screening"},{"date":"2026 Mar 24","pmid":"41881763","title":"Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis.","journal":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society"},{"date":"2026 Feb 27","pmid":"41871565","title":"Response to modulator therapy in a cystic fibrosis patient with a single identified CFTR variant not eligible for modulator treatment.","journal":"The Turkish journal of pediatrics"},{"date":"2026 Mar 23","pmid":"41869727","title":"Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.","journal":"JCI insight"},{"date":"2026 Mar 21","pmid":"41865142","title":"Recalibration: Exploring the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Self-Concept for Adults with Cystic Fibrosis.","journal":"The patient"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Vertex Pharms Inc","companyId":"vertex","modality":"Small molecule","firstApprovalDate":"2019","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-10T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-08-03T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":"NDA217660"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-09-25T00:00:00.000Z","mah":"VERTEX PHARMS INC","brand_name_local":null,"application_number":"NDA212273"},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8629162","territory":"US","patent_type":null,"expiry_date":"2025-06-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8354427","territory":"US","patent_type":null,"expiry_date":"2026-07-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8410274","territory":"US","patent_type":null,"expiry_date":"2026-12-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9931334","territory":"US","patent_type":null,"expiry_date":"2026-12-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9670163","territory":"US","patent_type":null,"expiry_date":"2026-12-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8754224","territory":"US","patent_type":null,"expiry_date":"2026-12-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10239867","territory":"US","patent_type":null,"expiry_date":"2027-04-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9974781","territory":"US","patent_type":null,"expiry_date":"2027-04-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11639347","territory":"US","patent_type":null,"expiry_date":"2027-04-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022352","territory":"US","patent_type":null,"expiry_date":"2027-04-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7645789","territory":"US","patent_type":null,"expiry_date":"2027-05-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8598181","territory":"US","patent_type":null,"expiry_date":"2027-05-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8623905","territory":"US","patent_type":null,"expiry_date":"2027-05-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7495103","territory":"US","patent_type":null,"expiry_date":"2027-05-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7776905","territory":"US","patent_type":null,"expiry_date":"2027-06-03T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8324242","territory":"US","patent_type":null,"expiry_date":"2027-08-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8415387","territory":"US","patent_type":null,"expiry_date":"2027-11-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11564916","territory":"US","patent_type":null,"expiry_date":"2029-08-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10646481","territory":"US","patent_type":null,"expiry_date":"2029-08-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11578062","territory":"US","patent_type":null,"expiry_date":"2031-03-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10081621","territory":"US","patent_type":null,"expiry_date":"2031-03-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11147770","territory":"US","patent_type":null,"expiry_date":"2033-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10272046","territory":"US","patent_type":null,"expiry_date":"2033-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8883206","territory":"US","patent_type":null,"expiry_date":"2033-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9012496","territory":"US","patent_type":null,"expiry_date":"2033-07-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11426407","territory":"US","patent_type":null,"expiry_date":"2035-10-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10758534","territory":"US","patent_type":null,"expiry_date":"2035-10-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10793547","territory":"US","patent_type":null,"expiry_date":"2037-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11517564","territory":"US","patent_type":null,"expiry_date":"2037-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11453655","territory":"US","patent_type":null,"expiry_date":"2037-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11179367","territory":"US","patent_type":null,"expiry_date":"2037-12-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:48:55.873812+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}